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Abstract
Matrilysin is a member o f  a multigene family o f  proteolytic enzymes called the matrix 
metalloproteinases (M M Ps). It has previously been determined that matrilysin has a 
role to play in the developm ent o f  colon cancers, however, its participation in other 
tumour types has not been fully explored. The aims o f this research were (i) to develop  
an ELISA for matrilysin; (ii) to examine human breast tumour tissue by a variety o f  
methods for expression o f  matrilysin; (iii) to investigate the expression o f  matrilysin in 
cancers o f  other tissues using cell lines; and (iv) to examine how  the expression of 
matrilysin could be modulated by polypeptide growth factors and cytokines.
A sensitive and specific one-step sandwich ELISA  was developed. This w as validated 
and shown to have excellent reproducibility. The limit o f  detection was 0 .45 ng/ml and 
the linear range was 5 - 5 0  ng/ml.
A  pilot-scale study o f  ten breast tumour samples and three normal breast tissue samples 
demonstrated the presence o f  matrilysin m R N A  and protein in both normal and tumour 
cells. Immunohistochemistry w as found to be the m ost useful and informative method 
o f  detecting matrilysin protein. The intensity o f  expression varied among tumour 
specim ens but did not correlate with stage o f  disease.
Matrilysin expression was examined in a variety o f  human tumour cell lines using RT- 
PCR and the matrilysin ELISA. O f the eight lines tested, only four produced the 
enzyme. Levels o f  matrilysin could be stimulated with cytokines. Interleukin-6, IGF-I 
and IGF-II, not previously reported as modulators o f  M M P activity, were among the 
m ost potent stimulators at both the m RNA and protein levels. These results were 
confirmed using matrilysin promoter-reporter gene constructs transfected into suitable 
cells.
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Chapter One
Introduction to the MMPs
i
1.1 INTRODUCTION
The extracellular matrix (ECM ) is a com plex network com posed o f  various 
proteins such as collagens, laminin and proteoglycans amongst others (Paulsson, 1992). 
For many years the extracellular matrix was thought to be an inert structure w hose only 
function was to provide structural support to organisms. It is now known that ECM  
has a profound influence on many normal and pathological processes including 
embryonic developm ent and establishment o f  tissue-specific functions (Boudreau et al., 
1995), bone rem odelling, arthritis, and tum ourigenesis (Peterson et al., 1992).
There are 4 main classes o f  proteinases believed to be involved in proteolytic 
degradation o f  the extracellular matrix (Shi et al., 1993): (i) serine proteinases e.g. 
plasminogen activators; (ii) cysteine proteinases e.g. cathepsins B and L; (iii) aspartyl 
proteinases e.g. cathepsin D  and (iv) metalloproteinases e.g. collagenases and 
stromelysins. M any o f  these proteinases interact in a com plex cascade which ultimately 
leads to matrix degradation. O f these different proteinases, the matrix 
metalloproteinases (M M Ps) are believed to be the normal, physiological mediators of  
matrix degradation. They are secreted proteins, placing them in the proper location for 
extracellular matrix degradation and their enzymatic activities are m ost potent at pH 
values close to neutrality (Matrisian, 1992). A lso, their combined substrate specificities 
include all the major m acrom olecules o f  the ECM.
1.2 M M P Structure and Function
The M M Ps are a multigene family o f matrix-degrading zinc metalloproteinases 
that degrade at least one com ponent o f  the ECM . M olecular cloning o f  the various 
family members has revealed considerable amino acid conservation and raises the 
possibility that the genes arose by duplication o f  a single primordial gene (Matrisian,
1992). So far in humans, fourteen members o f  the M M P family have been identified 
and eleven o f  these have been characterised [Table 1.1]. The molecular weights and 
substrates o f  the three m ost recently identified M M Ps (M T-M M P-2, M T-M M P-3 and 
M T-M M P-4) remain to be confirmed. The M M Ps have been known by various names
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through isolation by different groups but for the purposes o f  this review the designation 
recommended by the International Union o f  Biochemistry and Molecular B iology will 
be used (Nomenclature Committee, 1992). Therefore the 72kD a and 92kD a type IV  
collagenases will be referred to as gelatinase A and gelatinase B respectively. 
Similarily, P U M P -1 or matrin will be referred to as matrilysin. The M M P classification 
numbering system, as shown in Table 1.1, is also regularly used.
Table 1.1 : Properties o f human matrix metalloproteinases
1 Interstitial collagenase 55 45 Fibrillar collagens
Gelatin
Proteolglycan
2 Gelatinase A 72 66 Denatured collagens 
Collagen IV, V, VII, X 
Elastin
3 Stromelysin-1 57 45 Proteoglycan 
Collagen II, IV, XI 
Gelatins, Laminin, 
Fibronectin
7 Matrilysin 28 19 As for stromelysin-1
Elastin
Entactin
8! Neutrophil collagenase 75 58 As interstitial collagenase
9 Gelatinase B 92 86 As gelatinase A
10 Stromclysin-2 57 44 As stromelysin-1
11 Stromclysin-3 51 44 Similar to stromelysin-1
12 Mctalloelastase 53 45/22 Elastin
Type IV collagen
13 Collagenasc-3 65 55 Fibrillar collagens
! 14 Membrane type-MMP 63 ? Gelatinase A
Analysis o f  the amino acid sequences reveals that these proteins contain several 
distinct domains that are conserved am ong the various members and it is these 
conserved regions by which they are particularly characterised [Fig 1]. The first o f  
these is the leader sequence (approx 17 amino acids) which targets the m olecule for 
secretion, is subsequently removed and is therefore not present in the latent enzyme 
(Wilhelm et al., 1987). The second domain is the propeptide (approx 80 amino acids) 
which has been shown to be cleaved when M M Ps are activated and which contains the
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highly conserved sequence PR CG V/NPD (Grant et al., 1987; Stetler-Stevenson et al., 
1989a; N agase et al., 1990; Freije et al., 1994). The available data suggest that this 
region is involved in maintaining the enzym e in a latent state since mutations in this 
region result in an enzym e that no longer requires activation (Matrisian et al., 1991). 
In vitro, this activation can be achieved by a variety o f  agents including: conformational 
perturbants such as SD S and the organomercurials; oxidants such as NaOCl, sulfhydral 
alkylating agents; and, in som e cases, proteolytic cleavage by plasmin or trypsin (Grant 
et al., 1987; Wilhelm et al., 1987; Stetler-Stevenson et al., 1989a; H e et al., 1989; 
Springman et al. ,1990). There have also been a number o f  reports o f  spontaneous 
autoactivation (Van Wart and Birkedal-Hansen, 1990). In vivo, gelatinase A  is 
activated by other M M Ps, the membrane-bound M T-M M P-1 and M T-M M P-2 (Sato et 
al., 1994; Takino et al., 1995b). T w o o f  the membrane type metalloproteinases (MT- 
MMP-1 and M T-M M P-2) and stromelysin-3 contain an RXKR sequence between the 
propeptide and catalytic domain (Sato et al., 1994; Takino et al., 1995b). These 
enzymes cannot apparently be activated by agents such as the organomercurials but 
require proteolytic activation by m olecules such as furin (Pei and W eiss, 1995). This 
spectrum o f  activators suggests that a conformational change is required for activation 
and that a thiol bond is involved. The current view  o f  M M P activation is that the N- 
terminal part o f  the m olecule is folded around in the latent enzyme so that the cysteine 
residue in the conserved PRCG VNPD region com plexes with the essential zinc 
molecule o f  the catalytic domain. Activation results when a conformation change 
dissociates the cysteine (Cys 73) from the zinc atom with concomitant exposure o f  the 
active site. Accordingly, when Cys73 is ‘o n ’ the zinc, the activity o f  the enzym e is ‘o f f .  
This has been referred to as ‘the cysteine switch mechanism’ (Van Wart and Birkedal- 
Hansen, 1990).
The third domain is the catalytic domain (approx 170 amino acids) which 
contains the conserved sequence H ExxH xxG xxH  postulated to be the zinc binding 
domain similar to that found in the catalytic site o f  astacin, a close relative o f  the 
MMPs (Soler et al., 1994). Studies have shown that the metalloproteinases contain 
two metal binding sites at which zinc binds very strongly (Soler et al., 1994), one of  
which is the catalytic zinc and the second o f  which appears to have a major role in
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stabilizing tertiary structure. A lso present are tw o calcium ions, how ever these do not 
appear essential for activity but may play a role in inhibitor binding (Yuan et al., 1994).
The fourth domain which is present in all members o f  the M M Ps except 
matrilysin shares hom ology to hemopexin and vitronectin (Hunt et al., 1987) and is 
linked to the catalytic domain by a Pro-rich sequence o f  5 - 10 amino acids. This 
domain has been postulated to be involved in substrate specificity and indeed, specific 
residues within this domain (Tyr-214, A sp-235 and G ly-237) have been proposed as 
fundamental determinants o f  collagenase specificity (Sanchez-Lopez et al., 1993). In 
fact, the presence o f  these particular residues aided in the identification o f  a specific 
substrate for one o f  the new est M M Ps, collagenase-3 (Freije et al., 1994). As can be 
seen from Table 1.1, however, matrilysin, though lacking this domain, recognises 
similar substrates to stromelysins -1 and -2  both o f  which possess this domain. Murphy 
and co-workers have shown that a truncated form o f  gelatinase A  lacking this C- 
terminal domain had similar substrate specificities as the full length enzym e (Murphy et 
al., 1992). The truncated gelatinase A could no longer be activated by a membrane 
activator (possibly M T-M M P) and did not bind tissue inhibitor o f  metalloproteinases-2  
(TIM P-2). The conclusion, therefore, w as that this domain plays an important role in 
the regulation o f  active gelatinase A  by both activators and inhibitors. This theory has 
lead to speculation that matrilysin, as the only M M P that naturally lacks this domain, is 
less amenable to inhibition by the normal physiological inhibitors o f  these proteinases, 
the TIMPs (Crawford and Matrisian, 1995).
The gelatinases A and B both contain an additional domain which contains three 
repeats o f  a sequence hom ologous to the gelatin-binding domain o f  fibronectin (Collier 
et al., 1988; W ilhelm et al., 1989). This domain may mediate the sequestering o f  these 
enzymes within the ECM . Gelatinase B also contains an additional domain that has 
some hom ology to collagen (W ilhelm  et al., 1989). Finally, the transmembrane domain 
consisting o f  approximately 24 amino acids is found at the C-terminal o f  the membrane- 
associated metalloproteinase, M T-M M P (Takino et al., 1995a).
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mmp-2
mmp-3
mmp-7
mmp-8
mmp-9
mmp-10 
m mp-11
mmp-12  
mt-mmp
mmp-1
♦
PRCGVPD
signal/pro
J L
transmembrane
catalytic hinge
J L j
hemopexin
Figure 1.1 : Dom ain structure o f matrix metalloproteinases
A ll members o f  the M M P family contain at least three domains : the signal, pro- and the 
catalytic domains. The signal domain targets the m olecule for secretion, the pro­
domain maintains latency until it is cleaved and the catalytic domain contains both 
calcium- and zinc-binding regions. M ost family members also contain a domain with 
sequence similarity to hemopexin, while gelatinase A  and B contain a gelatin-binding 
domain and the M T-M M Ps contain putative membrane-spanning regions. Stromelysin- 
3 and the M T-M M Ps also possess a conserved RXKR sequence which appears to 
allow activation o f  these enzym es by furin.
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The M M Ps may be divided into three arbitrary subclasses with respect to their 
substrate specificity although the distinctions between the subclasses are becom ing less 
clear as more is known about the enzymatic activity o f  purified enzym es. A  fourth 
subclass comprising the membrane-bound M M Ps has also been suggested (Takino et 
al., 1995b). The Type I collagenase subclass has 3 members, namely interstitial 
collagenase, neutrophil collagenase and collagenase-3. These enzym es cleave the alpha 
chains o f types 1,11 and IE collagens at a single site. Interstitial collagenase is produced  
by fibroblasts and m acrophages in particular, while the expression o f  neutrophil 
collagenase is restricted to cells o f  the neutrophil lineage (Hasty et al., 1990a). 
Collagenase-3 appears to be particularly associated with breast carcinoma cells and its 
expression was not detected in a variety o f  normal tissues (Freije et al., 1994).
The type IV collagenase subclass contains tw o members : gelatinase A  and 
gelatinase B. Both o f  these enzym es degrade denatured collagens (gelatins) and are the 
principal enzym es responsible for type IV  basement membrane collagen degradation. 
The gelatinases have also been shown to possess som e elastolytic activity (Murphy et 
al., 1991). Expression o f  the zym ogen form o f  gelatinase A  is widespread and is 
frequently elevated and activated in malignant tumours (M onteagudo et al., 1990; 
Brown et al., 1990; Brown et al., 1993). Gelatinase B , the 92 kDa enzym e, was 
traditionally thought o f  as the macrophage gelatinase but it has also been described as 
being expressed in transformed and tumour-derived cells, neutrophils, com eal epithelial 
cells, cytotrophoblasts and keratinocytes (Collier et al., 1988; Wilhelm et al., 1989; 
Pyke et al., 1992; Lyons et al., 1993).
The third subclass is the stromelysin subclass which contains five members, 
including tw o highly hom ologous enzym es strom elysin-1 and stromelysin-2, and the 
smallest family member, matrilysin. The fourth member o f  this subclass, stromelysin-3, 
has been cloned and shown to be associated with tumour rather than normal tissue o f  
the breast and in various head and neck tumours (Basset et al., 1990; Muller et al.,
1993). W hile its sequence specificities have not been determined, a truncated version  
has been shown to possess caseinolytic activity and weak activity towards fibronectin 
and laminin (Murphy et al., 1993). The fifth member, metalloelastase, is specifically 
associated with m ononuclear phagocytes and, as its name suggests, is a potent degrader
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o f elastin (Shapiro, 1994). This subclass has the widest substrate specificity with the 
ability to degrade proteoglycans and glycoproteins such as fibronectin and laminin. The 
stromelysins also appear able to degrade type IV collagen and elastin with matrilysin 
being the m ost potent elastase (Murphy et al., 1991). The differential expression o f  the 
various members o f  the stromelysin subclass {e.g. stromelysin-1 is found in mature 
macrophages while matrilysin is found in developing pro-m onocytes (Busiek et al., 
1992)) may help to explain why there are several family members with similar substrate 
specificities. M ore recent studies o f  peptide substrates for the metalloproteinases have 
shown subtle differences in preferred residues within the region to be cleaved (N etzel- 
A m ett et al., 1993). A study by Navre and colleagues (Smith et al., 1995) em ployed a 
novel technique o f  creating phage display libraries to screen thousands o f  possible 
hexapeptides which are preferentially cleaved by matrilysin or stromelysin-1. Although  
the two proteinases appeared to have overlapping substrate specificities, close  
inspection revealed that certain subsites show distinct preferences for particular 
residues. This may mean that although both enzymes can cleave similar substrates, the 
rate o f  proteolysis can be quite different perhaps indicating an extra regulatory 
mechanism. Another important substrate recognised by the stromelysins is 
procollagenase (M M P-1) which, upon cleavage by either stromelysin-1 or matrilysin, 
can be fully activated (Murphy et al., 1987; Brinckerhoff et al., 1990; Abramson et 
al., 1995). Progelatinase B , while com plexed to TIM P, can also be activated by 
matrilysin (Von Bredow et al, 1996). The Glu 143 - Leu 144 bond o f  prourokinase is 
cleaved by matrilysin thus producing the low  molecular weight form o f  the plasminogen 
activator (M arcotte et al., 1992). These events suggest the involvement o f  
stromelysin-1 and matrilysin in a proteolytic cascade activating other proteinases even 
in the presence o f  inhibitors. A lso o f  physiological importance is the ability o f  
stromelysin-1 to inactivate the serine proteinase inhibitors (serpins) 0Ci proteinase 
inhibitor and (Xi antichymotrypsin (M ast et al., 1991) thus preventing inactivation o f  
other degradative enzym es especially associated with inflammation. Matrilysin has also 
been shown to degrade entactin, a basement membrane protein which bridges laminin 
and type IV collagen (Sires et al., 1993).
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1.3 Tissue Inhibitors o f M etalloproteinases (TIMPs)
The activity o f  the M M Ps is physiologically regulated by a specific class o f  
natural inhibitors, the tissue inhibitors o f  metalloproteinases or TIM Ps. The TIM Ps are 
a multigene family (Stetler-Stevenson et a l ,  1989b) which, at present, consists o f  three 
members : TIM P-1, TIM P-2 and TIM P-3. A  possible TIM P-4 has also been recently 
reported (Greene et a l ,  1996). There is an overall 38% identity between TIMP-1 and 
TIM P-2 at the amino acid sequence level, although the degree o f  similarity is higher at 
68%. TIM P-3 shares a 40% identity with TIMP-1 and 45% with TIM P-2. A ll three 
contain tw elve cysteine residues at virtually identical positions. These proteins bind 
non-covalently to active m etalloproteinases in a 1:1 molar ratio and specifically inhibit 
their enzymatic activity. TIM P-1 also forms a com plex with the inactive proform o f  
gelatinase B (W ilhelm et al., 1989) w hile TIM P-2 forms a com plex specifically with the 
proform o f  gelatinase A (Stetler-Stevenson et a l ,  1989b). A  9 amino acid C-terminal 
sequence present in TIM P-2 is thought to be responsible for its preference for 
interacting with gelatinase A  (W illenbrock et a l,  1993). This sequence is also present 
in TIM P-3 (Uria et a l ,  1994) but absent in TIM P-1. TIM P-1 and TIM P-2 also appear 
to be hom ologous to a growth factor activity termed ‘erythroid potentiating 
activity’(EPA) and have been shown to possess growth promoting qualities in some 
m odels (Docherty et al., 1985; Stetler-Stevenson etal., 1992).
TIM P-1 is a glycoprotein (M r 30kDa) and its cD N A  and amino acid sequence 
has been reported (Docherty et al., 1985; Carmichael et a l ,  1986) although 
purification and characterization o f  the protein from rabbit bone tissue had earlier been 
achieved by Cawston (1981) and by other workers from various other sources (W elgus 
and Stricklin, 1983; Murphy et a l ,  1981). Early studies investigating the link between 
TIMP-1 expression and invasive ability in cell line m odels show ed that TIMP-1 levels 
were decreased 1 0 - 2 0  fold in highly invasive as compared to the normal or poorly 
invasive cells (Hicks et a l ,  1984). U sing antisense TIMP-1 transfected into previously 
poorly invasive murine cells, Khokha and colleagues (1989) showed that an increase in 
invasive properties was directly linked to a reduction in TTMP-1 expression.
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The second member o f  the TIMP fam ily, TIM P-2 is a non-glycosylated protein 
(Mr 23 kDa) w hich was isolated and cloned by several different groups ( DeClerck et 
al., 1989; Goldberg et al., 1989; Stetler-Stevenson etal.,  1989b; B oone et al., 1990). 
The activity o f  TIM P-2 has also been w ell characterized. It reacts stoichiometrically 
with active interstitial collagenase and also prevents the activation o f  this enzym e from  
its 55kD a proform to its 45kD a active form (DeClerck et al., 1991a) The binding o f  
TIM P-2 to the inactive form o f  gelatinase A  does not prevent the enzym e becom ing  
activated suggesting that the TIM P-2 is bound to a site other than the active site (Ward 
et al., 1991). It has been suggested that the TIM P-2 prevents autocatalytic activation 
o f this gelatinase (Howard et al., 1991), but another possibility is  that it prevents the 
binding o f  gelatinase A  to M T-M M P, its apparent in vivo activator. A lso  the TIM P-2, 
w hile com plexed to gelatinase A , has been shown to retain inhibitory activity to other 
metalloproteinases (Kolkenbrock et al., 1991). The inhibitory effects o f  TIM P-2 on 
cell invasion has been demonstrated in a number o f studies (DeClerck et al., 1991b; 
Albini et al., 1991).
The third human TIMP, TIM P-3 has been recently cloned by L op ez-0tin ’s 
group (Uria et al., 1994) although an unpublished partial sequence had previously been 
lodged in the GenBank database by Apte and Olsen (A ccession N o. L 15078). This 
sequence codes for a mature protein (after cleavage o f  a secretory domain) o f  188 
amino acids with a predicted M r o f  21 .6  kDa. This third protein, although having a 40  
- 45% identity with TIM Ps 1 and 2, shares a much higher identity (82% ) with ChlM P- 
3, a metalloproteinase inhibitor identified by Hawkes and co-workers produced by 
transformed fibroblasts from chickens (Pavloff et al., 1992). TIM P-3 appears to be 
expressed in normal placental and ovarian tissues and in all breast carcinomas examined 
(Uria et al., 1994). Whether it is  functioning in breast carcinomas as an inhibitor or as a 
growth factor remains to be determined.
The major serum inhibitor o f  metalloproteinase activity is the large Ofe- 
macroglobulin protein (mr 7 50  kDa) which also inhibits other proteinases in a non­
specific manner (Borth, 1992).
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1.4 Regulation o f the M M Ps
The regulation o f  M M P activity is com plex and occurs at several different 
le v e ls : (i) at the transcriptional level, by oncogenes, tumour promoters, growth factors, 
glucocorticoids and adhesion molecules; (ii) at the activity level by processing o f  the 
latent precursor to an active enzyme; and (iii) total proteinase activity is modulated by 
the presence o f  TIMPs which are also independently regulated. A  large number o f  
studies have been aimed at elucidating the factors controlling expression at the 
transcriptional level o f  the M M P and TIM P genes. A  representation o f  the information 
thus obtained is presented in Table 1.2. A  more detailed examination o f  the 
mechanisms by which these factors regulate gene expression is given in the 
introductions to chapters five and six.
Table 1.2 : Factors affecting expression o f MM Ps and TIM Ps
¡ ¡ f e u .  H Ü U X L T Y P K I M I — li îS F E R K N i  ;E; w j
; ONCOGENES j c-Ha-ras Rat fibroblasts M M P-2 Stim ulates j Garbisa et al., 1987
!| ras
; Fibroblasts M M P-3 Stim ulates 1 Diaz-Meco et al., 
\ 1991
:  :
;
Ha-ras +/- 
v-myc
Rat fibroblasts M M P-9 Stim ulates j Bernhard et a l., 1994
;1 ?i\ ............................ 1
Ki-ras | Colon cancer line 
! SW 1417
M M P-7
!.......................j Stim ulates j
1 Yamamoto et al., 
\ 1995
; ADHESION 
MOLECULES !! Fibronectin receptor
; Synovial 
I fibroblasts
M M P -3, M M P -1 j! Stim ulates j; Werb et al., 1989
« 4 ^ 3 ! Melanoma line 
A375M  ___
M M P-2 Inhibits [ Seftor et al., 1993
3 ij ;| Truncated ! Fibronectin
i Adeno-carcinoma M M P-7 : Stim ulates | Yamamoto et al., 
! 1994
: j
i Cell contact i Rat fibroblasts M M P-9 Stim ulates ! Himelstein et al., 
1994....
[ h o r m o n e s Dexamethasone i Articular 
; chondrocytes
M M P -1 Inhibits ; McGuire-Goldring et 
\ al., 1983____
:I Progesterone j R a b b it f ib ro b la sts TIM P-1 Stim ulates : S a k y o  et al., 1 9 8 6
; P -estrad io l ; R ab b it f ib ro b la sts TIM P-1 ; Stim ulates 1 S a k y o  et al., 1 9 8 6
P rogestero n e i H um an  strom al 
fib ro b la sts
M M P-3 !  Inhibits 1 Osteen et al., 19 9 4
■ GROWTH 
j FACTORS
E G F 1 F ib ro b la sts M M P-3 Stim ulates ! McDonnell et al., 
ì 19 9 0
! T G F -P ; F ib ro b la sts M M P-3 i Inhibits ; K e rr  et al., 19 9 0
1 > P D G F | F ib ro b la sts M M P-3 | Stim ulates [ Diaz-Meco et al., 
\ 1991
1 ; T G F -P ; H e p ato m a  lin eH cp -G 2
TIM P-1 Stimulates | K o rd u la  et a l., 199 2
i ..............................  .j
| TNF-oc E n d o th e lia l ce lls M M P-3 I Stimulates ; Hanemaaijer et al., 1993 |
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TGF-a, EGF Keratinocytes M M P -9, M M P -1 ! Stimulates Lyons et a l., 1993
E G F Squamous cell 
lines
M M P-9 Stimulates Shima e t al., 1993
TNF-a Promyelocytic 
line HL-60
M M P-9 Stimulates Ries et a l., 1994
T G F -P Epithelial cells M M P-7 Inhibits Bruner et a l., 1995
C Y T O K IN E S IL-6 Hepatoma line 
Hep-G2
T IM P -l
!
Stimulates Kordula e t a l., 1992
IL-1 Keratinocytes MMP-9, MMP-1 Stimulates Lyons et a l., 1993
IL -la Trabecular
explants
MMP-9, MMP-3, 
TIMP-l
Stimulates Samples et a l., 1993
IFN -y Keratinocytes M M P -1, M M P -3 Stimulates Tamai e t a l., 1995
1L A ,IL-10, IFN-y Monocytes M M P-7 Inhibits Busiek et a l., 1995
TUMOUR
PROMOTER
PMA Fibroblasts M M P -1, T IM P -l Stimulates Overall and Sodek, 
1990
PMA Endothelial cells MMP-1, MMP-3 , 
MMP-9, TIM P-l
Stimulates Hanemaaijer et al., 
1993
M IS C . Concanavalin A Fibroblasts MMP-1, MMP-2, 
MMP-7
Stimulates Overall and Sodek, 
1990
Concanavalin A Breast cancer line 
MDA-MB-231
M T -M M P -1; Stimulates Yu et al., 1995
Concanavalin A Fibroblasts T IM P -l Inhibits Overall and Sodek, 
1990
Calcium phosphate 
crystals
Fibroblasts M M P -1, M M P -3 Stimulates McCarthy et al.,
1992
$ Prostaglandin E2 Dermal
Fibroblasts
M M P-1 Stimulates Mauviel et al., 1994
a-difluoro- 
■ methylomithinc
Colon cancer line 
SW 1116
M M P-7 Inhibits Wallon et a l., 1994
| cAMP Fibrosarcoma MMP-2, TIM P-l, 
TIMP-2
Stimulates Tanaka et a l., 1995
LPS Monocytes M M P-7 Stimulates Busiek et al., 1995
As can be seen, there is a large variety o f  agents which appear to influence the 
expression o f these proteinases and/or their inhibitors. It must be noted, however, that 
the majority o f  these studies are dealing with one factor in isolation which w ould not 
usually be the case physiologically. In som e cases the effects are not direct, as for 
example with a-diflurom ethylom ithine on M M P-7 expression (Wallon et al., 1994) 
where the effect o f  this com pound is to deplete cellular polyamines which in turn leads 
to the down-regulation o f  matrilysin. In other cases a factor which may be influenced 
by a number o f other factors is the regulatory agent examined e.g. cellular cAM P levels 
are affected by a variety o f  agents such as cytokines, drugs etc. how ever the up- 
regulation o f gelatinase A  and TIM P levels was as a direct result o f  the cAM P (Tanaka 
et al., 1995). O f particular interest are those factors which appear to differentially
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regulate proteinase and inhibitor levels thus shifting the balance towards proteolysis 
(e.g. concanavalin A ) or inhibition (e.g. progesterone). There are also examples o f  c o ­
ordinate regulation o f  proteinase and inhibitor (e.g. I L - la )  which would suggest other 
regulatory processes are also important.
1.5 Physiological roles o f M M Ps
The matrix metalloproteinases are principally known for their roles in the 
degeneration o f  bones and tissues associated with arthritis and tumour invasion and 
metastasis. In fact, the majority o f  these proteinases were first isolated and cloned  
from tumour-associated tissues (Liotta et al., 1991a). A s more expression and 
localization studies are performed, how ever, the roles o f  these proteinases in both 
‘normal’ and other disease states are being elucidated. They are now  implicated in a 
variety o f  events including embryo implantation and developm ent, wound healing, 
endometrial remodelling during the female reproductive cycle, photoageing and 
inflammatory cell responses as w ell as in pathological conditions such as emphysema, 
atherosclerosis, periodontal disease and, o f  course, arthritis and tumour invasion 
(Matrisian, 1990; W oessner, 1991; Matrisian, 1992). It should be noted at this point 
that MMPs are not the only proteinases which play integral roles in any or all o f  these 
processes, how ever the contributions o f  the other classes o f  proteinases are beyond the 
scope o f  this review.
Trophoblast cells o f  the placenta, an organ derived from a developing foetus, 
have the ability to tap into the maternal circulation allowing essential exchange o f  
nutrients and waste materials (Graham and Lala, 1991). This tapping o f  the maternal 
blood supply is dependent on a temporally and spatially controlled invasive ability 
exhibited by the trophoblasts (Fisher et al., 1989). A  number o f  investigators have 
shown that the principal mediators o f  trophoblast invasion are the gelatinases A  and B 
(Fisher et al., 1989; Librach et al., 1991; Graham et al., 1992; Cross et al., 1994).
The process o f  tissue remodelling seen in wound repair is considered similar to  
processes occurring in embryonic developm ent. Remodelling is achieved through 
progressive synthesis, degradation and resynthesis o f  extracellular matrix components
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(Clark, 1988). Both interstitial collagenase and stromelysin-1 have been shown to be 
responsible for the degradative aspects o f  this rem odelling process both in wound  
healing (Girard et al., 1993; Stricklin et al., 1993) and during the developm ent and 
involution o f  m ouse mammary glands (Crawford and Matrisian, 1995). Stromelysin-3 
has been observed in fibroblasts during cutaneous scar formation and its expression is 
suggested to be a normal w ound healing response (W olf et al., 1992). It is also  
expressed in the connective tissue o f  developing digits (Basset et al., 1990) and in 
involuting mammary glands (Lefebvre et al., 1992).
In adult humans, the uterine epithelium in w om en o f  reproductive age is one o f  
the few  areas where continuous growth and tissue remodelling events occur. During 
the proliferative (growth and remodelling) and menstrual (degradative) phases o f  the 
cycle, the enzym es matrilysin and strom elysins-1,2 and 3 are expressed in an apparently 
hormone-dependent manner (Osteen et al., 1994) although the suppression o f  
matrilysin during ovulation has been shown to be directly controlled by TGF-p rather 
than the hormone progesterone (Bruner et al., 1995). Matrilysin has also been shown  
to be expressed in normal exocrine glands where it is thought to act as a “pipe-cleaner” 
degrading proteinaceous material that could block the ducts (Saarialho-Kere et al., 
1995). Unlike other m etalloproteinases, matrilysin expression is limited to cells o f  
epithelial rather than stromal origin (Crawford and Matrisian, 1995). Constitutive 
expression o f  matrilysin is seen in developing prom onocytes (Busiek et al., 1992) and 
suggests its role particularly in severe inflammatory events such as cystic fibrosis 
(Busiek et al., 1995). Matrilysin expression by mesangial cells o f  the kidney is also 
thought to contribute to glomerular inflammatory injury (Marti et al., 1992).
The phenomenon o f  ‘photoageing’, that is the wrinkled appearance o f  sun- 
exposed skin is considered to be due to damage to skin collagen and elastin (W laschek 
et al., 1994). A recent report has shown that expression o f  interstitial collagenase, 
gelatinase B and stromelysin-1 is induced in human skin within hours o f exposure to  
ultraviolet B irradiation (U V B ) and suggests that these enzym es are the direct cause o f  
photoageing (Fisher et al., 1996).
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1.6 Pathological roles o f M M Ps
M M Ps have been implicated in a number o f  pathological conditions either 
directly, where the disease is a direct result o f  increased levels o f  enzymes leading to 
tissue degradation, or indirectly where a link is established between the disease and loss 
o f  an M M P control mechanism. An example o f  the latter is Sorsby’s Fundus 
Dystrophy, an autosomal dominant hereditary disease affecting vision (W eber at al, 
1994a). Point mutations in one or both alleles o f  the TIM P-3 gene appears to be the 
principal cause o f  the disease in affected families (W eber et al., 1994b; Jacobson et al.,
1995). Interestingly the disease often co-segregates with emphysema, a destructive 
lung disease, and periodontal disease. Emphysema is characterised by the destruction 
o f  pulmonary elastic fibres and is principally associated with smokers. The elastolytic 
ability o f  macrophages, the m ost abundant defence cell in the lung during states o f  
chronic inflammation (as produced in sm okers), has been shown to be inhibited by 
TIMP-1 (Senior et al., 1989). M acrophages produce tw o metalloproteinases with 
elastolytic ability, gelatinase B and metalloelastase (Shapiro et al., 1993), which appear 
to contribute to the pulmonary destruction characteristic o f emphysema (Shapiro,
1994). Periodontal diseases are characterised by the destruction o f  collagen fibres 
which provide the structural support o f  the tooth. Levels o f  active gelatinase B have 
been shown to be significantly higher in patients with these diseases than in controls 
(Teng et al., 1992). Interstitial collagenase activity has also been detected in inflamed 
periodontal tissues and correlated with attachment loss (V illela et al., 1987).
Atherosclerotic lesion developm ent involves migration o f  leucocyte and smooth 
muscle cells, accumulation o f  ECM  com ponents, creation o f  new capillary beds and 
arterial enlargement during plaque evolution all o f  which processes require ECM  
remodelling. A s atherosclerotic plaques develop and outgrow  the compensatory 
arterial wall enlargement, rupture and thrombosis can occur, events which also involve 
ECM  degradation. Libby and co-w orkers have demonstrated locally increased 
expression o f  gelatinase B, stromelysin-1 and interstitial collagenase in regions o f  
atherosclerotic plaque formation (Galis et al., 1994). U sing an in situ zymographic
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technique, this group demonstrated that these enzym es were present in an activated
form.
Stromelysin-1 and interstitial collagenase are the principal proteinases 
associated with rheumatoid- and osteo-arthritis (Hasty et al., 1991). Their presence 
and activity in vivo has been demonstrated by immunolocalisation using antibodies to  
the proteinases them selves (McCachren, 1991) and to their degradation products 
(D odge and Poole, 1989). The m R N A s for these proteinases have also been localised  
by in situ hybridisation to synovial lining layer cells in patients with rheumatoid arthritis 
(Gravellese et al., 1991). A  third metalloproteinase, gelatinase B is produced by 
macrophages present in the inflamed joints and also appears to play a role in the 
cartilage destruction associated with these diseases (Hembry et al., 1993).
Tumour invasion and metastasis has long been associated with 
metalloproteinase activity (Liotta et a l ,  1980). Many studies have established that the 
invasive ability o f  tumour cells can be increased by upregulation o f  proteinase activity ( 
Liotta et al., 1983; Matrisian et al., 1986; M cDonnell et al., 1990; Pow ell et al., 1993) 
or down-regulation o f  proteinase inhibitor activity (Khokha et al., 1989) while 
correspondingly, up-regulation o f inhibitor activity limits invasion (Alvarez et al., 1990; 
Frisch et al., 1990; DeClerck et al., 1992). Although each member o f  the M M P family 
has been implicated in tumour invasion, there are specific associations between  
particular proteinases and certain types o f  cancer. Table 1.3 lists a range o f  cancers and 
their associated M M Ps. M ost o f the proteinases are produced by stromal fibroblasts 
adjacent to the tumour cells or infiltrating macrophages and are secreted apparently in 
response to factors produced by the tumour cells them selves (W olf et al, 1992; 
Kataoka et al., 1993; W ang et al., 1994; Borchers et al., 1994). In contrast, MT- 
MMP-1 and matrilysin are produced exclusively by the tumour cells.
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T able 1.3 E xp ression  o f  M M P s in hum an tum ours
MrtanttpnatiBu** ilettfrtii-vs 1 ........... 1
Interstitial collagenase (MMP-1) Gastrointestinal McDonnell etal., 1991
Head and neck Okada etal., 1995
Breast Okada et al., 1995
Gelatinasc A (MMP-2) Lung Urbanski et al., 1992
Oesophageal Shima et al., 1992
Prostate Pajouhet al., 1991
Breast Okada et al., 1995
Colon Levy etal., 1991 
Poulsom et al., 1992
Stromelysin 1 (MMP-3) Oesophageal Shima et al., 1992
Pancreatic Bramhall et al., 1996
Brain Nakagawa et al., 1994
Matrilysin (MMP-7) Gastric McDonnell et al., 1991
Colon McDonnell et al., 1991 
Witty etal., 1994
j Prostate Pajouh etal., 1991 
Powell etal., 1993
Breast Basset et al., 1990 
Heppner et al., 1996
Gelatinase B (MMP-9) Lymphoma Kossakowska et al., 1993
Breast Montcagudo et al., 1990 
Zuckeretal., 1993
Lung Urbanski etal., 1992
Skin Pykeetal., 1991
Ovarian Naylor et al., 1994
Stromelysin 2 (MMP-10) Head and Neck Muller etal., 1991,1993
Stromelysin 3 (M M P -1 1) Breast Basset etal., 1990 
Wolf etal., 1993
Head and Neck Muller etal., 1993
Basal cell carcinoma Wolf etal., 1992 
Majmuder et al., 1994
Collagenase 3 (MMP-13) Breast Freije etal., 1994
MT-MMP-1 (MMP-14) Gastric Nomura et al., 1995
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A com m on feature o f  all the conditions described in the preceeding paragraphs 
is an imbalance o f  proteinases and inhibitors favouring proteolysis. As stated 
previously, in som e cases it is a specific effect o f  a reduction in inhibitor levels w hile in 
other cases, the degradative aspect o f the disease is manifested through an increase in 
active proteinase levels. This is an area o f  great interest as there is potential for therapy 
with specific metalloproteinase inhibitors. The anti-invasive effects o f  TIM P  
administration to laboratory animals has already been docum ented (DeClerck et al., 
1991) but it is small synthetic m olecules which have the greatest potential 
therapeutically. Already tw o such com pounds are in clinical trials [British 
Biotechnology com pounds, Baltimastat and Marimastat (Brown, 1996)] while many 
more are in developm ent. Inhibitors such as Baltimastat are small m olecules which fit 
tightly into the active site o f  the M M P enzym es as they mimic specific peptide residues 
on one side o f  a substrate’s cleavage site. The drugs were initially developed to 
prevent the extensive bone and cartilage degradation seen in rheumatoid arthritis. As 
the role o f  M M Ps in tumour invasion w as elucidated, however, developm ent o f  these 
synthetic inhibitors as anti-cancer agents began. These compounds are designed to 
complement existing cytoreductive treatments (Davies et al.,1993a; Giavazzi et al.,
1996), their aim being the control o f  metastatic disease rather than eradication.
In summary, the matrix metalloproteinases are a multigene family with the 
ability to degrade all com ponents o f the extracellular matrix. Their expression can be 
regulated at the transcriptional level by a wide variety o f  com pounds w hile at the 
activation level, their specific inhibitors, the TIMPs, and proteinase activators, often 
other members o f  the MMP fam ily, appear to be the principal controllers. They 
function in both normal physiological events and in pathological conditions such as 
arthritis and tumour invasion. Recent developm ents in the design o f  synthetic MMP  
inhibitors offer a new  therapeutic possibility to patients with solid tumours.
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1.7 T hesis O utline
The research presented in this thesis has been divided into four principal areas 
and in v o lv e s :
(A) The developm ent o f  a sensitive sandwich ELISA for matrilysin using 
antibodies provided by our collaborators (Chapter Three).
(B) The analysis o f  matrilysin expression in a small number o f  breast tumour 
tissue samples. M ethods o f  analysis investigated included RT-PCR for specific m RNA  
detection; and immunohistochemistry and western blotting for protein detection  
(Chapter Four).
(C) The investigation o f  the effects o f  a range o f  cytokines on expression o f  
matrilysin and stromelysin-1 by a number o f  different cell lines. The effects at the 
m RNA level were assessed using RT-PCR while protein levels were determined using 
the ELISA developed in chapter three (Chapter Five).
(D) The analysis o f  the matrilysin promoter. Transfections with promoter- 
reporter gene constructs were performed with the intention o f  quantifying the effects o f  
cytokines and TPA at the transcriptional level (Chapter Six).
Since the research described here covers a number o f  distinct but related topics, 
the thesis has been divided into eight sections which, it is hoped, will help clarify the 
results. There is a com m on Materials and M ethods section (Chapter T w o) and 
Bibliography (Chapter Eight). Chapters Three, Four, Five and Six each have their own  
introduction and results and discussion sections. Chapter One serves as a general 
introduction to the M M Ps, while Chapter Seven provides an overall summary and 
conclusion.
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Chapter Two
Materials and Methods
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2.1 MATERIALS
Reagents used in experimental work w ere o f  analytical grade and were purchased from 
Sigm a Chemical Co., P oole, D orset, England; BD H  Chemicals Ltd., Poole, Dorset, 
England and Riedal D e Haen AG , Seelze, Hannover, Germany.
M icrobiological media com ponents and PBS tablets were purchased from O xoid Ltd., 
Basingstoke, Hampshire, England.
Cell culture media was obtained from G ibco BRL, Paisley, Scotland. Foetal calf serum  
was supplied by Biowhittaker, Venders, Belgium. Other cell culture supplements were 
obtained from Sigma Chemical C o., P oole, D orset, England. D isposable plastics for 
cell culture were obtained from Costar, Cambridge, M A 02140 , U SA . Chamber slides 
were obtained from Nunc, G ibco-BR L, Paisley, Scotland. The cell lines used were 
obtained from European Collection o f  Animal Cell Cultures (ECACC), Porton D ow n, 
Salisbury, Wiltshire, England.
96-w ell ELISA plates were purchased from Costar, Cambridge, M A 02140, U SA .
The 16 amino acid matrilysin peptide (M AP peptide) [AEYSLFPNSPKW TSKV] was 
manufactured according to specifications by Immune System s Ltd., W estbury-on- 
Trym, Bristol, England.
The VECTASTAIN A BC  kit and biotinylated anti-rat antibody were obtained from  
Vector Laboratories, Burlingam e, C A  94010, USA.
Restriction endonucleases, Taq polymerase and other com ponents o f  RT-PCR assays, 
luciferase detection reagents and enzyme-labelled anti-mouse and anti-rabbit antibodies 
were purchased from Prom ega Corp., Southampton, Hampshire, England.
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Cytokines, in situ hybridisation reagents, the CAT ELISA  and the transfection reagent 
DOTAP, were purchased from Boehringer Mannheim, Hannover, Germany.
The BCA reagent for protein determination and the enzym e-labelled anti-rat antibody 
were obtained from Pierce Chem icals, Rockford, IL 61105, U SA .
Specific primers for PCR w ere made to specification by R  & D  System s, Abingdon, 
0 X 1 4  3Y S, England.
pZ523 columns and the associated PLG columns for preparation o f  D N A  were 
purchased from 5 ’—» 3 ’, Boulder, CO 80303, U SA .
Specific anti-matrilysin antibodies were kindly donated by a number o f  groups. pAb 
and mAb were from Dr Paul Cannon at Syntex Research, Palo Alto, CA 94303, U SA . 
Recombinant matrilysin w as also generously donated by Dr Cannon. 
pAt>2 and RmAb were obtained from Prof Lynn Matrisian, D ept o f  Cell B iology, 
Vanderbilt University School o f  M edicine, N ashville, TN  , U SA .
CAT-promoter and luciferase-promoter constructs as w ell as plasmids used for probe 
manufacture were all kindly donated by Prof Matrisian.
Equipment used is outlined in the relevant methods section.
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2.2 METHODS
2.2.1 PROTEIN ELECTRO PHORESIS
2.2.1.1 Polyacrylam ide Gel Electrophoresis (PAGE) (Non-Reducing)
PAG E, in the presence o f  sodium dodecyl sulphate (SD S) was performed using the 
discontinuous system  described by Laemmli (1970) using 10 % or 15 % (w /v) 
polyacrylamide gels as necessary. The 10 % [amounts for 15 % gel in brackets] 
resolving ge ls and 3 % stacking gels w ere prepared as fo llow s :
Resolving G e l : 3.3 ml [5.0 m l] 30  % (w /v) acrylamide containing 0.8 % (w /v)
bisacrylamide,
4 .0  m l [2.3 ml] distilled water,
2.5 m l [2.5 m l] 1.5 M  Tris, pH 8.8 containing 0 .4  % (w /v) SDS  
0.1 m l [0.1 ml] 10 % (w /v) SDS  
0.1 ml [0.1 ml] 10 % (w /v) ammonium persulphate and 
0.005 m l [0.005 ml] TEM ED.
Stacking G e l : 1.4 m l distilled water,
0.33 m l 30 % acrylamide solution
0.25 ml 0 .5  M  Tris, pH 6.8 containing 0 .4  % (w /v) SDS,
0 .02  m l 10 % SD S,
0.02 ml 10% ammonium persulphate and 
0.002  m l TEM ED.
Samples were dissolved in solublisation buffer (2 % (w /v) SDS; 0 .08 M  Tris, pH  6.8; 
10 % (w /v) glycerol; 0 .2  % (w /v) Coom assie Brilliant B lue). The gel was
electrophoresed in electrode buffer, pH 8.3 containing Tris (0 .025 M ), glycine (0.192
M) and 0.1 % (w /v) SDS at 30  m A using an A tto vertical mini-electrophoresis system  
until the blue dye reached the bottom o f  the gel.
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2.2.1.2 Staining with Coomassie Brilliant Blue
Gels were stained for 30 mins in 0.5  % (w /v) C oom assie Brilliant Blue in acetic acid : 
water : methanol (1 : 10 : 8, v /v /v), and destained overnight in the same solvent system.
2.2.1.3 Silver Staining
For silver staining, the gel w as fixed overnight by gentle shaking in a solution o f  
e th a n o l: acetic acid : water (30 : 10 : 60 v/v/v). It w as then incubated for 60 mins at 
room temperature in a solution o f  30 % ethanol (v/v), with the solution being replaced 
with fresh 30 % ethanol after 30 mins. The gel w as washed three times for 10 mins 
each wash by gentle shaking in distilled water. The water w as replaced with a freshly 
prepared solution o f  0.1 % (w /v) silver nitrate and the gel left shaking for 30 mins. 
After a brief wash in distilled water (20 secs), the gel w as developed by gentle agitation 
in a freshly prepared solution o f  2.5  % (w /v) sodium carbonate containing 0 .02 % (v/v) 
formaldehyde. W hen the desired contrast w as obtained, the reaction was quenched by 
adding a 1 % (v/v) acetic acid solution and follow ed by repeated washing in distilled 
water.
2.2.2 WESTERN BLOTTING
Following electrophoresis as outlined above, the gel w as soaked for 30 mins in cold  
(4°C) transfer buffer ( 0 .25 M  Tris, pH 8.3; 0 .192 M glycine plus 20 % (v/v) methanol). 
A  sheet o f  nitrocellulose cut to the same size as the gel and eight sheets o f Whatman 
filter paper were also soaked in the transfer buffer. The proteins were transferred from  
the gel to the nitrocellulose using a Bio-Rad semi-dry Blotter for 42 mins at 15 Volts. 
After transfer, the blot (nitrocellulose) was blocked for 1 hr in blocking solution [2.5 % 
(w /v) dried milk dissolved in Tris Buffered Saline plus Tw een [TBST] (10 mM Tris- 
HC1, pH 8.0; 150 mM  NaCl; plus 0.05%  (v/v) Tw een 20)] and then incubated 
overnight at 4°C with primary antibody at a suitable dilution (usually 1 : 1000) in 
blocking solution. The follow ing day, blots were washed three times for 10 mins each 
with TBST and then incubated for 3 hours gently shaking at room  temperature with a 
suitable enzyme-labelled secondary antibody diluted according to the manufacturer’s
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recommendation in T BST. Follow ing 3 x 10 min washes, the blots were developed  
without shaking at room  temperature with the appropriate substrate solution. For 
alkaline phosphatase (AP)-labelled antibodies, this w as BCIP (175 |ig /m l) and N B T  
(500 (ig/ml) in AP buffer (0 .1M  Tris, pH 9.5; 0.1 M  NaCl; 5 mM  M gCl2). For 
horseradish peroxidase (HRP)-labelled antibodies, the substrate diaminobenzidine 
(D A B ) was prepared by dissolving one 5 m g D A B  tablet in 15 ml TBS and adding 
fresh hydrogen peroxide to a final concentration o f  0 .0 2 4  %. (v/v).
2.2.3 ANTIBODY PURIFICATION
2.2.3.1 Ammonium sulphate precipitation
Rabbit antiserum w as diluted to a final protein concentration o f  3 % (w /v) as 
determined by BC A  protein m icroassay (section 2 .2 .7) and cooled  to 4°C. The pH was 
adjusted to 7 .4  with 1 M  NaO H . An equal volum e o f  cold 100 % (w /v) saturated 
ammonium sulphate solution (SA S) was added dropwise with stirring to the serum and 
the mixture left stirring continuously at 4°C for 1 hr. The suspension w as then 
centrifuged in an Hereaus M egafuge at 3000 rpm for 15 mins. The precipitate was 
washed twice with 40 % (w /v) SAS and, follow ing centrifugation, the pellet was 
solubilised in a minimum volum e o f  0 .15 M phosphate buffered saline (PB S), pH  7.4. 
To remove the salt, this solution w as dialysed for 24  hrs at 4°C against 0 .15  M PB S, 
pH 7.4 with repeated changes o f  buffer to ensure efficient dialysis.
2.2.3.2 Affinity Chromatography
2.2.3.2.1 Preparation o f  M AP affinity colum n
0.7 g o f  CNBr-activated sepharose was suspended in 10 ml 0.001 M HC1 and washed  
through a sintered glass funnel where it was then continuously washed for 10 mins with 
a total o f  200 ml 0.001 M HC1. This was follow ed by washing with 8 ml o f coupling  
buffer (0.1 M NaHCOs; 0 .5  M NaCl, pH 8.3). 15 m g o f matrilysin peptide (M AP  
peptide) was dissolved in 5 m l o f  the coupling buffer and placed in a universal container 
along with the washed gel. The mixture was left gently mixing on a shaking platform  
for 2 hrs at room temperature. The gel was then returned to a sintered glass funnel and
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washed with 20 ml coupling buffer before being returned to a universal container 
containing 10 ml blocking buffer (0.2 M glycine in coupling buffer, pH 8.0) and left 
shaking for 1 hr at room  temperature. To rem ove non-covalently bound protein, the 
gel was returned to the sintered glass funnel and w ashed with three cycles o f  alternating 
pH  consisting o f  30 m l 0.1 M  acetate buffer, pH  4.5  containing 0.5  M  NaCl, and 30  ml 
0.1 M  Tris buffer, pH  8.5 containing 0.5 M  NaCl. The gel was suspended in 0 .0 2  M  
PB S, pH 7 .4  and used to pour a column into a 2  cm  x  5 cm2 glass chromatography 
column. A  layer o f  0 .0 2  M  PBS w as added to prevent the gel from drying out.
2.2 .3 .2 .2  U se o f  M AP affinity column
The column was first washed with 30 ml 0 .02M  PB S, pH  7 .4  to remove any protein 
that may have leached off. 2 ml fractions were collected  and the absorbance measured 
at 280 nm [Shimadzu U V /V is Spectrophotometer] to ensure it was less than 0 .003  
absorbance units before applying the sample. 1 ml o f  the dialysed ammonium sulphate 
precipitate w as added slow ly to the column follow ed by washing with 0 .02  M  PBS to  
elute unbound material from the column. 1 ml fractions were collected and monitored  
for the presence o f  protein using U V  spectrophotometry (280  nm wavelength). The 
washing process w as continued until the absorbance fell below  0.003 absorbance units 
signifying no protein in the fractions. The wash buffer w as allowed to run into the top 
o f the gel and dissociating buffer (0.1 M  glycine-H Cl, pH 2.5) was added. 1 ml 
fractions were collected in eppendorfs containing 100 |i l  o f  0.1 M  Trizma, pH  9.5 - 
this was to counteract the denaturing effects o f  the low  pH. The fractions containing 
protein (monitored by B C A  microassay - section 2 .2 .7 ) were pooled and dialysed for 
24 hrs against 0 .02  M  PB S, pH  7 .4  before concentration by reverse osm osis on a 
sucrose bed. The colum n w as regenerated by washing with 20 ml each o f  (1) 0.1 M  
Tris, pH 8.0 , (2) 0.1 M  sodium  acetate, pH 4 .0  and (3) 0 .02  M  PBS, pH  7.4.
The above process was repeated until all o f  the ammonium sulphate precipitate had 
been passed through the affinity column. After the final regeneration, the colum n was 
stored for re-use at 4°C in 0 .02  M PBS containing 0 .02  % (w /v) sodium azide as 
preservative.
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2.2.4 ENZYME-LABELLING OF ANTIBODIES
2.2.4.1 HRP-Iabelling using the periodate method
5 mg purified IgG was dialysed overnight against 0.1 M sodium carbonate buffer, pH
9.2. The volum e was reduced, follow ing dialysis, to approximately 0 .4  ml by reverse 
osm osis on a sucrose bed. A  1.7 m g quantity o f  HRP w as dissolved in 170 (J.1 0.1 M  
sodium carbonate buffer, pH  8.3 in a reactivial. To this w as added an equal volum e o f  
0.1 M  sodium carbonate buffer, pH 8.5 containing 8 m M  sodium periodate and the 
mixture left for 15 mins at room  temperature in the dark. The 0 .4  ml IgG in sodium  
carbonate buffer, pH 9 .2  w as then added to the activated HRP along with 0 .13  g 
Sephadex G -25 beads and the mixture incubated for 3 hrs at room  temperature in the 
dark. The conjugate w as eluted from the reaction mixture by centrifugation at 2000  
rpm for 5 mins. To stabilise the conjugate, 40  (J.1 o f  0.1 M  NaOH containing 5 % (w /v) 
sodium borohydride was added to the supematent and this reaction mixture incubated 
for 30 mins at room  temperature in the dark, after which another 40 |il o f  the sodium  
borohydride solution w as added. The mixture was then incubated at 4°C for 1 hr. The 
conjugate was separated from unreacted HRP by ammonium sulphate precipitation as 
described in section 2 .2 .3 .1 . The final pellet was resuspended in 500 (il 0 .15M  PBS, 
pH 7 .4  and dialysed for 24  hrs against 0 .15  M PBS, pH 7 .4  with frequent changes o f  
buffer. Following dialysis, the conjugate w as aliquoted into 50 |il amounts and stored  
at 4°C.
2.2.4.2 Alkaline phosphatase labelling using one-step glutaraldehyde method
1 mg o f  IgG in a volum e o f  2.5 mis w as dialysed against a large excess o f  0.1 M  
phosphate buffer, pH 7 .4  at 4°C for 24  hrs. The IgG was then placed in a small glass 
bottle on a magnetic stirrer. T o this w as added 10 m g alkaline phosphatase dissolved  
in 1.5 ml 0.1 M phosphate buffer. 10 % (v/v) aqueous glutaraldehyde solution was 
added dropwise with constant stirring to a final concentration o f  0.2 % (v/v) and the 
mixture was left gently stirring at room  temperature for 2 hrs. To saturate unreacted 
groups, 200 (il o f  0.1 M lysine solution in 0.1 M phosphate buffer, pH 7 .4  was added 
and again the mixture left stirring at room  temperature for 2 hrs. The conjugate was
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separated from free enzym e by passage through an A cA 44  U ltrogel size exclusion  
column equilibrated in 0 .15  M PB S, pH  7.4. The conjugate which was eluted in the 
void volum e, was dialysed overnight against 0 .15 M PB S, pH 7 .4 , concentrated by 
reverse osm osis on a sucrose bed, and aliquoted into 50  |il amounts prior to storing at 
4°C.
2.2.5 BIACORE ANALYSIS
This procedure was performed on the Pharmacia BIA core System  2000  biosensor.
The monoclonal antibody (mAb) w as dialysed into 10 m M  sodium acetate buffer, pH
5.5 at a concentration o f  200  |ig/m l. It was then filtered through a 0.45 (im filter 
before being immobilised onto the surface o f  the gold  sensor chip. 35 |i l  o f  
recombinant matrilysin (rPump) or bovine serum albumin (B SA ) at a concentration o f  
100 Jig/ml in 0 .15  M P B S, pH 7 .4  was then passed over the immobilised antibody at a 
flowrate o f  5 jil/min and the response measured. After washing with 0.15 M  PBS, pH
7.4 , the purified polyclonal antibody or m onoclonal antibody at a concentration o f  200  
(ig/ml w as passed over the antibody-matrilysin com plex at the same flowrate and the 
response measured. The immobilised antibody surface w as regenerated by washing 
through the system  with 10 m M  HC1.
2.2.6 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAs)
2.2.6.1 Direct ELISA for purification analysis
The success o f  the purification m ethods was analysed using a direct ELISA system. 
100 (0.1 o f  recombinant matrilysin at a concentration o f  500 ng/ml in carbonate buffer, 
pH 9.6  (0.01 M sodium carbonate, 0 .035  M sodium hydrogen carbonate) was added to  
each well o f  ten columns o f  a 96-w ell ELISA plate. The last tw o columns were 
controls and these were coated with 3 % (w /v) B SA  in the same buffer. The plate was 
then covered and incubated at 37°C for 2  hrs. Follow ing washing the plate five times 
with PBST (0.15 M PBS, pH 7 .4  containing 0.05 % (v/v) T w een-20) and once with
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0.15 M PB S, pH  7.4 , to each well o f  the plate w as added 200 (0,1 blocking solution (3 
% (w /v) B SA  in PB ST ) and the plate incubated at 37°C for 1 hr. The plate w as then 
washed three times with PBST, inverted and shaken dry. Anti-serum, ammonium  
sulphate precipitate and affinity-purified antibody were diluted in PBS and 100 |tl 
added to appropriate wells. The plate w as incubated at 37°C for 2 hrs. Control wells 
containing no antibody, just PB S, were also included. The plate was washed 5 times 
with PB ST  and once with PBS. Commercial HRP-labelled anti-rabbit antibody was 
diluted to 1 : 3000  in PBST and 100 (J.1 o f  this w as added to each well. The plate was 
then re-covered and incubated at 37° for 30 mins follow ing which, it w as again washed  
5 times with P B ST  and once with PB S. 100 |i l  o f  the substrate for the enzym e (0.01 g
o-pheylenediam ine [OPDA] diluted in 25 m l o f  0 .2  M  citrate buffer, pH 5 .0  plus 5 (ll o f  
30 % (v/v) H2O2) w as added to each w ell and the plate incubated at 37°C for 30  mins. 
The absorbance o f  each well was read at 405 nm using a Titertek Twinreader Plus 
microtitre plate reader.
2.2.6.2 Direct ELISA for analysis of enzyme conjugates
A 96-w ell ELISA plate was coated with 0 .5  |!g/m l recombinant matrilysin prepared in 
carbonate buffer and blocked with B SA  as described in section 2 .2 .6 .1 . Dilutions o f  
the HRP-labelled antibodies were prepared in PBS and 100 |i l  o f  these added to 
appropriate w ells. Follow ing incubation at 37°C for 1 hr and washing 5 times with 
PBST and once with PB S, 100 |i l  o f  the substrate OPDA (prepared as described in 
section 2 .2 .6 .1) w as added to each well. The plate w as then incubated at 37°C for 30  
mins and the absorbances read at 405 nm.
2.2.6.3 Two-step sandwich ELISA
The w ells o f a 9 6 -w ell ELISA plate were coated with 100 p,l o f the m onoclonal anti- 
matrilysin (mAb) at its optimal dilution in carbonate buffer, pH 9 .6  and the plate 
incubated at 37°C for 2 hrs. Follow ing washing 5 times with PB ST  and once with 
PBS, the plate w as blocked by the addition o f  200 (xl o f  3 % (w /v) B SA  in PB ST  and 
incubated at 37°C for 1 hr. Dilutions o f  the standard recombinant matrilysin were then
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added to duplicate w ells (100 |il/w ell) and the plate incubated for 1.5 hrs at 37°C. The 
plate was again washed 5 times with PBST and once with PBS after which 100 |i l  o f  
the HRP-labelled polyclonal anti-matrilysin antibody (HRP-pAt>2) prepared in PBST at 
its optimal working dilution w as added to each well and the plate incubated for 1 hr at 
37°C. The plate w as washed as before and then 100 (il o f  the substrate solution  
(OPDA prepared as described in section 2 .2 .6 .1) w as added to each well. Following  
incubation at 37°C for 30 mins, the reaction was stopped by the addition o f  30 (il o f  2 
M HC1 to each w ell and the absorbances read at 492  nm.
2.2.6.4 One-step mAb / HRP-pAb2 sandwich ELISA
The wells o f  a 96-w ell ELISA  plate were coated with 100 |il o f  mAb prepared at its 
optimal working dilution in carbonate buffer and blocked with B SA  as described in 
section 2.2 .6 .3 . Follow ing washing (5 times with PBST plus once with PBS), 
dilutions o f  standard recombinant matrilysin or test samples (100  (ll/well) plus 50 |il o f  
the HRP-pAt>2 prepared in PBST at its optimal working dilution were added to 
duplicate w ells and the plate incubated for 1.5 hrs at 37°C. The plate was then washed  
5 times with PB ST  and once with PBS prior to addition o f  100 p.1 o f  the substrate 
(OPDA in citrate buffer as described in section 2 .2 .6 .1 ) and further incubation for 30  
mins at 37°C. The reaction w as stopped by the addition o f 30 |i l  2 M HC1 per w ell and 
the absorbances read at 492 nm.
22.6.5 One-step mAb / RmAb sandwich ELISA
The w ells o f  a 96 -w ell ELISA plate were coated with 100 |il m Ab diluted to its optimal 
working concentration in carbonate buffer, pH 9.6 and the plate incubated for 2 hrs at 
37°C. The plate w as w ashed three times with PBST before being blocked by the 
addition o f 200 |al o f  2 % (w /v) B SA  prepared in PB ST  to every w ell and the 
incubation o f  the plate for another 2 hrs at 37°C. D ilutions o f standard recombinant 
matrilysin or test sam ples prepared in cell culture m edium  without serum (DM EM  S0) 
were added to duplicate w ells (100 (ll/well) as w ell as 100 jj.1 o f  the rat m onclonal anti- 
matrilysin antibody diluted in PBST to its optimal working dilution. The plate was
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returned to the 37°C incubator for a further 1.5 hrs before being washed 5 tim es with  
PBST and once with PBS. 100 p.1 o f  the com m ercial HRP-labelled anti-rat antibody 
diluted to its working concentration in PB ST  w as then added to each w ell and the plate 
incubated for 45 m ins at 37°C. The plate w as w ashed as before and 100 fil o f  the 
appropriate substrate for the enzym e (O PD A  in citrate buffer as described in section  
2.2.6 .1) w as added to each w ell and the plate incubated for a final 30 m ins at 37°C.
The colour reaction was stopped by the addition o f  30  p.12 M HC1 to each w ell and 
the absorbances read at 492  nm.
2.2.7 BCA PROTEIN MICROASSAY
In this assay, Cu++ reacts with the protein under alkaline conditions to give Cu+, which 
in turn reacts with BCA to give a coloured product. T w o separate reagents are 
supplied in the commercially available assay kit : A , an alkaline bicarbonate solution  
and B, a copper sulphate solution. W orking solution is prepared by mixing 1 part 
reagent B with 50 parts reagent A. 2 00  |i l  o f  this working solution w as added to 10 fil 
test sample or protein standard in w ells o f  a microtitre plate. The plate was gently 
shaken to ensure thorough mixing and incubated at 37°C for 30 mins. The absorbance 
o f  each w ell was read at 5 60  nm using a Titertek Twinreader Plus microtitre plate 
reader. Protein concentrations were determined from a standard curve in the range 0  - 
1 mg/ml.
2.2.8 DNA PREPARATION METHODS
2.2.8.1 Preparation of competent cells
Using a sterile inoculating loop, Escherischia coli D H 5 a  were scraped from a frozen 
stock and inoculated into 5 m l o f  sterile SEB m edium  (1 % (w /v) tryptone; 0.5  % (w/v) 
yeast extract; 1 % (w /v) NaCl; 10 mM  M gC^; 10 raM MgSO<t). This culture was 
grown overnight with agitation (200  rpm) at 37°C. The following day, 1 ml o f  the 
D H 5 a  culture was inoculated into 100 ml o f  fresh, sterile SEB medium and the culture 
grown at 37°C at 200  rpm until the O .D . at 550 nm had reached 0 .6  ( 2 - 3  hrs). The
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culture was then centrifuged at 2500 rpm for 12 mins at 4°C. The pellet was 
resuspended in 33 ml o f  FSB , pH  6.4 (10 mM  CH3COOK, 100 mM  KC1, 45 mM  
MnCl2.4H20 ,  10 mM CaCl2.2H20 ,  3 mM H AC0CI3, 10 % (v/v) glycerol). The 
resuspended pellet was left on ice  for 10 mins and then centrifuged at 2500  rpm for 10 
mins at 4°C. The pellet w as resuspended in 8 ml o f  cold (4°C) FSB. D M SO  was then 
added dropwise until it reached a final concentration o f  3.5 % (v/v). The mixture was 
left for 10 mins at 4°C after which the same quantity o f  D M SO  was again added. The 
cells were quickly aliquoted into 200 |i l  amounts in pre-chilled eppendorfs and flash- 
frozen in liquid nitrogen prior to storage at -80°C.
2.2.8.2 Transformation of competent cells
10 ng o f  the required D N A  was placed in a sterile microfuge tube. To this was added 
100 |i l  o f the com petent cells which had been briefly thawed between the fingers. The 
tube was swirled gently and placed on ice  for 30 mins. The cells were then heat- 
shocked by placing the tube in a waterbath at 42°C for 90 secs after which they were 
returned to ice for 2 mins. 1 ml o f  sterile LB medium, pH 7.5 (1 % (w /v) tryptone; 0.5  
% (w /v) yeast extract; 1 % (w /v) NaCl) w as added to the tube and the cells incubated 
at 37°C for 1 hr with gentle agitation (200 rpm). The cells were centrifuged at 6000  
rpm for 1 min in an Hereaus M icrofuge and the supematent removed. The pellet was 
gently resuspended in 0 .2  ml LB medium and then plated out on LB agar plus 
ampicillin (LB medium containing 1.5 % (w /v) agar and, after sterilising, 35 (ig/ml 
ampicillin) plates which were incubated overnight at 37°C in an inverted position.
2.2.8.3 Minipreparation of plasmid DNA
Single colonies o f  bacteria from the transformed cells grown on the LB ampicillin 
plates were selected and each placed into sterile universal containers containing LB 
medium supplemented with 35 (ig/ml ampicillin. These minicultures were grown  
overnight at 37°C and 150 rpm. The follow ing day, 1.5 mis o f  each o f  the growing 
cultures were transferred to sterile microfuge tubes and centrifuged at 10000 rpm for 1 
min after which the supernatents were aspirated. The pellets were resuspended in 100 
jj.1 o f  solution 1 (50 mM  glucose, 25 mM  Tris-HCl, pH 8.0; 10 mM ED TA , pH 8.0)
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and vortexed. 200 (il o f  solution 2 (0 .2  M NaOH; 1% (w /v) SD S) was added to each 
tube and the tubes mixed by gentle inversion after which 150 (il cold (4°C) solution 3 
(3 M potassium  acetate, pH 4.8) w as added and the tubes were placed on ice for 5 
mins. The tubes were then centrifuged for 5 mins at 10000 rpm after which the 
supernatents were carefully transferred to fresh microfuge tubes and the pellets 
discarded. 4 5 0  (il o f  phenol : chloroform : 2 M  Trizma ( 1 : 1 : 1 ,  v/v/v) was then 
added to each tube and the mixtures vortexed and then centrifuged at 10000 rpm for 2 
mins. The upper layer in each tube was carefully transferred into a fresh tube and 1 ml 
o f  100 % ethanol added to it. The tubes were placed at -80°C for 5 mins to help 
precipitate the D N A . The suspensions were then centrifuged at 12000 rpm for 10 mins 
and the supernatents removed. 2 50  (il o f  0.3 M  sodium acetate was added to the 
resultant pellets and m ixed. 500 (il o f  100 % ethanol w as added and the mixtures let sit 
at room  temperature for 10 minutes prior to being centrifuged at 10000 rpm for 10 
mins. Again the supernatents were rem oved and the pellets tw ice washed with 70  % 
(v/v) ethanol and then dried at 37°C before being resuspended in 25 (il TE, pH 8.0 (10  
mM  Tris-HCl; 1 mM  ED TA ) and stored at 4°C until ready to digest.
2.2.8.4 Maxipreparation of plasmid DNA
Once it had been established by restriction digests (see section 2 .2 .8 .6  below) that 
transformed bacteria did contain the correct plasmids, 500 ml LB medium  
supplemented with ampicillin (35 (ig/m l) was inoculated with a 5 ml miniculture 
prepared as for the minipreparation procedure (section 2.2.8.3) and the culture grown  
overnight at 37°C and 200  rpm. The procedure used to isolate the plasmid D N A  was a 
modification o f  the alkaline lysis method and utilised pZ523 spin columns for final 
purification o f  the plasmid D N A .
The bacterial cells were pelleted from the 500 ml culture by centrifugation at 10000  
rpm for 5 minutes at 4°C. The pellet was resuspended in 15 ml solution A (25 mM 
Tris-HCl; 10 mM  ED TA , pH 8.0) and vortexed until fully in solution. 15 ml o f  
solution B ( 0 .2  M NaOH, 1% (w /v) SD S) was added and mixed by gentle swirling 
until the lysate appeared essentially uniform and translucent. To this was then added 
15 ml ice-cold  solution C (7.5M  ammonium acetate) and the mixture thoroughly mixed
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by gentle inversion. The suspension w as then centrifuged at 10000 rpm for 30 mins at 
4°C to pellet the protein precipitate. The supematent w as carefully transferred to a 
fresh centrifuge tube and room  temperature isopropanol added to a final concentration  
(v/v) o f  0 .6X . This was carefully m ixed by gentle inversion and centrifuged at 10000  
rpm for 30 mins at 20°C and the resultant supem atent discarded. 12 ml o f  70  % (v/v) 
ethanol w as added to the pellet and the suspension briefly centrifuged for 1 - 2 mins at 
10000 rpm to re-pellet the D N A . The supem atent was discarded and the pellet washed  
with 12 ml o f  95 % (v/v) ethanol. After carefully aspirating the supematent, the pellet 
was left to dry at 37°C for approximately 15 mins. The pellet w as then dissolved in 1.5 
ml o f  TE containing RNase A  at a final concentration o f  50  (ig/m l and transferred to a 
PLG tube (provided with the pZ523 colum ns) prior to being incubated in a 37°C  
waterbath for 15 mins. The sample w as extracted with 2 ml o f  phenol : chloroform : 
isoamyl alcohol (12.5 : 12 : 0 .5 , v /v /v) and centrifuged at 1500 rpm for 2 mins. The 
phenol : chloroform : isoamyl alcohol extraction and centrifugation w as repeated after 
which the sample was extracted with chloroform  : isoamyl alcohol (24 : 1, v/v). 
Following a further spin at 1500 rpm for 2 mins, 360 [il 5  M  NaCl was added to the 
aqueous phase and the total sample volum e adjusted to 1.8 ml with TE prior to loading 
onto the pZ523 spin column. The colum n w as centrifuged in a swinging bucket rotor 
for 12 mins at 1100 rpm. The plasmid D N A  was precipitated from the column eluant 
by addition o f  1.2 ml room temperature 100 % isopropanol and centrifuging at 10000 
rpm for 20  mins at 20°C. The pellet w as washed 4  times with 4  ml o f  70% (v/v) 
ethanol and then once with 95 % (v/v) ethanol prior to being dried briefly at 37°C. 
Finally, the plasmid D N A  was resuspended in 300ftl TE and stored at 4°C.
2.2.S.5 Spectrophotometric analysis of nucleic acids
D N A  or R N A  concentration was determined by measuring the absorbance at 260 nm, 
the wavelength at which nucleic acids absorb maximally (A™«). A  50 (ig/ml 
preparation o f  pure D N A  has an absorbance o f  1 unit at 260 nm w hile 40  [ig/ml o f  pure 
R NA also has an absorbance reading o f  1 at this wavelength. The purity o f  an RNA or 
D N A  preparation was determined by reading absorbances at 260 nm, the ?wnax for 
nucleic acids, and at 280 nm, the A^ ax for proteins and obtaining the ratio o f  these
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absorbances. Pure D N A  with no protein contamination has an Abs26o /  Abs28o ratio o f
1.8 while for pure R NA, the ratio is 2.0. Low er ratios indicate the presence o f  protein 
w hile higher ratios often indicate residues o f  organic reagents.
2.2.8.6 Restriction digests
D N A  was digested with restriction endonucleases for identification purposes or for 
linearizing prior to probe manufacture. For mini-preparation D N A , the digest mixture 
contained 5 (il D N A , 2 .5 |il o f  the lOx reaction buffer (supplied with the enzyme by the 
manufacturer), 16.5 (il o f  a 25 [ig/m l solution o f  RNase A  and 1 (il (15 - 20  units, 
approximately) o f  the appropriate restriction enzyme. For maxipreparation D N A , 1 (ig 
o f  D N A  w as prepared in a reaction solution containing lOx reaction buffer and 1 p.1 
restriction enzym e. The digests were incubated at the appropriate temperature for the 
enzym e (usually 37°C) in a water bath for at least tw o hours.
2.2.8.7 Agarose gel electrophoresis
An agarose gel w as prepared by boiling the appropriate quantity o f  agarose in 100 ml 
o f  0 .5X  TBE buffer, pH 8.2 (0 .04  M Tris; 0 .02  M boric acid; 1 mM ED TA ). The 
percentage gel used depended on the sizes o f  D N A  being visualised with a lower 
percentage (0 .6  - 1.2 % (w /v)) being used for visualising large sized D N A  (e.g. over 2 
kb) and higher percentage gels (2 - 3 % (w /v)) reserved for small D N A  fragments (e.g. 
200 - 500 bp). Once cooled  to approximately 60°C, the gel was cast into the Hybaid 
Horizontal G el Electrophoresis system.
Samples for electrophoresis were prepared by mixing them with a suitable quantity o f  
6X  gel loading buffer (40 % (w /v) sucrose; 0 .25 % (w /v) bromophenol blue). 
Typically 12.5 [i.1 o f  the digest mixtures were mixed with 2.5 |i l  o f  the loading buffer 
and the samples loaded into the wells o f  the set gel. The gel was run at 120 V in 0 .5X  
TBE. The electrophoresis w as com pleted when the blue loading dye had run to within 
0.5 cm o f the bottom  o f  the gel. The gel was then stained by submersion in a solution 
o f  0.5  p.g/ml ethidium bromide for 20 mins, briefly rinsed in distilled water and 
visualised by placing on a U V  transilluminator.
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2.2.9 CELL CULTURE M ETHODS
All cell culture techniques were performed in a sterile environment using a Holten  
laminar air flow  cabinet. Cells were visualised with an Olympus CK2 inverted phase 
contrast m icroscope.
2.2.9.1 Culture of adherent cells
SW 480, SW 620, W iDR, L oV o, A 549, EJ and M CF-7 cells were maintained in 
D ulbecco’s modification o f  E agle’s medium (DM EM ) supplemented with 5 % (v/v) 
foetal calf serum (FCS) [DM EM  S5], 2 mM  L-glutamine, 1 mM  H EPES, penicillin (1 
unit/ml) and streptomycin (1 (ig/m l). All cultures were seeded into 25 cm2 and 75 cm2 
tissue culture flasks. A s these were all strongly adherent cells, trypsinisation was 
required for harvesting prior to sub-culturing. For trypsinisation, the growth medium  
was decanted and the flask rinsed with 2 mis o f  trypsin-EDTA (0.025 % (w /v) trypsin 
with 0 .02  % (w /v) ED TA  in 0 .15 M PB S, pH 7.4) to rem ove any residual FCS which 
contains a trypsin-inhibitory activity ((X2-macroglobulin). 2 ml o f  fresh trypsin-EDTA  
was then placed in each flask and the flask incubated at 37°C for 5 - 10 mins or until all 
the cells could be visualised as having detached from the flask. The cell suspension was 
decanted into a sterile universal container containing 5 ml D M EM  S5 and centrifuged at 
2000 rpm for 4  mins. Cells were resuspended in culture medium at 2  x 10s - 1 x  106 
cells/ml, using 20 ml o f  medium per 75 cm2 culture flask and 10 ml per 25 cm2 flask. 
All cell lines were incubated in a humid, 5 % (v/v) C 02 atmosphere at 37°C in an 
Heraeus cell culture incubator.
2.2.9.2 Culture of cells in suspension
K 562 cells were maintained in D M EM  supplemented with 10 % (v/v) FCS, 2 mM  L- 
glutamine, 1 mM HEPES, 1 unit/ml penicillin and 1 |ig /m l streptomycin. Cultures were
5 6 2seeded at densities o f 2 x l 0  - 1 x 1 0  cells/m l, using 20 ml per 75 cm flask. Cells 
were incubated in culture flasks until approximately 90  % confluent. They were then 
harvested by flusing them with medium from the culture flask surface using a sterile 
pasteur pipette. After centrifuging at 800 rpm for 5 mins, the cell pellet was
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resuspended in an appropriate amount o f  medium and placed into flasks. The cells 
were incubated in a humid 5 % C 0 2 atmosphere at 37°C.
2.2.9.3 Cell counts
Cell counts were performed using an improved Neubauer haemocytometer slide. 
Trypan blue exclusion dye w as routinely used to determine cell viabilities. T o 100 [il 
cell suspension was added 20 fil trypan blue, and the mixture left to incubate for tw o  
mins. A  sample o f  this mixture was added to the counting chamber o f  the 
haematocytometer and the cells visualised by light m icroscopy. Viable cells excluded  
the dye and remained clear w hile dead cells stained blue.
2.2.9.4 Storage and recovery of cells
Cells required for long term storage were frozen in liquid nitrogen and maintained in a 
cryofreezer (Cooper Cryoservice Ltd.). After centrifuging, the cell pellet was 
resuspended at a concentration o f  1 x 106 cells/m l in FCS containing the 
cryopreservative D M SO  at a final concentration o f  5 % (v/v). 1 ml aliquots were  
transferred to sterile cryotubes, lowered slowly into the gas phase and eventually 
immersed in the liquid nitrogen.
Cells were recovered from liquid nitrogen by thawing rapidly at 37°C and transferring 
to a sterile universal tube containing 5 ml D M EM  S5. The cells were centrifuged at 
2000 rpm for 4  mins resuspended in fresh medium, transferred to culture flasks and 
incubated at 37°C in 5% C 0 2.
2.2.9.5 Mycoplasma detection
Cells were screened periodically for contamination by m ycoplasma using an indicator 
cell line (normal rat kidney - NRK) and the DNA-intercalating agent bisbenzimid 
(H oechst 33258). A vial o f  mycoplasma-free NRK cells was grown in antibiotic-free 
medium at 37°C in 5 % C 0 2 for at least 3 passages. Cells were removed from flasks 
by trypsinisation (as described in section 2 .2 .9 .1) and resuspended at a concentration o f  
1 x 104 cells/ml in antibiotic-free DM EM  S5. 1 ml aliquots o f  this suspension were  
grown overnight at 37°C on sterile coverslips placed in petri dishes. The following day,
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2 ml o f  culture medium from the cell line to be screened w as added to the coverslips 
and the NRK  cells returned to the incubator and grown for 2 further days. After 
incubation, the coverslips w ere rem oved and washed 3 times in 0 .15 M PB S, pH  7.4. 
The cells were then fixed for 6 mins in a 1 : 1 (v/v) mixture o f  m eth an ol: acetone at - 
20°C. The cells were again washed tw ice in PBS and stained with H oechst 33258  
prepared at a concentration o f  0 .05 (ig/ml in P B S, for 10 mins. The coverslips were 
then washed 3 times with PB S, dried and mounted on slides. The cells were examined  
under a fluorescent m icroscope (Leitz Labrolux m icroscope) using a lOOx oil 
immersion lens. Uncontam inated cells exhibited strong fluorescence in the nucleus 
only, while contaminated cells also had fluorescence distributed throughout the 
cytoplasm.
2.2.9.6 Cytokine and TPA treatment of cells in culture
Cell lines were routinely cultured for at least 2  passages prior to cytokine or TPA  
treatment. For cytokine experiments, cells were cultured until approximately 80 % 
confluent after which the growth medium was decanted and the cells rinsed with sterile 
0.15 M  PBS, pH 7.4. 8 ml o f  fresh serum-free D M EM  was then added to each 75 cm2 
flask (4 ml to each 25 cm2 flask and 1 ml to each 35 mm  well o f  a 6 well plate). The 
cells were returned to the incubator overnight. The follow ing day flasks were  
supplemented with one or other o f  the follow ing cytokines or TPA (final 
concentrations in brackets) : IL -lp  (25 ng/ml), IL-2 (1 unit/ml), IL-6 (100 units/ml), 
IGF-I (25 ng/ml), IGF-II (25 ng/m l), EGF (50 ng/ml), bFGF (25 ng/ml), TGF-J3 (1 
(ig/m l), EFN-y (125 ng/ml) and TPA (6 .2  ng/ml). The cells were then returned to the 
incubator for 8 hours after which the medium from each flask (‘conditioned m edium ’) 
was collected and the cells harvested for R N A  isolation (section 2 .2 .11) or transfection 
analysis (section 2 .2 .10). Conditioned medium was clarified by centrifugation at 4000  
rpm for 10 m ins and stored at -80°C for further analysis.
2.2.9.1 Calcium phosphate-mediated transfection
This method was first described by Graham and Van der Eb (1973). 24 hrs prior to 
transfection, cells were trypsinised and seeded at a density o f  3 x 106 cells per w ell o f  a
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6-w ell tissue culture plate. Various amounts o f  D N A  were aliquoted in sterile universal 
containers and the volum e adjusted to 410  fil with sterile water. 480  (il o f  2 X  HBS  
(HEPES buffered saline : 280  mM  NaCl; 50 mM  H EPES, 1.5 mM  Na2H P04), was 
aliquoted for each sample o f  D N A  into separate tubes. 60  jil o f  2.5  M  CaCh was 
added into the tube containing the D N A  with continual m ixing using a vortex mixer. 
Immediately the D N A -C aC l2 mixture was added into the 2 X  H B S, again dropwise and 
with continuous mixing using a vortex mixer. This mixture w as then left standing at 
room  temperature for exactly 30 mins after which it w as added dropwise to the cells on  
the 6-w ell plate and the plate returned to the 37°C incubator for 6 hrs. T o aid the entry 
o f  D N A  into the cells, a glycerol shock was utilised. This involved rem oving the 
medium from the cells and placing 1 ml o f  10 % (v/v) glycerol in IX  H BS in each o f  
the wells and leaving for 3 mins. The glycerol was then rem oved, the cells rinsed in 
PBS and serum-free medium and then re-fed with 2  ml fresh D M EM  Ss. The cells 
were then returned to the incubator for 48 hrs before transfection analysis (section  
2.2 .10) or the the medium w as replaced 24 hrs later with serum-free DM EM  and the 
cells treated with cytokines as in section 2.2.9.6.
2.2.9.8 DEAE-Dextran mediated transfection
Cells to be transfected were prepared as described in section 2 .2 .9 .7 . Various amounts 
o f  the plasmid D N A  (0 .25 - 3.0  |ig ) were m ixed with 10 mM Trizma-HCl, pH 7.5  
containing 0.05 % NaCl to a final volum e o f  100 (xl. This w as then mixed with an equal 
volum e o f  DEAE-dextran solution (1 mg/ml in lOmM Trizma-HCl, pH  7.5; 0 .045 % 
(w /v) NaCl). M eanwhile, growth medium was rem oved from the cells and they were 
washed tw ice with lOmM Trizma, pH 7.5 containing 0 .05 % NaCl. The D N A -D E A E  
dextran mixture was then dropped slowly into the centre o f  the cells. The cells were 
incubated for 15 mins at room  temperature before the D N A -D E A E  dextran mixture 
was carefully removed and the cells were rinsed once with the trizma solution. The 
cells were then fed normal growth medium and returned to the incubator. 
Transfections were analysed 48 hrs later (section 2.2.10).
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22.9.9  DOTAP-mediated transfections
Cells were seeded at 3 x  106 cells per 35 mm w ell o f  a 6 well tissue culture plate one 
day prior to transfection. Quantities o f  D N A  w ere diluted to a concentration o f  0.1 
(ig/ji.1 in 20 mM HEPES buffer, pH 7.5 . In separate tubes, quantities o f  the DO TAP  
reagent were diluted to a final concentration o f  0 .3  |ig / |i l  with 20 m M  HEPES. The 
D N A  and D O TA P solutions were then mixed together and left standing at room  
temperature for 15 mins. The D N A -D O T A P  mixture w as then added to 1 m l o f  serum- 
free culture medium. M eanwhile, the cells were rem oved from the plate and 
centrifuged at 800 rpm for 4  mins. Each pellet w as then gently resuspended in the 1 ml 
o f  serum-free culture medium containing the D N A -D O T A P  mixture and the cells 
returned to the plate. The plate w as returned to the incubator for 5 hrs after which the 
cells were again rem oved, centrifuged at 800 rpm for 4  mins and re-fed with 1 ml fresh 
serum-free culture medium. The cells were harvested after 48 hrs for transfection 
analysis (section 2 .2 .10) or treated with cytokines after 24  hrs (concentrations used as 
given in section 2.2 .9 .6), harvested and then analysed.
2.2.10 TRANSFECTION ANALYSIS
2.2.10.1 In situ assay of P-galactosidase
In all transfections the plasmid pC H l 10, coding for p-galactosidase, was co-transfected  
with the matrilysin promoter-containing plasmids as its presence could be easily 
detected and used as an assessm ent o f  transfection efficiency. The enzym e activity o f  
p-galactosidase can be detected in situ, on the plate, using the synthetic substrate x-gal. 
48 hrs follow ing transfection, cells were washed tw ice with 0.15 M PBS, pH 7 .4  and 
then fixed with 5 ml fix solution (0.2 % (v/v) glutaraldehyde; 0 .02 M phosphate buffer, 
pH 7.3; 0 .004  M EGTA; 0 .0 0 2  M M gCl2) for 10 mins at room  temperature. This step 
was repeated once. The cells were then washed tw ice for 10 mins each wash with 5 ml 
rinse solution (0 .0 2  M phosphate buffer, pH 7.3; 0 .002  M  MgCl2; 0.1 mg/ml sodium  
deoxycholate; 0 .2  (ll/ml N P -40) before 1 ml o f  stain solution (1 mg/ml X-gal; 1.65 
mg/ml K3Fe (C N)6 ; 1.65 m g/ml K4 F e(C N)6 in rinse solution) was added to each well 
and the plates returned to the incubator overnight. The follow ing day, the cells were
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examined under the m icroscope. Cells that stained blue produced fi-galactosidase and 
were therefore successfully transfected. Untransfected cells remained clear.
2.2.10.2 Harvesting cells after transfection
Cell lysates were prepared using the Reporter Lysis Buffer (Promega). Briefly, the 
medium w as decanted from the cells and they were rinsed tw ice with 0 .15 M PB S, pH
7.4. 250  |i l  o f the lysis reagent w as then placed on the cells for 15 mins after which the 
lysate was scraped into a microfuge tube and centrifuged at 5000 rpm for 2  mins. The 
supematents were transferred to fresh tubes and stored at -80°C until required.
2.2.10.3 Assay of [i-galactosidase in cell lysates
100 |il o f  chlorophenyl red 0 -D  galactoside (CPRG) solution (15 mg/ml CPRG  
prepared in buffer A  : 100 mM  NaH2 P 0 4, pH  7.2; 10 mM  KC1; 1 mM  M gC^) was 
placed in a microfuge tube. T o this was added 4 00  jo.1 buffer A  containing 10 mM p- 
mercaptoethanol and 25 (0.1 o f  the cell lysate prepared as described in section 2.2 .10.2 . 
Standards were prepared using a commercial stock o f  the enzyme p-galactosidase, in 
the 0.2 - 5 .0  ng/ml range and these were also assayed. All tubes were incubated 
overnight in a 37°C waterbath. Absorbances were then read at 560 nm and the 
concentration o f  active enzym e in the transfected cells determined from a standard 
curve.
2.2.10.4 CAT ELISA
The activity o f  the chloramphenicol acetyl transferase (CAT) in the matrilysin-promoter 
CAT construct-transfected cells was analysed using a commercially available CAT  
ELISA kit (Boehringer Mannheim). Cell lysates were prepared as outlined in section
2.2.10.2. CAT enzym e standards for the ELISA were prepared as suggested by the 
manufacturers in the 0 .0  - 0.91 (ig/ml range. The anti-CAT antibodies coated on the 
surface o f  the w ells o f  the ELISA plate were rehydrated using the sample buffer 
provided. 200 (il o f  each sample and standard was pipetted into appropriate w ells o f 
the plate (the samples actually contained 37.5 (il o f  lysate made up to 200 |il with 
PBS). The plate w as covered and incubated at 37°C for 1 hr after which it was washed
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5 times with washing buffer. 200 (J.1 o f  the digoxigenin-labelled anti-CAT antibody 
solution was then added to each w ell and the plate covered and again incubated for 1 hr 
at 37°C. The plate w as washed as before and 200  |i l  o f  an HRP-labelled anti- 
digoxigenin antibody solution added to each w ell. The plate was covered and 
incubated at 37°C for a further hour. Follow ing another washing step, 200  |i l  o f  the 
peroxidase substrate solution w as applied to each w ell and the plate incubated at room  
temperature for 45 mins after which the absorbance at 405  nm was measured for each 
well.
2.2.10.5 Luciferase assay
The activity o f  the enzym e luciferase in the matrilysin promoter-luciferase construct 
transfected cells was determined using the luciferase assay reagent from Prom ega and a 
Labsystems Lumiskan luminometer. 10 (il o f  each lysate was pipetted into the w ells o f  
a white luminometer 96-w ell plate and the plate placed into the luminometer to  
equilibrate to assay temperature (23°C). Immediately prior to measuring lum inescence, 
100 (il o f  the luciferase assay reagent was added to the lysate-containing w ell and the 
luminescence measured as an integral reading taken over 30 secs with a lag time o f  10 
secs to allow the machine to set up for measurement. The values obtained for 
luciferase activity were normalised using the P-galactosidase values (obtained as 
outlined in section 2 .2 .10 .3 ) to correct for differences in transfection efficiency, and 
expressed as fold increase over control levels.
2.2.11 RNA EXTRACTIONS
RNA is easily degraded by the ubiquitous RNase enzym es. These enzym es are resistant 
to autoclaving but they can be deactivated by the chemical diethylpyro-carbonate 
(DEPC) when it is added to solutions at a final concentration o f  0.1 %. Solutions 
containing amines such as Tris cannot be DEPC-treated directly as the D EPC  is 
inactivated by these chemicals. These solutions were prepared in DEPC-treated water. 
All other solutions for R N A  work were DEPC-treated and gloves and sterile plastics 
used at all times. The procedures must be carried out quickly and on ice to help prevent 
degradation o f R N A  by endogenous R Nases.
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2.2.11.1 RNA extraction from cultured cells
The cells were detached from the surface o f  the flasks by trypsinisation, if  necessary, 
and the pellets washed tw ice with cold (4°C) 0 .15  M  P B S, pH 7.4 . The final pellets 
were resuspended in 1 ml o f  ice-cold  Tris-saline, pH  7.2  (25 mM Tris; 0 .13  M  NaCl; 5 
m M  KC1) and transferred to sterile microfuge tubes. The cells were centrifuged at 
2000 rpm for 1 min and the supernatents discarded. The cells were then resuspended in 
250 ji.1 Tris-saline and an equal volum e o f  lysis buffer (Tris-saline, pH  7 .2  containing 1 
% (v/v) N P-40, 5 mg/ml sodium deoxycholate and 0.1 mg/ml dextran sulphate) added. 
The tubes were gently m ixed by inversion and centrifuged at 2000 rpm for 1 minute. 
Supernatents were then carefully transferred (without disturbing pellets) to fresh 
m icrofuge tubes containing 0 .5  ml p h e n o l: chloroform : isoamyl alcohol [PCI] (25 : 24  
: 1, v/v/v) and 25 (J.1 o f  20  % (w /v) SD S and 15 (J.1 o f  5 M NaCl added quickly to each 
tube. The tubes were vortex-m ixed for 5 secs before being centrifuged at 13000 rpm 
for 5 mins. The upper aqueous phase was carefully transferred from each tube to a 
fresh tube containing PCI and the tubes vortexed and centrifuged as in the previous 
step. This was repeated until no protein (seen as a white precipitate) was visible at the 
aqueous /  organic interphase in each tube. The extracts were then added to microfuge 
tubes containing 250  |i.l chloroform  : isoamyl alcohol (24 : 1, v /v) to rem ove any 
residual phenol and the vortex and centrifugation repeated as before. The upper 
aqueous phase in each tube was then transferred into a tube containing 1 ml 100 % 
ethanol and the tubes placed at -20°C overnight to precipitate the R N A . The 
precipitate was pelleted by centrifugation at 10000 rpm for 20 mins and the final pellet 
resuspended in 50 |il DEPC-treated water. The concentration and purity o f  the RNA  
was assessed spectrophotometrically as outlined in section 2.2 .8 .5 . Samples were also 
run on RNA gels (section 2 .2 .11 .3 ) to check R N A  integrity. The R N A  isolates were 
stored at -80°C until required.
2.2.11.2 RNA isolation from human tissue samples
A piece o f frozen tumour tissue (approximately 100 m g w et weight) w as ground in 
liquid nitrogen using a morter and pestle to obtain a fine powder. The powdered tissue
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was added to 1 ml denaturing solution ( 4  M  guanidinium thiocyanate; 25 m M  sodium  
citrate, pH 7.0; 0.5  % (w /v) N-lauroylsarcosine; 0.1 M  (3-mercaptoethanol) and mixed. 
To this w as added 0.1 ml o f  2 M  sodium acetate, pH  4 .0  and the suspension m ixed by 
inversion. 1 ml o f  water-saturated phenol follow ed by 0 .2  ml o f  chloroform : isoamyl 
alcohol (24 ; 1, v /v) were then added and the suspension thoroughly mixed. The 
mixture was then left at 4°C for 15 mins prior to being centrifuged at 9000 rpm for 20  
mins also at 4°C. The upper aqueous phase w as transferred to a fresh tube and the 
RNA precipitated by the addition o f  1 ml 100 % isopropanol and incubation at -20°C  
for 30 mins. This suspension w as centrifuged at 10000 rpm for 10 mins and the 
supematent discarded. The pellet was redissolved in 0 .3  ml o f  denaturing solution and 
again precipitated by the addition o f  0.3  ml 100 % isopropanol and incubated for 30  
mins at -20°C. This w as centrifuged at 10000 rpm for 10 mins and the pellet 
resuspended in 75 % (v/v) ethanol and vortexed. The tube w as then incubated for 15 
mins at room  temperature before being centrifuged at 10000 rpm for 5 mins. The 
supematent w as discarded and the pellet dried briefly. The pellet was then re-suspended  
in 50 f i l  DEPC-treated water and the R N A  analysed spectrophotometrically as outlined 
in section 2 .2 .8 .5 . Samples were also run on R N A  gels (2 .2 .11 .3) to check for RNA  
integrity. The R N A  isolate w as stored at -80°C until required.
2.2.11.3 RNA analysis by gel electrophoresis
To check that R N A  isolated by either method (2.2.11.1 or 2 .2 .11 .2) was intact and had 
not been degraded, samples were run on 1 % agarose gels. The gels were prepared as 
outlined in section 2.2.8.7. The RNA samples (5 (il) were prepared for electrophoresis 
by mixing with 15 |i l  sample buffer (50 % (v/v) deionized formamide; 8.3 % (v/v) 
formaldehde; 0 .027 M M OPS, pH 7.0; 6.7 mM sodium acetate; 0 .67 mM ED TA ) and 
3 (J.1 loading buffer (50 % (v/v) glycerol; 1 mM  EDTA; 0 .4  % (w /v) bromophenol blue; 
1 p.g/(il ethidium bromide) and the sample heated for 10 mins at 65°C prior to loading 
on the gel. The gel was run in 0 .5X  TBE as described in section 2.2.8 .7. As ethidium  
bromide was included in the loading buffer, there was no need for further staining and 
the gel could be visualised direcdy on a U V  transilluminator. The presence o f  2
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strongly staining bands, representing the 28 S and 18 S ribosomal subunits, signified 
intact RNA. Degradation could be seen as a smear running down the length o f  the gel.
2.2.12 REVERSE-TRANSCRIPTION PCR (RT-PCR)
The polymerase chain reaction (PCR) has emerged as a powerful tool for amplifying 
small quantities o f  D N A  for analysis. RT-PCR is a modification o f  the technique which 
allows analysis o f  small quantities o f  specific m RNA. Total R N A  is first converted to 
cD N A  using a reverse transcriptase enzym e. Specific cD N A s are then amplified in the 
PCR by inclusion o f  the appropriate primers. D etails o f  the primers used are shown in 
Table 2.2. The PCR used was semi-quantitative as a constitutively expressed gene, (3- 
actin, was always amplified in the same tube with the matrilysin or stromelysin target. 
This acted as an internal control and, by calculating ratios o f  matrilysin or stromelsyin 
to (3-actin, relative amounts o f  the targets could be determined from reaction to  
reaction.
2.2.12.1 Reverse transcription
1 |ig  o f  total RNA (prepared as outlined in sections 2 .2 .11.1 or 2 .2 .11 .2 ) was mixed  
with 0.5  |ig  o ligo  dT primers and the mixture brought to a final volum e o f  5 (ll with 
sterile water. This priming reaction was incubated at 70°C for 10 mins. To this was 
then added 4  |i l  5X  transcription buffer (supplied with the reverse transcriptase enzyme 
by the manufacturer), 2 (il 100 mM  dithiothreitol, 1 (il RNasin, 1 |i l  o f  a mix o f  dATP, 
dCTP, dGTP and dTTP each at a concentration o f  10 mM , 6 |il sterile water, and 1 (il 
o f  M oloney murine leukaemia virus reverse transcriptase (M M LV-RT). The reaction 
mixture w as incubated at 37°C for one hour before being heated to 95°C for 2 mins to 
inactivate the enzym e. The resulting cD N A  was stored at 4°C until required for PCR.
2.2.12.2 PCR
A 4 5 |il PCR mix was prepared by placing 5 fil o f  the 10X reaction buffer supplied with 
the Taq polym erase enzyme, 1 [tl each o f  dATP, dTTP, dCTP and dGTP each at a 
concentration o f  lOmM, 1 |i i  o f  each o f  the forward and reverse primers required in the
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reaction, 0 .5  (il Taq D N A  polymerase and sterile water to bring the volum e to 45 p i  
To this reaction mixture was added 5 jll o f  cD N A  prepared as in section 2 .2 .12.1 and 
the total overlaid with 50 pi mineral oil. The tube w as placed on a Hybaid 
thermocycling machine and incubated for 3 mins at 95°C follow ed by 30 cycles o f  1 
min at 95°C, 1 min at 47°C and 3 mins at 72°C. The final step w as a 7 minute 
incubation at 72°C. The PCR products were then rem oved from under the oil and 
placed in fresh tubes. 15 |il amounts were run on 2 % agarose gels as described in 
section 2 .2 .8 .7 . The gels were view ed and saved on disc using a UH P Gel 
Docum entation System. The relative intensity o f  each band was measured using a 
QUIPS im age analysis package.
Table 2.2 Primers for PCR
Target iVjoiers
■* ‘ s\\N'  s k  • \  ft-xi vivi’-y :i
Matrilysin 5’ TGT ATCC A ACCT ATGG A A ATG 3’ 
3’ CATTTATTGACATCTACGCGC 5’
341 (cDNA) Witty et al., 1994
Stromelysin-1 5’ CTTTCCAGGGATTGACTC 3’ 
3’ A AC ATA AA A ATG ACCGGC 5’
324 (cDNA) Matrisian et  al., 
1985
p-actin 5’ CAACTTCATCCACGTTCACC 3’ 
3’ GAAGAGCCAAGGACAGGTAC 5'
225 (cDNA) Takeshita et al., 
1994
The primers were chosen so that they amplified sequences specific to the particular 
gene. A lso, primers were chosen to span an intron. This meant that any amplification 
o f  genom ic rather than cD N A  w ould result in larger products than those expected.
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2.2.13 IN  SITU  HYBRIDISATION
2.2.13.1 Probe labelling
The plasmids pG7PumpEX and pG7Pump XE (shown in appendix A ) were obtained 
from Prof. Lynn Matrisian, Vanderbilt University, Nashville, Tennessee, U SA . These 
plasmids consisted o f  an 800 bp fragment o f  the matrilysin cD N A , encom passing an 
EcoRI site to XmnI site subcloned into pG em 7Z(+) in both the forward (EX) and 
reverse (XE) orientations. The pGem 7 vector has both SP6 R N A  polym erase and T7 
RNA polymerase initiation sites and, as the fragment w as subcloned between them, 
either enzym e could be used to generate both sense and anti-sense R N A  transcripts. 
For example, if  pG7PumpEX w as linearised with EcoRI, the enzym e SP6 could be 
used to generate an antisense transcript while a sense transcript could be generated 
using the T7 enzym e follow ing linearising with Hind HI.
Prior to labelling, 10 |og o f  plasmid w as linearised using either o f  the restriction 
enzymes Hind III or EcoRI ( see section 2 .2 .8 .6 ) and the digests cleaned by a p h e n o l: 
chloroform extraction. This involved adding the digest mixture to an equal volum e o f  
phenol : chloroform ( 1 : 1 ,  v /v), vortex-m ixing, and centrifuging at 10000 rpm for 5 
mins. The upper aqueous phase was transferred to a fresh tube and an equal volum e o f  
chloroform added. Again the mixture was vortexed and centrifuged at 10000 rpm for 
5 mins. The linearised D N A  was precipitated by placing the upper aqueous layer into a 
tube with 2.5  volum es o f  100 % ethanol and 0.5 volum e 7.5  M  ammonium acetate and 
the tube placed at -80°C for 2 hrs. The precipitated D N A  w as pelleted by 
centrifugation at 10000 rpm for 15 mins and the pellet w as washed with 70 % (v/v) 
ethanol to rem ove excess salt. The D N A  was dried briefly at 37°C before being 
resuspended in 20 (0,1 DEPC-treated water.
The probes were labelled with digoxigenin using the SP6/T7 DIG R N A  labelling kit 
from Boehringer Mannheim. T o a sterile microfuge tube on ice were added 2 (0.1 10X  
transcription buffer (kit com ponent), 12 |ol sterile DEPC-treated water, 2 (ol NTP  
labelling mixture (kit com ponent), 2 (il (l|0.g) linearised plasmid D N A  and 2 fol SP6 or 
T7 polymerase (kit com ponent). The tube was centrifuged briefly to ensure all 
components o f  the reaction were together at the bottom o f  the tube, and the tube
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incubated for 2 hrs in a 37°C waterbath. To stop the reaction, 2 (il o f  0.2 M  EDTA, 
pH 8.0, w as added. The labelled R N A  was then precipitated with 2 .5  (il o f  4  M  
lithium chloride and 75 |i l  pre-chilled (-20°C) ethanol. The tube w as incubated at 
80°C for 2  hrs after which the R N A  was pelleted by centrifugation at 12000 rpm for 20  
mins. The pellet was washed once with 50(0.1 cold  70 % (v/v) ethanol, dried and 
resuspended in lOOfil DEPC-treated water.
2.2.13.2 Probe evaluation
The sensitivity o f  the labelled probe could be estimated by dot blot experiments where 
various dilutions o f  denatured pG7Pum pEX or pG7Pum pXE plasmid were dotted onto  
a nylon membrane. The D N A  was bound to the membrane by baking for 30 mins at 
120°C. The blot w as prehybridised by sealing it in a plastic bag with 10 ml 
hybridisation buffer (50 % (v/v) formamide; 5X SSC  [0.75 M  NaCl, 0 .075  M  sodium  
citrate, pH  7.0;]; 2 % (w /v) blocking reagent [Boehringer Mannheim]; 0.1 % (w /v) N - 
lauroylsarcosine; 0 .02  % (w /v) SD S) and placing it in a 50°C incubator for 1 hour. For 
hybridisation, the labelled probe was diluted to a concentration o f  50  ng/ml in 2  - 5 ml 
hybridisation buffer and this put into the plastic bag with the blot to replace the 10 ml 
o f  buffer used for pre-hybridisation. The hybridisation w as performed for 16 hrs at 
50°C. The blots were washed tw ice for 5 mins each wash in 2X  SSC  at room  
temperature, and tw ice with 0 .1X  SSC  for 15 mins each wash at 68°C. After washing, 
the blots were rinsed in detection buffer 1 (100  mM Tris-HCl; 150 mM NaCl, pH 7.5) 
and blocked for 30 mins in detection buffer 2 ( 1 %  (w /v) blocking reagent (Boehringer 
Mannheim) prepared in detection buffer 1). Once blocked, the blots were probed with 
alkaline phosphatase-labelled anti-digoxigenin antibody (1 : 5000  dilution in detection  
buffer 2) for 30 mins. The blots were then washed twice for 15 mins each wash with 
detection buffer 1 before being developed for 6 hrs with BC IP/N BT (175 (ig/ml BCIP, 
500 (ig/ml N B T  prepared in detection buffer 3 [100 mM Tris-HCl; 100 mM NaCl; 50  
mM  M gClz, pH 9.5]). The colour reaction was stopped by rinsing the blots in distilled 
water.
48
2.2.13.3 In situ hybridisation
Cell culture growth slides (i.e. cells that had been grown on slides rather than the base 
o f a cell culture flask) had been fixed in 3 % paraformaldehyde for 1 hr at 4  °C and 
stored at -20 °C. Cells were permeabilised with 0.1 M  HC1 for 10 mins follow ed by a 
proteinase K (10 (ig/ml) digestion at 37°C for 10 mins. The digestion was stopped by 
placing the slides in DEPC-treated water for 5 mins follow ed by 0 .2  % (w /v) glycine 
prepared in 0 .15 M  PB S, pH  7 .4  for 10 mins. The cells were then post-fixed in 4  % 
(w /v) paraformaldehyde dissolved in 0 .15  M  PBS, pH 7 .4  for 30 mins at 4°C. Slides 
were prehybridised for 1 hour at 50°C by covering with 50 |i l  o f  prehybrisation buffer ( 
5 X  SSC; 50 % (v/v) formamide; 250 |ig /m l yeast tRNA; 250 (ig/ml herring sperm  
DNA; 4  mM  E D TA ) and placing in a humid chamber in the incubator. Hybridisation 
buffer was identical to prehybridisation buffer except that the herring sperm D N A  was 
omitted. 5 (il labelled probe w as added to 35 |i l  hybridisation buffer and the mixture 
boiled for 10 m ins and then placed directly on ice. After the prehybridisation, the slides 
were carefully dried and the probe/hybridisation buffer mixture placed on each section. 
The slides were then placed in the humid chamber and incubated for 16 hrs at 50°C. 
The slides were washed tw ice for 15 mins each wash at room temperature with 2X  
SSC. Any remaining unhybridised probe was then rem oved by a 30 minute digestion  
with RNase A (100  (ig/ml R N ase A  in 2X  SSC ). The slides were washed more 
stringently for 20 mins at 42°C with 0.1 X  SSC  and for a further 10 mins at room  
temperature with 0 .1X  SSC. The slides were washed briefly with detection buffer 1, 
blocked for 30 mins with detection buffer 2  and probed with the alkaline phosphatase 
anti-DIG antibody (1 : 500  dilution in detection buffer 2) for 1 hr at room  temperature. 
Following two 15 min washes with detection buffer 1, the slides were developed  
overnight with BC IP/N BT. The colour reaction w as stopped by rinsing the slides in 
distilled water before they were mounted and photographed.
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2.2.14 IM M UNOH ISTOCHEM ISTRY
M atdlysin protein in sections cut from tumour samples or normal tissue w as examined  
using the rat m onoclonal anti-matrilysin antibody and a Vectastain A BC  kit from  
V ector Laboratories. 5 |im  formalin-fixed, paraffin-embedded tissue sections were cut 
and placed on poly-L-lysine coated slides. Before beginning the immunohistochemical 
procedure, these sections were dew axed and rehydrated by placing in xylene baths for 
two 8 min incubations fo llow ed by a series o f  ethanol baths o f  decreasing concentration 
(100 %, 80 %, 60 % and 30 % (v/v)) for 2 mins in each. Any endogenous peroxidase 
activity that may have been present in the tissue w as quenched by incubating the 
sections for 30 mins in 0.3 % (v/v) H20 2 prepared in methanol. The sections w ere then 
washed for 5 mins in 0 .15 M  PBS, pH 7.4 . The sections were blocked by incubating 
for 20 minutes with goat blocking serum (kit com ponent). After removing excess 
serum, the sections were then incubated for 30 mins with the rat m onoclonal anti- 
matrilysin antibody (RmAb) (1 : 200  dilution in 0 .15 M  PB S, pH  7.4). Follow ing a 5 
min wash in PBS, the sections were incubated with biotinylated anti-rat solution (kit 
com ponent) for 30 mins. The slides were again washed for 5 mins in PBS. They were 
then incubated for 30 mins in V EC TA STA IN  A BC  reagent (kit com ponent) before 
again being washed for 5 mins in PBS. The slides were developed with peroxidase 
substrate solution (D A B ) prepared as outlined in section 2 .2 .2 . After suitable colour 
developm ent, the sections were rinsed in tap water and counterstained with 
haematoxylin.
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2.2.15 PROTEIN ISOLATION FROM TISSUE SAMPLES
A  piece o f  frozen tissue (w et w eight approximately 100 m g) w as ground to a fine 
pow der using a morter and pestle and liquid nitrogen. The powdered tissue was 
resuspended in 0.5 m is 50  m M  Tris-HCl, pH  7 .4  and gently shaken on ice  for 5 mins. 
Triton-XlOO w as then added to a final volum e o f  1 % (v/v) and the mixture agitated on  
ice for 20  mins. Cellular debris w as pelleted by centrifugation for 20 mins at 12000  
rpm at 4°C. The supernatent w as collected, analysed for protein content using a BC A  
m icroassay (section 2 .2 .7 ) and stored at -80°C until required.
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Chapter Three
Development of an ELISA for Matrilysin
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Introduction
In the early 1970s, the developm ent o f  the principle o f  enzym e immunoassays and 
methods for the labelling o f  antibody or antigen with enzym es provided a w hole new  
surge o f  research in immunoassay procedures (Engvall and Perlmann, 1971; Van  
W eeman and Schorrs, 1971). Enzyme-linked immunosorbent assays (ELISAs) are 
examples o f  heterogeneous assay systems i.e. the analyte-detector (antibody-antigen) 
com plexes are separated from free analyte or detector using a solid phase. This 
approach has many o f  the properties o f  an ideal im m unoassay : it is versatile, robust, 
simple to perform and uses stable reagents econom ically, qualities which make it ideal 
for the routine screening o f  large numbers o f  clinical samples. This chapter is 
concerned with the developm ent o f  such an assay system  for the measurement o f  the 
M M P matrilysin in conditioned media from cells in culture and, ideally, in tumour 
extracts from patients with breast tumours.
3.1 Antibody-based assays
Antibodies have a number o f  properties which make them suitable assay 
reagents. First, and principally, is their specificity, antibodies can distinguish between  
closely related m olecules through binding a single different epitope and even between  
enantiomers o f  the same m olecule (Carlsson and Glad, 1989). The binding strength o f  
antibodies to their specific antigens is  very strong and allow s the use o f  detergent-based 
washing steps to disrupt weak, non-specific interactions. Antibodies can be prepared 
relatively easily, either as polyclonal mixtures obtained by immunisation o f  a suitable 
animal and collection o f  anti-serum (Hudson and Hay, 1980), or as monoclonal 
preparations. M onoclonal antibody production requires the fusion o f  splenocytes from  
an immunised animal with non-antibody producing myeloma cells resulting in specific 
antibody-producing hybridomas (Kohler and M ilstein, 1975). Genetic methods o f  
producing specific antibody fragments have only recently been developed (Nissim  et 
al., 1994) and the use o f  these recombinant fragments in routine immunoassays has yet
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to be proved. Antibodies can generally be easily labelled with enzym es or other 
reporter m olecules with minimal effect on either the antibody or label activity (Catty 
and Raykundlia, 1989) although significant losses o f  activity have been reported 
(Ishikawa et al., 1983).
The specificity o f  any antibody is determined by the immunogen used in its 
production. Originally, only large protein m olecules were used, although small 
m olecules such as drugs can be used provided such ‘haptens’ are conjugated to carrier 
proteins. The antibodies produced m ust be carefully purified to rem ove those specific 
for the carrier or for the link region between hapten and carrier (Tijssen, 1985). M ore 
recently, peptide im m unogens coding for specific epitopes have been used (Lemer, 
1982). As they are such small m olecules (typically 2 kDa or less), they too m ust be 
conjugated to carrier proteins to induce an immune response (Burrin and Newm an,
1991). These have been beneficial in producing highly specific antibodies, although 
care must be taken in designing such peptides as often it is the tertiary structure o f  an 
epitope, not necessarily formed from a continuous amino acid sequence, that is 
recognised by an antibody. A lso, the correctly folded epitope may only be produced  
from the primary peptide sequence in the context o f  a larger m olecule (Burrin and 
Newm an, 1991).
3.2 Types of ELISA
ELISAs are generally classified into com petitive and non-com petitive assays. 
In a simple non-com petitive ELISA, the antigen is bound to a solid surface {e.g. the 
wells o f  a polystyrene ELISA  plate) and an enzyme-labelled specific antibody is added 
(Edwards, 1985). Follow ing washing to rem ove unbound antibody, a suitable enzyme 
substrate is added. The amount o f  substrate converted (usually from a colourless 
substrate to a coloured product) by the enzym e is directly proportional to the amount 
o f  labelled antibody present which, in turn, is directly proportional to the amount o f  
antigen bound to the surface. The concentration o f  coloured product is easily 
measured determining its optical density. A  modification o f  this procedure, which can 
be used to increase sensitivity, involves the use o f  an unlabelled antigen-specific
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antibody as the primary antibody, follow ed, after washing, by an enzym e-labelled anti­
species antibody which will recognise and bind to the primary antibody. The increase 
in sensitivity or amplification occurs because potentially tw o or more labelled 
antibodies can bind to each primary antibody. A  further advantage is that each specific 
primary antibody does not have to be labelled separately.
The use o f  a coating antibody to coat the solid  phase surface can be used to 
further increase sensitivity o f  a non-com petitive E L ISA . This coating antibody 
‘captures’ antigen and increases its local concentration. The antigen is then bound by 
the primary ‘detecting’ antibody follow ed by the enzym e-labelled secondary antibody. 
This sandwich or antigen-capture tw o-site im m unoassay can theoretically achieve a 
sensitivity capable o f  detecting a single bound antigen m olecule (Catty and Raykundlia, 
1989) although, in general, the reported sensitivities are in the picogram range.
Colourless
Substrate
Coloured
Product
Enzyme-labelled
antibody
Detecting antibody
Antigen ------------
Capture antibody
Fig. 3.1 : Diagram of sandwich ELISA
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When designing such a system , a number o f  points m ust be borne in mind for optimal
sensitiv ity:
•  The antigen must possess multiple epitopes for antibody binding;
•  The capture and primary (detecting) antibodies should recognise different 
epitopes;
•  The capture antibody should preferably be a m onoclonal o f  high affinity - the use 
o f polyclonal antibodies which recognise a number o f  different epitopes can 
greatly reduce the number o f  binding sites available to the primary antibody. A lso , 
it is generally the capture antibody w hich defines the sensitivity o f  the assay (Catty 
and Raykundlia, 1989);
•  The primary antibody can be either m onoclonal or polyclonal - m onoclonals are 
often o f  higher affinity and are o f  defined specificity whereas polyclonals are more 
stable (Edwards, 1985);
•  The capture and primary antibodies should be o f  different species so that the 
enzym e-labelled secondary antibody w ill only bind to a com plex containing 
primary antibody and not any other com ponent o f  the ‘sandwich’.
Competitive ELISA s can be used to measure either antibody or antigen 
concentrations and are often used for antibody isotyping and serum antibody 
quantitations (Catty and Raykundlia, 1989). In these assays, a plate is coated with 
either standard antibody or antigen to which a standard labelled antigen or antibody can 
bind optimally. The optimal substrate conversion produced by the enzyme label is 
reduced when som e o f  the binding sites on the coating layer are taken by unlabelled test 
antigen or antibody. In effect, the labelled standards are com peted out by unlabelled 
m olecules in the test sample and the resultant reduction in substrate conversion is easily 
measured. In this case, optical density readings decrease as concentration o f  analyte 
increases.
The principal advantages o f  ELISA format assays are speed, ease o f  use, low  
cost, quantitative ability and a high sample processing rate. Once developed, they can 
usually be modified for use in an automated environment further emphasising their 
advantages. They are, therefore, perfectly suitable for routine quantitative analysis o f  a
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large number o f  samples. The simplest assays for routine use would utilise easily- 
obtainable clinical samples with little or no pre-processing required such as urine, 
saliva, w hole blood or, m ost often, serum or plasma. Unfortunately detectable analyte 
levels in these fluids may not be representative so alternative samples such as tumour 
extracts m ay have to be used.
3.3 M M P  E L IS A s
ELISAs for matrix metalloproteinases 1 to 9 have been used for determination 
o f  their levels in serum, plasma and tumour extracts. Table 3.1 at the end o f  this 
section, summarises the various assays, their sensitivities and the types o f  samples with 
which they have been used. A lm ost all o f  these assays have used the sandwich format 
with two m onoclonal antibodies raised against different epitopes o f  the specific 
proteinases.
The demonstration that these enzym es could be found in plasma (Johansson and 
Smedsrod, 1986; Vartio and Baumann, 1989; M outsiakis et al, 1992) led to the 
developm ent o f a number o f  assay systems. The principal disadvantage o f  plasma is the 
presence o f  interfering proteins such as (X2-macroglobulin, the non-specific protease 
inhibitor. N evertheless, a number o f  researchers have demonstrated the effectiveness o f  
their ELISA systems with plasma samples. Gelatinase A  (M M P-2) in human plasma 
was found to be significandy increased in the second half o f  pregnancy (Zucker et al,
1992) due to the extensive connective tissue turnover associated with a growing foetus. 
The range o f  levels in a normal population w as determined to be 61 - 828 (ig/1 with an 
average value o f  509 ±  178 (ig/1 for men and 389 ±  193 (ig/1 for women. This ELISA  
could detect latent and activated enzym e, TIM P-com plexed enzyme and a 2- 
m acroglobulin-complexed gelatinase A  although, in the latter case, the efficiency o f  the 
assay was reduced to 65%. An alternative immunoassay for gelatinase A uses a ‘one- 
step’ approach where the antigen is allowed to simultaneously react with both the 
capture and primary antibodies (Fujimoto et al, 1993). This assay has a sensitivity 
almost ten times greater than the Zucker assay. Progelatinase A and progelatinase A- 
TIMP com plexes are recognised equally well. In a study o f  sera from patients with
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various diseases, significantly increased progelatinase A  levels were seen in patients 
with hyperthyroidism, primary biliary cirrhosis and hepatocellular carcinoma compared 
to normal controls. The normal serum level w as calculated to be 570 ± 1 1 8  |ig /l which 
is similar to the normal plasma level. Interestingly, this study also found conditions 
where significantly low er than normal progelatinase A  levels were evident. These  
included rheumatoid and osteo-arthritis and stom ach and pancreatic cancers. This may 
be because progelatinase A  produced by cells at the sites o f  disease is quickly activated 
or degraded and not released into the bloodstream.
Interstitial collagenase (M M P-1) in human serum was found to have a much 
lower concentration in the normal population o f  8.5 ±  5 .2  |ig /l using antibodies which 
could recognise both the zym ogen and activated forms o f  the enzym e (Zhang et al,
1993). This ELISA  could also detect, though with vastly decreased sensitivity, M M P-
1-TIM P-l and M M P-1-TIM P-2 com plexes.
U sing different combinations o f  m onoclonal antibodies, a group from Celltech  
have created separate immunoassays for procollagenase (M M P-1) and collagenase- 
TIMP com plexes with limits o f  detection o f  1 ng/ml and 4.5  ng/ml, respectively  
(Cooksley et al, 1990). These ELISAs were then used with human serum samples 
from patients with rheumatoid arthritis or prostate cancer as well as healthy subjects. 
Significant elevations in collagenase levels were seen in both rheumatoid arthritis and 
prostate cancer patient sera compared to age-matched controls (Baker et al, 1994). 
Samples from patients with metastatic d isease also showed significantly increased levels 
over non-metastatic samples. The ELISA  w as used to monitor treatment with levels 
returning to normal fo llow ing a six-month therapeutic regimen.
In a study o f  progelatinase B (M M P-9) in plasm a (Zucker et al, 1993), levels in 
breast cancer and colon cancer patients were shown to be significantly increased over 
normal controls. The ELISA used did not recognise activated enzym e and some 
reduction in detection due to progelatinase com plexes with either a 2-macroglobulin or 
TIMP-1 did occur. In contrast, assays developed by Tschesche and colleagues 
(Bergmann et al, 1989) could recognise both latent and active gelatinase B and 
neutrophil collagenase. Both sandwich and com petitive assays were developed, 
however the sandwich format proved more sensitive for both enzymes. These
58
sandwich E L ISA s were used for the measurement o f  gelatinase B and neutrophil 
collagenase in breast tumour extracts (Duffy et al, 1995) thus bypassing the possible 
inhibitory effect o f  <X2-macroglobulin. L evels o f  the enzym es appeared to correlate 
with each other and with levels o f  T1MP.
So-called one-step sandwich assays have recently been developed for 
stromelysin-1 (M M P-3) (Obata et al, 1992) and matrilysin (M M P-7) (Ohuchi et al, 
1996) by Prof. Okada’s group in Japan. The stromelysin ELISA  can detect latent and 
active enzym e as well as TIM P-com plexed stromelysin. This assay w as used to show  
significantly higher levels o f  the enzym e in sera o f  patients with rheumatoid arthritis 
(666 ±  135 ng/ml) when compared to normal controls (134 ±  74  ng/ml) or, 
interestingly, sera from osteoarthritis patients (139 ±  76  ng/ml). The assay is notable 
for its use o f  polystyrene balls as the solid phase coated with the capture antibody 
rather than the surface o f  an ELISA plate. After allowing the antibody-antigen- 
antibody com plex to build up, these balls could then be placed in test tubes containing 
an appropriate substrate solution and the colour reaction allow ed to proceed. A lso  
noteworthy w as the lack o f  interference from (X2-macroglobulin seen in this study.
The matrilysin ELISA although sensitive (limit o f  detection is 0 .05 |ig /l in the 
presence o f  E D T A ) has a major time disadvantage. The total assay time is over 72  
hours with coating, blocking and antigen/primary antibody binding steps each requiring 
24 hours. The researchers found a major reduction in sensitivity (32 (J,g/1 compared to  
0.05 (O.g/1) if  the assay was not carried out in the presence o f  20  mM  ED TA . They 
suggested, based on gel filtration experiments, that matrilysin exists as large polymers 
in serum and it is  these polym ers, formed in the presence o f  EDTA, that are detected by 
the ELISA. L evels o f  pro-matrilysin in sera from healthy subjects was found to be in 
the range o f  10.7 ±  18.8 ng/ml.
Alternative approaches to classic M M P im munoassays involve the use o f  
specific substrates as the capture layer. A n assay for gelatinase A  used gelatin to coat 
a microtitre plate prior to addition o f  sam ple (W acher et al, 1990). A  specific antibody 
to the gelatinase was then used and the assay proceeded as normal. The sensitivity is 
not very high when compared to the sandwich ELISAs with a lim it o f detection o f
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approximately 300 ng/m l. A  non-specific assay used to determine overall ECM- 
degradative ability o f  a sample utilises an ELISA for the ECM  com ponent laminin 
released from a collagen-coated layer o f  matrigel (R oss and Laurenza, 1995). The 
amount o f  laminin measured using a straightforward imm unoassay is  directly 
proportional to the amounts o f  active, non-com plexed proteases present in  a sample. 
This assay has how ever only been used with ce ll lines to determine growth factor 
effects on cellular degradative ability.
Table 3.1 : M M P ELISAs
MMP DETECTION LIMIT/ 
SENSITIVITY
ELISA FORMAT SAMPLE TYPE REFERENCE
Interstitial 
collagenase (MMP-1)
0.12 ng/ml One-step
sandwich
Serum Zhang et al, 1993
Interstitial 
collagenase (MMP-1)
1 ng/ml Sandwich Serum Cooksley et al, 
1990
Interstitial
collagenase - TIMP-1
4.5 ng/ml Sandwich Serum Cooksley et al, 
1990
Gelatinase A 
(MMP-2)
300 ng/ml Substrate capture Conditioned
Medium
Wacher et al, 1990
Gelatinase A (MMP- 
2)
2 ng/ml Sandwich Plasma Zucker et al, 1992
Gelatinase A 
(MMP-2)
0.24 ng/ml One-step
sandwich
Serum Fujimoto et al, 
1993
Stromelysin-1
(MMP-3)
20 ng/ml One-step
sandwich
Serum and 
synovial fluid
Obata et al, 1992
Matrilysin
(MMP-7)
0.05 ng/ml (+EDTA) 
3 2  ng/ml (-EDTA)
One-step
sandwich
Serum Ohuchi et al, 1996
Neutrophil 
collagenase (MMP-8)
2.5 ng/ml (Comp *) 
0.25 ng/ml (Sand *)
Competitive and 
sandwich assays
Plasma
Tumour extracts
Bergmann et 
al,1989
Duffy et al, 1995
Gelatinase B 
(MMP-9)
0.25 ng/ml (Comp) 
0.1 ng/m l (Sand)
Competitive and 
sandwich assays
Plasma
Tumour extracts
Bergmann et 
al,1989
Duffy et al, 1995
Gelatinase B (MMP- 
9)
0.8 ng/ml Sandwich Serum Zucker et al, 1993
* ‘com p’ indicates a com petitive assay and ‘sand’ indicates a sandwich assay.
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RESULTS AND DISCUSSION
Our aim w as to develop a sensitive and specific assay for matrilysin using antibodies 
provided by our collaborators. A  panel o f  three antibodies - a m ouse m onoclonal 
raised against recombinant matrilysin (mAb), a rabbit polyclonal raised against a 
matrilysin-specific peptide (pAt>2) and a rat m onoclonal antibody raised against the 
recombinant matrilysin (Rm Ab) - were used in various combinations and assay formats. 
An additional polyclonal antibody raised against a purified matrilysin preparation 
(pAb) w as also used in preliminary experiments. The antibodies were first 
characterised as to their reactivity with matrilysin, purified and labelled as necessary, 
and assay formats optim ised and, finally, validated.
3.4. Western Blot to Demonstrate Specificity of Antibodies
The western blotting experiment w as performed according to the method in section
2.2.2. 1 |ig  o f  recombinant matrilysin (includes both the 28 kD a zym ogen and, due to  
autocatalysis, the 18.5 kD a active form o f  the enzym e) w as loaded into each o f  three 
lanes o f  a 15 % polyacrylamide gel. An earlier blot demonstrated the presence o f  both 
forms o f  the matrilysin enzym e in approximately equal amounts using a polyclonal 
antibody, pAb, which recognised both active and latent matrilysin (Figure 3.4.1). After 
running the gel, blotting onto  nitrocellulose and blocking, the blot w as cut into three 
and the p ieces probed separately with one o f  the antibodies [ m Ab, pAb2 or RmAb] at a 
dilution o f  1 : 1000 in blocking solution. After washing, the probed blots were 
incubated with suitable commercially available enzym e-labelled antibodies : alkaline 
phosphatase (AP)-labelled anti-m ouse at 1 : 2500  for the mAb-probed blot, AP-labelled 
anti-rabbit at 1 : 2500 for the pAt>2-probed blot, and horseradish peroxidase (HRP)- 
labelled anti-rat at 1 : 5000  for the RmAb-probed section. The blots were subsequently 
developed with the appropriate substrates - D A B  for the HRP-labelled antibody and 
BC IP/NBT for the A P-labelled antibodies (Figure 3.4.2).
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All antibodies recognised the 28 kDa zym ogen form o f  the enzym e. Only pAt>2 also  
recognised the 18.5 kDa active form although its affinity for this appears much less 
than for the higher molecular weight form as evidenced by the much fainter signal.
CNJ
t 30
___ ^ 2 2
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Figure 3.4.1 Western blot demonstrating that the recombinant matrilysin contains both 
the 28 kDa and 18.5 kDa forms o f  the enzym e and these can be recognised by the 
rabbit polyclonal anti-matrilysin antibody pAb. For this blot, the pAb was used at a 
dilution o f  1 : 1000. The two left hand lanes contained recombinant matrilysin and 
molecular weight markers were loaded in the right hand lane. The sizes (in kDa) are 
indicated. T w o clear bands o f roughly equal intensity (indicated with arrows) can be 
seen demonstrating the presence o f both forms o f the enzyme.
4 2
m m * *  „  - 1 » 3 0
2 2
1 7
pAb2 mAb RmAb M.W.
Figure 3.4.2
Western blot to demonstrate specificities o f  anti-matrilysin antibodies. The blot was 
prepared as described in the text with prestained molecular weight markers (M.W . - 
measured in kDa) loaded in the extreme right-hand lane. The arrow points to the 
intense band at 28 kDa indicating the zym ogen form o f matrilysin. A  faint lower band 
can also be seen in lane 1 indicating that pA t>2 also recognises the 18.5 kDa active form  
o f matrilysin.
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3.5 Purification o f pAb2
The pAb2 w as provided in the form o f  anti-serum and, in order to reduce possible non­
specific binding, was purified by ammonium sulphate precipitation. This technique, 
also known as ‘salting out’, is a cheap and simple method o f  rem oving non-specific 
proteins w hile avoiding direct effects on the protein o f  interest. It also has the effect o f  
concentrating the purified protein. Proteins precipitate at particular salt concentrations 
due to the exposure o f  hydrophobic residues facilitating hydrogen bonding between  
protein m olecules. The salt concentration at which precipitation occurs is specific for 
different proteins although pH, temperature and total protein concentration can also 
influence the result. For immunoglobulin G (IgG ), the recom m ended initial protein 
concentration is 3 % (w /v) w hile the salt concentration should be 40 % (Tijssen, 1982). 
The method used was as described in section 2.2.3.1.
H aving com pleted the ammonium sulphate precipitation, an ELISA w as attempted 
using a capture layer consisting o f  m ouse mAb, pAb2 as the secondary antibody with 
AP-labelled anti-rabbit as the detecting antibody. It was found that the detecting 
antibody bound not only to pA t>2 but also, non-specifically, to other com ponents o f  the 
assay. For this reason, it w as decided to direcdy label pAt>2 with the enzym e HRP. 
Prior to labelling, the antibody had to be pure as otherwise the labelling method would  
be very inefficient and the possible labelling o f non-specific proteins could result in high 
background in an ELISA system. T o achieve the recommended level o f  purity, an 
affinity-chromatography method was chosen. The 16 amino acid matrilysin peptide 
(M AP), against which pAt>2 had been raised, w as coupled to cyanogen bromide- 
activated sepharose beads (2 .2 .3 .2 .1 ). The ammonium sulphate precipitated crude 
pAb2 mixture was applied to these beads and, after allowing non-specific proteins to 
run off, was eluted with a low  pH buffer (see section 2.2.3.2 .2).
3.5.1 Purification analysis by SDS-PAGE
Appropriately diluted anti-serum, ammonium sulphate precipitated pAb2 and affinity- 
purified pAb2 as well as a sample o f  a commercial IgG were run on a 10 % SD S-
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polyacrylamide gel under non-denaturing conditions (section 2 .2 .1). The enrichment o f  
the -1 3 0  kDa IgG band, as well as almost total removal o f  the large 60 kD a serum 
albumin band, can clearly be seen in the gel shown in figure 3.5.1. Unfortunately the 
affinity-purified pAt>2 is too dilute to be stained with Coom assie B lue so a second gel 
which was stained with a silver-staining technique is also shown (figure 3 .5 .2). Upon  
silver staining, the large amount o f  non-specific proteins actually present in the anti­
serum can clearly be seen while a single band at approximately 120 kDa is seen in the 
sample o f  affinity-purified pAt>2.
Figure 3.5.1 SDS-PAG E analysis o f  
pAb2 purification. The molecular weight 
markers (measured in kDa) were loaded 
in the left-hand lane and their sizes are 
indicated. Lane 2 contains the anti-serum, 
lane 3 contains the ammonium sulphate 
precipitate, lane 4  the affinity-purified 
pA t>2 and lane 5 a com m ercial IgG for 
comparison. This gel was stained with 
C oom assie B lu e .
Figure 3.5.2 SD S-PA G E analysis o f pA t>2 
purification. The m olecular weight markers 
(measured in kDa) are loaded in lane 1 on the 
left (sizes as indicated), anti-serum in lane 2, 
ammonium sulphate precipitate (too dilute) in 
lane 3 and the affinity-purified pAb2 in lane 4. 
This gel was stained using a silver staining 
technique which is more sensitive than 
Coom assie Blue staining.
M W  2 3 4 5
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3.5.2 Purification analysis by ELISA
Using a direct ELISA format (2 .2 .6 .1 ), where 50 ng o f  recombinant matrilysin was 
coated directly onto the w ells o f  an ELISA plate, an increase in titre after each 
purification step could be demonstrated. In this case, the titre w as defined as that 
dilution at which an absorbance o f  approximately 0 .5  could be obtained. The data is 
represented graphically in figure 3.5.3.
— ■— antkserum  
— o-—  a .s .p p t
D ilution ' 1
Figure 3.5.3 Graph o f  absorbance at 405 nm vs. reciprocal dilution for a direct ELISA  
for matrilysin. The three lines represent the absorbances obtained for various dilutions 
o f anti-serum, ammonium sulphate precipitated crude pA t>2 (a.s. ppt) and affinity 
purified pAt>2 (aff. pur.). The increased absorbance at each dilution indicates the 
success o f  the purification and resulting enrichment for specific pAbz.
From the graph in figure 3 .5 .3 , it can be seen that the titre for the anti-serum was 
approximately 1 : 10, for the ammonium sulphate precipitate it was approximately 1 : 
25, while for the affinity purified pAt>2, it had increased to 1 : 300.
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3.6 Demonstration of suitability of sandwich ELISA using BIAcore
Real-time biospecific interaction analysis (BIA ) is a general technique for observing the 
progress o f  biom olecular interactions as they occur. One o f  the interacting components 
is immobilised to a sensor chip surface, and the change in the surface concentration  
resulting from binding o f  the other com ponent is measured using surface plasmon 
resonance (SPR). M easurements in BIA core rely on the refractive index o f  the bound 
m olecules which is directly related to the surface concentration. V alues are given in 
arbitrary response units (RU).
The BIA core system  w as used (as described in section 2 .2 .5) to demonstrate the 
specific binding o f  mAb to recombinant matrilysin (also known as rPump) and the 
binding o f  the purified pA t>2 to this com plex. The antibody, m Ab, was first immobilised 
to the surface o f  the sensor chip using EDC /N H S chemistry (figure 3.6.1). The 
increase in RU from baseline to 8428 after capping to rem ove any unbound m olecules, 
indicates a satisfactory immobilisation. The baseline w as then reset and a solution o f  
recombinant matrilysin passed over the immobilised mAb. An increase in RU o f  2642  
indicates the binding o f  the matrilysin to mAb. A solution o f  pAt>2 was then passed  
over this com plex and a further increase in RU obtained again indicating binding (figure 
3.6.2). This suggests that antigenic determinants for both antibodies are present and 
available for binding simultaneously on the surface o f  the matrilysin m olecule and, 
therefore, that the sandwich format is suitable. The absence o f  response when a non­
specific ligand (B SA ) is used is demonstrated in figure 3.6.3.
The possibility o f  using m Ab as both capturing and secondary antibody is demonstrated 
in figure 3 .6 .4  where an increase in RU is seen when matrilysin binds to the 
immobilised mAb and a further increase occurs when this com plex is bound by more 
mAb. This suggests that the recombinant matrilysin m olecule has multiple recognition  
sites for this antibody.
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APROG PiC Time Window AbsResp SÍ2 Slope LR5P Baselinq Bg'RnSB B
Immobilise 3 135.00 10.00 10 H6 0.46311 -0 02665 0 47918 YES 0 Baseline
immobll.se 3 2013.60 5 00 20110 7.09613 -3.77054 0.86297 NO 9964 mAb
Immobilise 3 2580.60 5.00 18574 7.14285 -3 81261 0.42474 NO 8428 capped
Figure 3.6.1 Sensorgram obtained from the BIAcore system  demonstrating successful 
im m obilisation o f  m Ab to the sensor chip surface. The plot indicates progressive 
interactions between the chip surface and the protein. The three stars indicated on the 
plot are the points at w hich the measurements shown below  the graph, were taken. The 
relative response (RelResp), measured in arbitrary response units (RU), indicates 
changes in refractive index due to m olecules adsorbing to the surface o f  the sensor 
chip.
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0 2 0 0  4 0 0  6 0 0  8 0 0  1 0 0 0  1 2 0 0  1 4 0 0  1 6 0 0
Time [s]
APROG FC Time Window AbsReso £2 Slope LRSD Baseline EfilR95fi
PUMP 3 119 90 500 18308 051452 -0.13599 0.50000 YES 0 baseline
PUMP 3 649 60 5.00 20950 5.66589 -3 01557 0 58580 NO 2642 100ug/ml PUMP
PUMP 3 1182.10 500 21707 2 27890 -1.18962 0 54792 NO 3399 pAb2
PUMP 3 1649 00 10.00 18113 7.17883 -2.15815 0.57920 NO -195 Regenerated
Figure 3.6.2 Sensorgram demonstrating the formation o f  a ‘sandwich’ com plex. The 
baseline o f  0 represents the im m obilised mAb on the surface o f  the sensor chip. W hen  
a solution o f  rPump is passed over the chip, an increase in RelResp is seen. As before, 
the stars indicate the points at w hich measurements were taken. A further increase is 
seen when the purified pA t>2 is passed over the mAb-rPump com plex. A  pulse o f  acidic 
solution can then be used to rem ove the com plex leaving the im m obilised m Ab only on  
the sensor chip ( ‘R egenerated’).
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Time [s]
Tiros Window AbiRetp S P  SIo m  tR SD  Bawling RelRasp |d
5150 5 00 17484 0 «361 0 07024 0 *4027 YES 0 Baseline
551.50 5 00 17476 0.45616 0 0738J 0.46J20 NO -* 200u(|/ml_BSA
Figure 3.6.3 Sensorgram demonstrating the lack o f  response when B SA  is passed over 
the im m obilised mAb. N o significant change in RelResp is seen after a solution o f  B SA  
is passed over the m Ab indicating a com plete lack o f  interaction and, therefore, 
no non-specific binding.
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0 2 0 0 4 0 0 6 0 0  
T i m e  [ s ]
8 0 0 1 0 0 0
APROG EC Tlmo Window AbsReso SB SlOPq LRSO Baselino R e lR n o
pump 3 51.50 500 16195 0.87988 -0.27578 0.79234 YES 0 Basalin«
pump 3 524.50 5.00 19495 1:26454 -0.74538 0.28169 NO 1300 100wo/ml
pump 3 1053.50 5.00 20047 15.51715 -9.32676 1.27407 NO 1852 mAb
F igure 3.6 .4  Sensorgram demonstrating a mAb-rPump-mAb sandwich. The increase 
in binding seen when a solution o f  m Ab is passed over rPump bound to im m obilised  
mAb indicates that a number o f  m Ab binding sites are available on the rPump molecule.
3.7 Enzyme Labelling of pAb2 and mAb
The results o f  the BIAcore analysis suggested that both m A b /  pA t>2 and m A b /  mAb  
sandwich ELIS A s for matrilysin were possible. A s m entioned previously, an attempt 
at a mAb /  pA t>2 had been unsuccessful due to non-specific interactions between the 
enzym e-labelled anti-rabbit detecting antibody and various com ponents o f  the assay. A  
m Ab /  m Ab system  w as also, as expected, unsuccessful as the enzym e-labelled anti­
m ouse detecting antibody could bind to both the capture and secondary layers. Before  
proceeding with E L ISA s therefore, both the m Ab and pA t>2 were directly labelled with 
the enzym e HRP using a standard periodate m ethod (section 2.2.4.1).
3.7.1 Spectrophotometric Analysis of HRP-labelled conjugates
The wavelength at w hich IgG absorbs m ost strongly is 2 80  nm w hile H RP absorbs 
m axim ally at 403 nm. B y  measuring absorbances o f  the conjugates at these two  
wavelengths, an estimation o f  how successful the labelling procedure w as could be 
made. The Abs403/A bs28o ratio offers a guide to the amount o f  enzym e conjugated  
which is an important elem ent in determining conjugate performance. Ratios in the 
range 0.25 - 0.5 offer high enzym e activity without prejudice to antibody titre, and have 
low  background characteristics (Catty and Raykundalia, 1989).
ANTIBODY CONJUGATE Abs at 280 nm Abs at 403 nm A bs403/A bs280
HRP - pAb2 0.159 0.038 0 .240
HRP - mAb 0.241 0 .0 1 4 0.058
Table 3.7.1 Absorbance values at 280  nm and 430  nm for the mAb-HRP and pAb2- 
HRP conjugates. The ratio between the absorbance readings at the two different 
wavelengths is calculated.
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The ratio for the H RP-pAb2 conjugate is only just below  the recommended value w hilst 
the ratio for the m A b is very low  indicating much few er HRP m olecules per antibody 
m olecule. This conjugation experiment was repeated a number o f  tim es but the HRP- 
mAb ratio could never be substantially improved. Conjugation to another enzym e, 
alkaline phosphatase (A P) was also tried for this antibody using a one-step  
glutaraldehyde method (see section 22.4.2). Again, poor labelling was achieved so this 
approach was abandoned.
3.7.2 Direct ELISA to demonstrate antigen-binding activity of conjugates
The w ells o f  an ELISA plate were coated with 0.5 fig/m l rPump and, after blocking, 
various dilutions o f  the H RP-labelled antibodies added. After developing with the 
substrate O PDA, the absorbances at 405 nm were measured. Evidence that the 
conjugates have retained antigen-binding activity is given by the decrease in absorbance 
with increasing dilution and the lack o f signal with no antigen present. These values 
are presented in Table 3 .7 .2  on the fo llow ing page.
Taken together, the above results demonstrated that both the m Ab-HRP and p A b r  
HRP conjugates retained both enzym e and specific matrilysin-binding activity. From  
the titres in Table 3 .7 .2  and the ratios in Table 3.7.1, it can be seen that the pA t>2 had 
been more successfully labelled than the mAb. Prior to using these conjugates in the 
developm ent o f  sandwich ELISAs, they were concentrated ten-fold using ultra­
filtration columns.
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CONJUGATE DILUTION Abs4os (Mean ±  S .D .)
HRP - pAbz 1 : 10 0 .385 +  0 .009
1 : 2 0 0 .226  ± 0 .0 1 9
1 :5 0 0 .123 ± 0 .0 0 2
1 :1 0 0 0.099  ± 0 .0 0 2
N o  antibody /  N o  antigen 0.071 ± 0 .0 0 9
HRP - m Ab 1 : 1 0 0.158  ± 0 .0 0 6
1 :2 0 0.095 ± 0 .0 0 2
1 :5 0 0 .079  ± 0 .0 0 1
1 : 100 0.071 ± 0 .0 0 3
N o  antibody /  N o  antigen 0.076  ± 0 .0 1 1
Table 3.7.2 Results o f  direct ELISA to test HRP conjugates. Test w ells w hich had  
been coated with B S A  instead o f  rPump as a negative control gave similar readings as 
the ‘no antibody’ control w ells. This indicated that the conjugates retained specific  
anti-matrilysin activity.
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3.8 Optimisation o f m atrilysin ELISAs
To determine optimal working dilutions o f  coating antibody (mAb) and labelled  
secondary antibodies, a checkerboard sandwich ELISA system  w as used. 
Concentrations o f  coating antibody decrease across the plate w hile concentrations o f  
secondary antibody decrease dow n the plate. The amount o f  antigen (recombinant 
matrilysin) is the same in each well.
Increasing Dilution  
o f secondary antibody
 ►
Increasing Dilution o f  Coating Antibody
Figure 3.8.1 Diagram o f  checkerboard ELISA plate used for determining optimal 
combination o f  antibody dilutions.
Using this system, a combination o f  1 : 4 0 0  coating mAb with 1 : 100 HRP-pAb2 
secondary antibody was found to be m ost suitable as it gave a strong absorbance 
reading (0 .634  ±  0 .011) that was five times higher than background (0 .139  ±  0 .012)  
when an antigen concentration o f  0.5 (lg/m l was used.
When this assay w as attempted with the HRP-m Ab conjugate as the secondary 
antibody, only the undiluted conjugate resulted in a strong signal with any dilution o f  
coating antibody. U sing only neat conjugate was not feasible so the mAb /  mAb 
sandwich system  was no longer investigated.
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3.8.1 Determination of limit of detection and linear range
Using the dilutions o f  coating and secondary antibodies determined as m ost suitable 
from the previous experiment, a sandwich ELISA in which a range o f  concentrations o f  
antigen w as analysed was assembled. This assay showed linear quantitative binding in 
the range 20  - 640  ng/w ell (equivalent to 200  - 6400  ng/ml) with a detection limit o f  
15 ng (150  ng/ml) [Figure 3.8.2a], Inspection o f  the figures for detection limits 
presented in Table 3.1 w ill reveal that the values obtained for this matrilysin ELISA  do  
not compare favourably with other M M P ELISA s. B y making this ELISA a ‘one-step’ 
system, in which the analyte (matrilysin) and secondary antibody (HRP-pAbi) are 
added simultaneously to the pre-coated ELISA plate, a small increase in sensitivity was 
achieved. The limit o f  detection w as now  10 ng (100  ng/ml) with a linear range o f  100 
- 1000 ng/ml [Figure 3.8.2b]. N o  further increase in sensitivity could be achieved with 
this system. The use o f  a labelled anti-species antibody which could recognise the 
secondary antibody should, theoretically, amplify the signal and improve sensitivity. 
This, however, w as not possible in this case because o f  non-specific binding effects.
At this point, a third anti-matrilysin antibody (RmAb) became available. A s it w as a 
monoclonal antibody and, therefore, secreted by a hybridoma cell line, limited quantity 
was not a factor that had to be considered. This fact automatically made it a more 
favourable option than pAt>2 o f  which only a limited amount w as available, as the 
animal from which it had been obtained had been sacrificed.
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(A)
Matrilysin Concentration (ng/ml)
Figure 3 .8 .2  Standard curves obtained for mAb /  HRP-pAt>2 sandwich ELISAs. (A) is 
for the traditional system  where each com ponent is added sequentially w hile (B) is that 
obtained when a one-step approach is used. The regression coefficients are (A) 0.997  
and (B) 0.995. Although a wider linear range is seen in (A), the one-step method has a 
lower limit o f  detection making it more sensitive.
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3.8.2 Checkerboard ELISAs for RmAb
A s both mAb and RmAb are m onoclonal antibodies, either should be suitable for the 
capture/coating layer in a sandwich ELISA system. W hen a RmAb coating and mAb 
detecting layer w as used with a third enzym e-labelled anti-mouse antibody to provide 
the signal, high background signals w ere obtained. This appeared to be due to the 
labelled anti-m ouse antibody also binding to the rat-derived coating layer. W hen the 
alternative system  w as used i.e. mAb coating, RmAb as detecting antibody and a 
labelled anti-rat as the secondary antibody, no such background w as observed. This 
m Ab /  RmAb system  w as thus chosen for further optimisation.
U sing a checkerboard system  similar to that described previously for the mAb /  HRP- 
pA t>2 system, an optimal combination o f  1 : 5000  mAb for the coating layer and 1 : 
3000 RmAb for the detecting layer w as selected. The secondary antibody (HRP- 
labelled anti-rat) was used at the manufacturer’s recommended dilution o f  1 : 10000. 
A s the one-step design had been observed to increase sensitivity in the mAb /  HRP- 
pAt>2 system , it w as the method used for all m Ab /  RmAb assays.
3 .8 .3  Determination of linear range and limit of detection
U sing the optimal dilutions o f coating, detecting and secondary antibodies and a range 
o f  matrilysin concentrations (0 - 320 ng/m l), a sandwich ELISA (2.2 .6.5) was 
performed. The data obtained is presented in tabular form in Table 3.8.1 and 
graphically in Figure 3.8.3. The lim it o f  detection was 0.45 ng/m l and the linear range 
was 5 - 5 0  ng/m l. The sensitivity o f  this system  is over 200 tim es higher than the m Ab  
/  HRP-pAb>2 system  which had a lim it o f  detection o f  100 ng/ml. It also compares 
favourably with figures obtained for other M M P ELISAs and is as sensitive as the 
recently published matrilysin ELISA, although the linear range is not as wide (Ohuchi 
et al., 1996). The authors o f  that study found a vast difference in sensitivity o f  their 
assay when ED TA  was used in the sam ples/ standards. E D TA , however, did not 
increase the sensitivity o f  our assay. In fact a reduction in the linear range was 
observed when ED TA  was used. This is  shown in Figure 3.8.4.
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Matrilysin Concentration (ng/ml) Absorbance at 492 nm (Mean ±  S .D .) 
n =  4
0 0 .047 ± 0 .0 0 2
5 0 .102  ± 0 .0 0 3
10 0 .276  ± 0 .0 1 5
20 0.458 ± 0 .0 1 6
40 0 .697  ± 0 .0 1 6
80 1.048 ± 0 .1 1 2
160 1.396 ± 0 .0 2 3
320 1.778 ± 0 .0 4 2
T ab le  3 .8 .1  Establishment o f  linear range and lim it o f detection for the m A b /  Rm Ab  
sandwich ELISA  system. The lim it o f  detection is the low est concentration value  
which g ives an absorbance reading at least 2.5 standard deviations higher than the zero 
value.
Matrilysin Concentration (ng/ml)
Figure 3.8.3 A  plot o f  the data from Table 3.8.2. A s can be seen the graph is only  
linear for the first five concentrations after which it begins to plateau.
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■—  noED TA  
 w ithEDTA
Matrilysin Concentration (ng/ml)
Figure 3.8.4
Effect o f  using EDTA in the preparation o f  standards for the m Ab /  RmAb sandwich  
ELISA for matrilysin. The absorbance values obtained for the low er concentrations o f  
matrilysin (0 - 25 ng/ml) are approximately equal. W hen the matrilysin concentration is 
increased, however, the absorbance value for those sam ples prepared with ED TA  is 
lower than when ED TA  is omitted. The r value for the standards with no ED TA  is 
0.996. This was calculated across the linear range , 0 - 5 0  ng/ml. W hen EDTA is 
included, the r value is  0 .997 , however, this only applies to the linear part o f  the graph, 
0 - 2 5  ng/ml.
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3.9 Validation of Sandwich ELISA
To determine the intra-day accuracy and precision o f  the mAb /  RmAb sandwich 
ELISA, five calibration sets o f  recombinant matrilysin w ere prepared in DMEM S0 
(serum-free cell culture growth medium) and assayed on the same day. The inter-day 
variability for samples in D M E M  S0 was determined by preparing a calibration set on 
five different days, with assay on the day o f  preparation.
3.9.1 Intra-day accuracy and precision
For the intra-day variation analysis, absorbance values were interpolated at half- 
m axim al signal to give mean concentration and coefficient o f  variation (CV). The mean  
w as 24.98  ±  0 .59 ng/ml with a CV o f  2.37 %. The standard curve from which this 
information was obtained is presented in Figure 3.9.1 below .
Matrilysin Concentration (ng/ml)
Figure 3.9.1 Standard curve obtained for the m Ab /  Rm Ab sandwich ELISA for
matrilysin. The linear range was 5 - 5 0  ng/m l (r =  0.995).
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3 .9 .2  In ter-d ay  accu racy  an d  precision
To calculate inter-assay variability on different days, sam ples (n =  5) were spiked with a 
known concentration o f  matrilysin and assayed along with the calibration sets. The 
results are presented in Table 3.9.1 below.
D ay C alcu la ted  C oncentration  (ng/m l) 
(P ercen tage recovery in brackets)
1
2
3
4
5
Mean ± S.D. (C.V.)
31.57 (105.2 %) 
2 9 .74  (99.1 %) 
29 .85  (99.5 %) 
30.48 (101.6  %) 
3 0 .5 6 (1 0 1 .9 % )  
30.44 ±0.65 (2.14 %)
T able 3 .9 .1  Inter-assay validation. Sam ples were spiked with 30 ng/m l recombinant 
matrilysin and concentrations determined from calibration sets assayed at the same 
time. The low  C. V. indicates an assay with excellent reproducibility.
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Summary
Antibodies prepared against full recombinant matrilysin or a specific peptide sequence 
were kindly provided by Dr. Paul Cannon, Syntex Research, California and Prof. Lynn 
Matrisian, Vanderbilt University, Tennessee. These antibodies were first characterised 
as to their binding o f  the zym ogen and/or active forms o f  the matrilysin enzyme. The 
polyclonal anti-serum w as purified and enriched for specific anti-matrilysin antibodies 
by ammonium sulphate precipitation follow ed by affinity colum n chromatography. The 
feasibility o f  a sandwich-type immunoassay for the matrilysin m olecule was 
demonstrated using BIA core. Both a m ouse m onoclonal and the purified polyclonal 
antibody were labelled with the enzym e HRP. A  sandwich ELISA system  using the 
m ouse m onoclonal antibody as the coating layer and the HRP-labelled polyclonal 
antibody as the secondary antibody was developed. This assay, although linear in the 
range 100 - 1000 ng/ml, w as not very sensitive having a low er limit o f  detection o f  100  
ng/ml. A second sandwich ELISA system using a coating layer o f  the m ouse  
monoclonal antibody, a secondary layer o f  a rat m onoclonal antibody and a detecting 
layer o f  HRP-labelled anti-rat antibodies was then developed. As the specificity o f  a 
sandwich ELISA is defined by the capture layer, all the assays developed recognised  
only the latent form o f  matrilysin. This second ELISA w as sensitive, having a limit o f  
detection o f  0 .45 ng/ml, and had a linear range o f  5 - 50  ng/ml. The low  C V s obtained 
for intra- and inter-day demonstrated excellent accuracy and precision. This assay was 
used to quantify matrilysin secretion by cells in culture and the data is presented in 
chapter 5.
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Chapter Four
Matrilysin Expression in Human Breast Tumours
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Introduction
4.1 T u m ou rigen esis and m etastasis
The critical difference between a (relatively) com forting diagnosis o f  a benign 
tumour compared to the fear-inspiring diagnosis o f  malignant cancer is the evidence o f  
metastasis. This spread o f  malignant cells throughout the body that ‘seed s’ secondary 
tumours is the primary cause o f  death o f  m ost cancer patients (V ile, 1995).
The developm ent o f  m ost cancers involves tw o distinct stages - transformation 
and metastasis - which m ay or may not be temporally separated (V ile, 1995). Cells o f  a 
primary tumour are said to be growth transformed when they no longer respond to  
normal cell division and growth controls. The usual controllers o f  cell proliferation are 
the products o f  proto-oncogenes (Knudson, 1985; W einberg, 1985). Their protein 
products include growth factors, transmembrane receptors, inner membrane and 
cytoplasmic signal transduction proteins and nuclear proteins such as the transcription 
factors (Bishop, 1991). A  mutation in a proto-oncogene giving rise to an oncogene  
may result in continuous cell division signals. In opposition to the division-promoting 
signals o f  the proto-oncogenes are the growth-inhibiting or differentiation-inducing 
tumour suppressor genes also known as anti-oncogenes. Mutations in or loss o f  these 
genes contributes to tumourigenesis by allowing continuous cell division and tumour 
growth (Sager, 1989). A s cell division and differentiation are tightly controlled, the 
transformation process requires the accumulation o f  multiple genetic mutations 
(Vogelstein and Kinzler, 1993). In the case o f  colon cancer, a step-by-step progression 
from normal epithelium through benign adenoma to a fully malignant tumour has been 
defined (Fearon and V ogelstein, 1990). In this m odel, mutations in at least three 
tumour suppressor genes (p53, APC and DCC ) and one proto-oncogene (Ki-ras) are 
required.
Once transformed into tumours, cells can remain benign for a long time. In breast 
cancer for exam ple, the period o f  transition from hypeiproliferative but non-invasive 
disease to invasive cancer is estimated to average 6 years (Spratt et al., 1986). 
However, as the cells are frequently dividing, various other genetic mutations can
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accumulate. Many o f  these are irrelevant but som e can push the tumour into the 
second phase o f  the disease, metastasis. One o f  these genetic events may result in 
mutation or loss o f  a putative metastasis suppressor gene, nm23 (Liotta et al., 1991a). 
This gene was identified by differential hybridisation o f  mRNAs from clones o f  a 
murine melanoma cell line exhibiting either high or low  metastatic potential. This gene  
was consistently expressed in higher amounts in the low  metastatic variants in four 
different metastasis m odels. The activity o f  the gene was also shown to be low  in 
breast tumours from patients with positive lymph nodes and other signs o f  poor  
prognosis (Bevilacqua et al., 1989). Proof that the anti-metastatic activity resulted 
directly from nm.23 expression w as obtained by transfecting highly metastatic 
melanoma cells with the nrri23 gene and injecting these into nude m ice (Leone et al., 
1991). Consistently low er numbers o f  m etastases were found in m ice injected with the 
transfected cells than in controls. The association o f  high nm23 expression with low  
metastatic potential which apparently applies to ovarian (Mandei et al., 1995) and 
gastric (Nakayama et al., 1993) carcinomas as w ell as breast cancer, is not absolute. In 
other tumours, e.g. colorectal cancer (Zeng et al., 1994), lung cancer (Higashiyama et 
al., 1992), thyroid cancer (Zou et al., 1993) and neuroblastoma (Leone et al., 1993) it 
is instead advanced disease which is associated with high levels o f  nm23. The N M 23  
protein has been identified as a nucleoside diphosphate (NDP) kinase (Marx, 1993a). 
ND P kinases catalyze the transfer o f  the terminal phosphate group o f  5 ’ triphosphate 
nucleotides to 5 ’ diphosphate nucleotides and may function in G protein regulation 
thereby suggesting a role for nm23 in signal transduction (Liotta et al., 1991b). A  
second nm23 gene named nm.23-H2 has been cloned (Stahl et al., 1991) and, although 
it shares approximately 90% hom ology with the first nm23, it has been suggested to  
function as a transcription factor (PuF) particularly associated with the proto-oncogene  
c-myc (Postel et al., 1993).
In order to break away from a primary tumour and establish a secondary 
growth at a distant body site, a metastatic cell must express a number o f  biological 
functions (Liotta et al., 1991a). M etastasis, like tumourigenesis, is also a multi-step 
event. C ells must detach from the primary tumour, invade locally, enter the circulation, 
arrest at a distant site, extravasate into the target organ tissue and proliferate as a
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secondary colony all while escaping immune system  interference. Only a very low  
percentage (less than 0.05%) o f  metastatic cells in the circulation survive to form  
secondary tumours (Liotta et al., 1974; N icolson, 1991). This may, in part, be due to 
the requirement for a suitable ‘so il’ for the metastatic cell ‘seed’ - specific target organs 
only are suitable for growth o f  secondary tumours from particular primary tumours 
(Fidler, 1993). For a tumour cell to invade, whether locally or through a blood vessel, 
basement membrane ( the layer o f  collagens, fibronectins and proteoglycans separating 
epithelial, endothelial and parenchymal cells from underlying stroma) m ust be breached. 
This process can be divided into three stages (Stracke and Liotta, 1992) : (i) tumour 
cell adherence to basement membrane via cell surface receptors (e.g. integrins), (ii) 
degradation o f  membrane via local proteolysis, and (iii) migration o f  the cell through 
the lysed membrane. The local dissolution o f  the basement membrane barrier appears 
to be a critical turning point in the progression from benign to metastatic disease (Kohn 
and Liotta, 1995). U sing  the exam ple o f  breast cancer, carcinoma in situ, an essentially 
benign lesion, remains surrounded by an intact basement membrane. In the transition 
to invasive carcinoma, however, tumour cells penetrate the epithelial basement 
membrane and interact with the stromal cells. The important m olecules which appear 
to be differentially expressed in the invasion process are cell adhesion m olecules, 
proteinases and motility factors (Van Roy and M areel, 1992; Kemler, 1993; Schor, 
1994; Dorudi, 1995; Kohn and Liotta, 1995). Although the proteinases are the 
principal subjects o f  this review , it should be remembered that the other factors are 
equally important. In fact, general unregulated proteolysis alone would be counter­
productive as a tissue matrix with appropriate adhesion m olecules is required for 
proper traction o f  an invading cell (Stracke and Liotta, 1992).
4.2 Breast cancer and indicators o f prognosis
By the time many patients present with breast tumours, occult or detectable metastases 
may be present. The involvem ent o f  lymph nodes - a sign o f  metastasis - is the simplest 
and most reliable prognostic marker in patients with stage I or stage II disease (Hayes, 
1996). Approximately one third o f  newly diagnosed breast cancers will have axillary 
node involvem ent (M cGuire and Clark, 1992). In these cases, aggressive systemic
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therapy is indicated. It is the remaining two-thirds o f  newly-diagnosed breast cancers 
for which other, accurate prognostic markers are required. Although node-negative  
patients have a better chance than their node-positive counterparts o f  remaining 
disease-free follow ing surgery (to rem ove the primary tumour), there is still a 30%  
chance that the cancer will return (Marx, 1993b). Determining which patients fit into 
the 30% category and are thus suitable subjects for adjuvant therapy has been 
dependent on using the standard prognostic indicators o f  tumour size, histopathological 
classification, histological and nuclear grade, hormone receptor status and, more 
recently, D N A  ploidy and S phase fraction determination (McGuire and Clark, 1992). 
A brief explanation o f  each o f  these established prognostic markers follow s.
T um our Size : Breast tumour staging is based on primary tumour size (T), lymphatic 
spread (N) and the presence or absence o f  distant m etastases (M ). Stage I disease, 
referred to as TiNoMo is therefore defined as a small tumour o f  2 cm  diameter or less, 
with no evidence o f  lymphatic spread or more distant metastases (H ayes, 1996). 
Widespread use o f  mammography has led to the increased detection o f  small primary 
tumours allowing treatment o f  stage I disease before any progression to a more 
aggressive tumour can occur. A  large American study has shown that patients with 
tumours less than 1 cm  in diameter had a 5 year survival rate o f  almost 99% (Carter et 
al., 1989). In a group o f  patients w hose tumours were between 1 and 3 cm , the 5 year 
survival rate was 91 %. A  second study show ed a 20  year recurrence rate o f  just 14% 
in patients with tumours less than or equal to 1 cm  in diameter (Rosen et al., 1989). 
W hen the tumour size w as between 1.1 and 2 cm , the 20  year recurrence rate increased  
to 31 % while patients with larger tumours had a recurrence rate o f  over 50%. The 
importance o f  tumour size is reflected in the advice from the American National 
Institutes o f  Health (NIH) Breast Cancer Consensus Conference that patients with 
tumours less than 1 cm in diameter should not usually receive adjuvant therapy 
(McGuire and Clark, 1992).
Histopathological Classification : There is increasing evidence that certain
pathological features are helpful in anticipating the likely behaviour o f  an individual 
tumour. Ductal carcinoma in situ, pure tubular carcinoma, papillary carcinoma and
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typical medullary carcinoma are subtypes o f  breast carcinoma with excellent prognosis 
in node-negative patients with long-term recurrence rates o f  less than 10% (Rosen et 
al., 1989). By definition, carcinoma in situ, that is carcinoma confined by an intact 
basement membrane, w ill not metastasize as the tumour cells have no access to 
lymphatics or blood vessels and can therefore be rem oved leading to a com plete cure 
(Leader et al., 1995). It is, however, this com plete rem oval o f  all cancerous cells that 
is difficult to achieve. Limited surgery with or without radio- or chemotherapy, 
mastectomy or even bilateral mastectomy m ay be necessary.
Hormone Receptors : Human breast cancer is dependent upon the ovarian hormone 
oestrogen for its onset and progression (Lippman and D ickson, 1989). The oestrogen  
initially acts as a growth factor for the tumour cells. A s the cells proliferate and 
becom e more de-differentiated however, they may lose their dependence on oestrogen  
and grow without the external growth signals provided by the hormone (Marx, 1993b). 
The presence or lack o f  oestrogen receptors (ER+ or ER -, respectively) has been an 
important determinant o f  both prognosis and treatment, a poorer prognosis being 
associated with ER- tumours. N evertheless, the use o f  hormone receptor status as a 
marker for malignant potential is now controversial. Studies have shown only an 8 - 
10% difference in disease-free survival in node-negative patient groups divided on the 
basis o f  ER status (M cGuire and Clark, 1992). Som e o f  the controversy stems from 
the measurement methods used with a radioactive ligand binding assay and immuno- 
histochemistry being the m ost usual (H ayes, 1996). Several researchers have shown  
discordance between values obtained by the two techniques (Mink et al., 1995; Gaffney 
et al., 1995). The disparity appears to result from the presence o f  oestrogen receptors 
on uninvolved normal tissue adjacent to the tumour in the biopsy samples used for ER  
determination. When using immunohistochemistry, this normal tissue and any positive 
staining associated with it can be ignored whereas the ligand binding assay does not 
allow for straightforward differentiation between tumour and normal tissue. Another 
cause for doubt o f  the prognostic value o f  ER status is the finding that in post­
menopausal w om en, highest (ER++) as opposed to intermediate (ER+) levels indicated 
a poorer prognosis in terms o f  recurrence-free survival (Thorpe et al., 1993). A  
second study, while confirming this finding, discovered a disparity between ER protein
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and m RNA suggesting the high ER protein levels are the result o f  a m odified ER gene 
product (Sancho-Gam ier et al., 1995). A s a prognostic indicator, receptor status only 
appears to be helpful when com bined with other information, how ever, it is  useful in 
determining which patient’s tumours may respond to anti-oestrogen e.g. tamoxifen 
therapy (H ayes, 1996).
Nuclear and Histologic Grade : The degree o f  differentiation o f  a tumour and the
extent o f  mitosis evident in these cells can be evaluated by an experienced pathologist. 
It is, however, a subjective measure and valid results may not be obtained from a less 
experienced person (M cGuire and Clark, 1992). A  tumour classed as histological and 
nuclear grade I is well-differentiated and the nuclei show  little variation in size and 
shape. Grade II nuclei are o f  variable size and shape and possess prominent nucleoli 
whereas grade III nuclei are large, irregular, contain multiple nucleoli and frequent 
m itoses (Leader et al., 1995). Patients w hose tumours are classified as grade I have a 
5 year survival rate o f over 90% (M cGuire and Clark, 1992).
S-phase Fraction and Ploidv : The developm ent o f flow  cytometry as a routine 
analytical method has allow ed the determination o f  D N A  content (ploidy) and 
proliferative activity (S-phase fraction) o f  tumour cells. The use o f  ploidy as a 
prognostic marker is som ewhat controversial although there is evidence to suggest the 
more aneuploid (as opposed to diploid) a tumour, the worse the prognosis. Clark et al. 
(1989) evaluated the prognostic value o f  the combination o f  data on ploidy and S- 
phase fraction in node-negative patients and, after adjusting for other prognostic 
markers, found that ploidy w as an independent prognostic factor, while in diploid 
tumours, S-phase fraction yielded additional prognostic information. Other researchers 
have found significant correlations between ploidy and tumour grade and ploidy and S- 
phase fraction (Rosanelli et al., 1995), and between proliferative activity and 
histopathological grade (Schonbom  et al., 1995).
D espite the use o f  the prognostic factors outlined above, every year thousands 
o f  patients die w hose progression to metastatic disease w as not anticipated. Groups o f  
these patients may fall into subsets for whom  other, less well-characterized, markers
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have a role. These could include c -erbBHneu, p53, EGF-receptor, pS2, stress 
response proteins, topoisom erase 2, nm23 and angiogenesis markers.
4.3 Proteinases as prognostic m arkers in breast cancer
A  positive correlation between tumour aggressiveness and proteinase levels has 
been docum ented for all four classes o f  proteinases including serine, cysteine, aspartyl 
and metalloproteinases (Liotta et al., 1980; Rochefort et al., 1990; Matrisian et al., 
1991; Duffy, 1992; Blasi et al., 1993; N agle et al., 1994; Yamashita et al., 1994). All 
o f  these classes o f  proteinases have been investigated as possible prognostic markers in 
breast cancer.
Aspartvl Proteinase - Cathepsin D : The lysosom al proteinase, cathepsin D , is
synthesised by both normal and tumour tissues, how ever, significant over-expression o f  
the protein appears associated with increased disease recurrence in breast cancer 
patients (M cGuire and Clark, 1992). A  study using western blotting found an 
increased level o f  expression o f  a 31 kD a form o f  the protein in tissue from malignant 
breast tumours compared to that from benign tissue or normal controls (Schultz et al.,
1994). This 31 kDa form was not seen in sera from the same patients which, instead, 
contained only 52 kD a and 27 kD a forms o f  the protein. U sing an enzym e assay, the 
same researchers found significantly increased amounts o f  activity in tissue from breast 
cancer patients compared to benign tissue or normal controls suggesting that the 31 
kDa form is the proteolytically active form o f  the enzym e involved in breast cancer 
progression. The prognostic significance o f  cathepsin D expression w as also analysed 
using immunohistochemistry in a series o f  151 breast cancers (Aaltonen et al., 1995). 
Strong expression w as detected in 22% o f  cases and significantly associated with 
histological type and presence o f  m etastases. Patients with cathepsin D over­
expression had a significantly low er survival probability than patients with low  
expression. U sing multivariate analysis, however, these investigators found cathepsin 
D  to have no independent prognostic value over conventional prognostic factors. In 
contrast, an earlier study using a cathepsin D  radio-immunoassay found the 
concentration o f  cathepsin D  in tumour cytosol to be strongly related to both 
metastasis- and disease-free survival in a group o f  122 patients (Spyratos et al., 1989).
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U sing multivariate analysis, qualitative (i.e. high or low  levels) but not quantitative 
cathepsin D  analysis was associated with survival and was more important than lymph 
node status. Their m ost important finding w as o f  a high cathepsin D  concentration in 
those patients w ho later developed metastases but for whom  conventional prognostic 
factors (tumour size, lymph node involvement, ER status and D N A  ploidy) had 
indicated a good prognosis.
Cysteine Protein ases - Cathepsins B and L : The prognostic impact o f  these
lysosom al proteinases for disease-free and overall survival w as evaluated in a study o f  
167 breast cancer patients using ELISA s for each o f  the enzym es (Thom ssen et al.,
1995). The median values for each o f  the enzym es in cancerous specimens was 
approximately 10 times higher than the corresponding values in normal samples. 
Multivariate analysis for disease-free survival showed cathepsin L  as a strong and 
independent factor comparable to lymph node status and histopathological grade. 
Patients with high content o f  either cathepsin B or L had a statistically significant 
increased risk o f  disease recurrence than patients with low  levels. Alterations in the 
trafficking o f  cathepsin B so that it is no longer confined to lysosom es has been 
suggested as the basis for its involvem ent in breast cancer malignancy (Sloane et a l ,
1993).
Serine Proteinase - Urokinase Plasminogen Activator : Urokinase plasminogen 
activator (uPA) is synthesized as an inactive proenzyme (pro-uPA) which can be 
activated by plasmin or cathepsins B or L (Duffy, 1992). It is inhibited by tw o specific 
plasminogen activator inhibitors, PAI-1 and PA I-2, the second o f  which is a stronger 
and more specific uPA inhibitor (Bouchet et al., 1994). Plasm inogen activation by uPA  
occurs at the cell surface where the inactive pro-uPA is bound by its cellular receptor 
uPAR (Vile, 1995). When activated, uPA remains bound to uPAR where it is capable 
o f  converting plasminogen to the trypsin-like serine proteinase plasmin. Plasmin can 
itself degrade som e ECM  proteins and, more importantly, can convert other zymogens 
to their active forms by proteolysis (W ilhelm et al., 1987; H e et al., 1989). In this way 
highly focalised centres exist where controlled areas o f  proteolysis can occur at the 
leading edge o f  an invading cell (V ile, 1995). U sing an ELISA system, it has been
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shown that high uPA levels correlate with reduced disease-free and overall survival in 
breast cancer patients (Duffy, 1990). A s a predictor o f  disease-recurrence, uPA was 
better than axillary node involvement, tumour size or ER status when assessed by 
univariate analysis. In multivariate analysis, uPA was an independent risk factor for 
both disease-free and overall survival. M easurement o f  uPA as w ell as P A I-1 and PAI- 
2 levels was undertaken in another study (B ouchet et al., 1994). A  poor prognosis 
correlated with high levels o f  both uPA and PA I-1. Conversely, low  levels o f  PAI-2  
was also found to be a marker o f  poor prognosis. These researchers concluded, after 
subjecting all variables studied to statistical analysis, that PAI-1 provided the same 
prognostic information as uPA whereas PAI-2 increased the prognostic value o f  uPA. 
M atrix m eta lloproteinases : Studies showing involvem ent o f  various members o f  the 
MMP fam ily in breast cancer are numerous (Bae et al., 1993; W olf et al., 1993; Zucker 
et al., 1993; Soini et al., 1994; Yu et al., 1995; Patel and Schrey, 1995; Heppner et al., 
1996). These studies, however, were small in size and were performed with the 
intention o f  determining localisation and expression levels rather than prognostic 
impact.
As they were both initially isolated from breast tumour cD N A  libraries both 
stromelysin-3 and collagenase-3 are especially associated with this cancer (Basset et 
al., 1990; Freije et al., 1994). Although no large scale studies assessing the true 
prognostic significance o f  either o f  these enzym es has yet taken place, there is some 
preliminary data to suggest they may be useful. In a study o f  stromelysin-3, W olf et al. 
(1993) showed expression o f  the proteinase in all invasive carcinomas examined and in 
som e in situ carcinomas where other factors indicated a high risk o f  the developm ent o f  
an invasive phenotype. Stromelysin-3 w as not expressed in benign breast 
fibroadenomas or normal tissue. Similarly, collagenase-3 is not expressed in normal or 
benign breast tissue but was detected in all examined breast carcinoma samples (Freije 
etal., 1994).
Gelatinase A , w hile present in both metastatic and non-metastatic breast tumour 
tissue, appears to be increasingly activated in metastatic disease. Quantitative 
zymography was used to demonstrate increased ratios o f  activated enzym e to total 
gelatinase A in breast carcinomas o f  increasing grade (D avies et al., 1993c). A
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different study found no marked correlation between gelatinase A expression and 
established staging and prognostic markers (Brown et al., 1993) although the 
activation o f  gelatinase A  did appear to be a more com m on event in invasive breast 
disease. It should be noted that both o f  the investigations just mentioned were small, 
pilot studies o f  approximately twenty patient samples. An earlier, larger study 
evaluated gelatinase A  expression along with other basement-membrane associated  
markers (laminin receptors, type IV collagen and laminin) in 187 node-negative breast 
cancer patients (Daidone et al., 1991) High levels o f  gelatinase A  (or laminin 
receptors) did not influence disease-free or overall survival but were strong indicators 
o f local-regional diffusion o f  the disease.
The assessm ent o f  the prognostic value o f  M M P levels in breast cancer should 
be easier as more sensitive and specific ELISAs becom e available. Already assays for 
interstitial collagenase and TIM P-1 have been used to assess metastatic potential in 
prostate cancer where they w ere found to be as valuable as prostate-specific antigen 
and alkaline phosphatase, established prognostic factors for this disease (Baker et al.,
1994). An assay for gelatinase B detected significantly raised levels o f  the enzym e in 
plasma from patients with breast cancer as compared to normal controls (Zucker et al.,
1993). N o correlation w as found between gelatinase B levels and breast cancer staging 
how ever the sample number w as small and correlations with other prognostic markers 
were not analysed. A  later study which investigated neutrophil collagenase, gelatinase 
B and TIMP-1 levels by ELISA  show ed that none o f  these correlated with tumour size 
or lymph node status but the collagenase and gelatinase levels inversely correlated with 
ER levels (Duffy et al., 1995).
There are few  reports o f  matrilysin expression in tumour tissue. In 
gastrointestinal carcinomas, it has been established that matrilysin expression is 
associated with tumour developm ent as it is not seen in normal tissue but is expressed  
in carcinomas (M cDonnell et al., 1991). The presence o f  matrilysin in glandular tissue 
has also been demonstrated (Saarialho-Kere et al., 1995). This investigation included 
normal mammary tissue in which matrilysin expression w as localised to the secretory 
epithelium o f  ducts and ductules. A  recent report demonstrated matrilysin expression  
in both normal and tumour sam ples o f  breast tissue (Heppner et al., 1996).
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In the work to be presented in this chapter, the aim w as to examine a small 
number o f  breast tumour samples for expression o f  both matrilysin protein and m RNA  
using a number o f  different techniques. W e hoped to determine the m ost suitable and 
informative detection m ethod and to establish whether matrilysin expression has any 
potential as a prognostic marker o f  malignant breast disease.
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Results and Discussion
4.4 Tissue samples
This study included only a small number o f  samples as it w as intended as a 
preliminary analysis o f  different detection m ethods. Breast tissue samples were  
obtained from the Pathology D ept., Mater M isericordieae Hospital, Dublin. Both  
frozen pieces o f  tissue and paraffin-embedded blocks were obtained. Ten samples were 
classified as infiltrating ductal carcinoma and w ere identified as samples Ti to T !0. 
Three paraffin-embedded blocks from histologically normal breast tissue were also  
obtained. These were identified as samples N i to N 3. A ll tissue samples had been  
examined and classified by Prof. Peter Dervan, Consultant Pathologist. Details o f  the 
tumour tissue samples are presented in Table 4.1.
Table 4.1 Breast Tum our Tissue Samples
’ ...::: ' -.:.y : • ;
Patient A*** Diagnosis' Ttimmjr size
Tj F 72 ; Infiltrating ductal carcinoma 2 x 2 x  1.5 cm
t 2j ; F 75 i Infiltrating ductal carcinoma j 
[P.D.]
; 5 x 3.5 x 6 cm
T, F 53 i Infiltrating ductal carcinoma i 3 x 3 x 3 cm
t 4 ...F .... 63 I Infiltrating ductal carcinoma i 6 x 4 x 3 cm
1 T5 F 54 f Infiltrating ductal carcinoma 2 x 2x  1.5 cmi
; [P.D.]
t 6 F 42 j  Infiltrating ductal carcinoma 
j [M.D.]
1.7 x 1 x 1 cm
t 7 F 37 ! Infiltrating ductal carcinoma 4 x 1 x 1 cm
j T8 F unknown | Infiltrating ductal carcinoma 4 x 3 x 3 cm
t 9 F unknown 1 Infiltrating ductal carcinoma 3 x 3 x 1 cm
T10 F 71 j Infiltrating ductal carcinoma ; 3 x 3 x 1 cm
* F =  female.
+ P.D. indicates poorly differentiated and M .D. indicates moderately differentiated.
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4.5 RNA isolation
The RNA was isolated using a modification o f  the method o f  Chomczynski and 
Sacchi, (1987). The procedure is outlined in section 2 .2 .11 .2 . R N A  could only be 
isolated from tumour samples as no frozen samples, just paraffin embedded blocks o f  
the normal tissue samples were available. The integrity o f the isolated R N A  was 
checked using agarose gel electrophoresis in the presence o f  the reducing agent, 
formaldehyde (2.2.11.3). The gel obtained is shown in Figure 4.1. The presence o f  two  
bands representing the 28S and 18S ribosomal subunits is indicative o f  non-degraded 
RNA.
Figure 4.1 Agarose gel 
electrophoresis showing  
intact RNA isolated from  
breast tissue samples Ti - Tio.
The bands representing the 
28S and 18S ribosomal 
subunits can be clearly seen.
Som e smearing, indicative of  
RNA degradation is also  
visible.
4.6 Reverse Transcription - Polymerase Chain Reaction (RT-PCR)
The R N A  isolated from the breast tumours w as analysed for expression o f  
matrilysin-specific m RNA using RT-PCR. This technique is a modification o f  the 
polymerase chain reaction used for amplifying specific pieces o f  D N A . In RT-PCR, the 
mRNA was first converted to cD N A  using a viral reverse transcriptase enzyme. Prior 
to reverse transcription, the m RNA was primed with o ligo  d(T) primers which bind to 
the polyadenylated tail associated with mature m RNA. Once cD N A  was obtained, an 
aliquot can be amplified using PCR. The cD N A  w as mixed with Taq polymerase, 
nucleotides and a pair o f  primers specific for the target D N A . In all RT-PCR reactions 
described here, tw o sets o f primers were included in every reaction. The first set 
recognised matrilysin cD N A  and amplified a fragment o f  341 bp. A s these primers
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spanned an intron, any genom ic D N A  amplified would result in a larger product o f  700  
bp. The second set o f  primers recognised the constitutively expressed ‘housekeeping’ 
gene, (3-actin and amplified a region o f 225 bp. These primers were included as an 
internal control for each reaction. Figure 4 .2  is a photograph o f  the products obtained 
after performing RT-PCR on the ten breast tumour samples.
Figure 4.2 3 % agarose gel showing products o f  RT-PCR for matrilysin and [3-actin. 
Lane numbers are indicated. Lane 1 contains 100 bp size marker, Lane 2 contains a 
negative control (water used in place o f  RN A ), Lanes 3  - 12 contain tumour samples T t 
- Tio. The upper arrow indicates the matrilysin band at 341 bp. The second arrow 
indicates the lower (3-actin band at 225 bp.
The presence o f  matrilysin-specific bands in 8 /  10 samples o f  infiltrating ductal 
carcinoma indicated that active transcription o f  matrilysin was occurring in a high 
proportion o f  tumour samples. T w o samples were negative although this may have 
been a fault in the reaction as no [3-actin product was obtained. Although equal 
amounts o f total R N A  were used in the original RT reaction, the intensities o f  the (3- 
actin bands varies between samples. The concentration o f  total R N A  isolated was 
assessed spectrophotometrically. This technique is accurate only when the sample 
being analysed is com pletely pure and undegraded as degraded R N A  will contribute to 
an absorbance measurement but may not be reverse transcribed.. It would be expected 
that isolates from tissue sampes would contain different amounts o f  degraded RNA  
which would have interfered with the spectrophotometric measurement. RT-PCR is
1 2 3 4 5 6 7 8 9 10 11 12
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reported as being a very sensitive technique able to detect as little one cell positively  
expressing a particular gene (Rappolee et al., 1989). This means that the actual 
number o f  cells in any sample o f  tissue positively expressing matrilysin may be small. 
The possibility also exists that the positive m R N A  is not arising from tumour cells but 
from normal cells within the tissue sample. The limitation o f  this technique, therefore, 
is that, unless an hom ogenous sample containing only one cell type is used, the source 
o f  a positive result is unknown.
4.7 W estern blotting
M ethods for detecting protein are often more suitable than m RNA detection  
methods as problems with R N A  degradation do not arise. This is especially true when  
using archival material which may not have been collected and stored in RNase-free  
conditions. Protein m ethods, however, often depend on the availability o f  a suitable 
antibody raised against the protein o f  interest. A number o f antibodies against 
matrilysin were available for use, however, none o f  these had previously been tested  
with tissue samples. For immunoblotting, a polyclonal antibody, pAbi, which 
recognised both the zym ogen (28 kDa) and active (18 kDa) forms o f  the matrilysin 
enzyme was used. This w as the only antibody o f  those available which could equally 
recognise both forms o f  the protein (see section 3.4, chapter three).
Total protein w as isolated from the tumour samples using a simple detergent-
based procedure (2 .2 .15). The protein content o f  the isolates was assessed using a 
BC A  microassay (2 .2 .7 ), and an equal amount (200  |ig ) o f  each sample run on a 12 % 
SD S-PA G E gel (2 .2 .1). The blotting and probing procedure was performed exactly as 
outlined in section 2 .2 .2 , with the primary antibody (pAbi) used at a dilution o f  1 :
1000 and secondary antibody (AP-labelled anti-rabbit IgG) used at a dilution o f  1 :
2500. The blot was developed with BC IP/N B T  and photographed. It is shown in 
Figure 4.3.
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Figure 4.3 W estern blot demonstrating the presence o f  matrilysin in breast tissue 
samples Ti - T i0. Lane 1 contains a positive control (recombinant active [18 kDa] 
matrilysin), lane 12 contains molecular weight markers and the tissue samples are 
loaded in lanes 2 - 1 1 .  The sizes o f  the M W  markers (measured in kDa) are indicated 
at the right o f  the figure. An arrow on the left points to the matrilysin bands.
As can be seen, non-specific staining is evident in all o f  the tissue samples. It is not 
known which component o f  the tissue isolates is  responsible for the darkly staining high 
molecular w eight band. Matrilysin bands o f  both sizes (28 and 18 kDa) are evident at 
the bottom o f  the blot. Alm ost all o f  the tissue samples appear to contain the zymogen  
form o f  matrilysin, while a number also contain the active form. This high proportion 
o f positively-expressing samples is similar to that obtained with RT-PCR.
The degree o f  non-specific staining evident with this antibody makes it 
unsuitable for use in other procedures such as immunohistochemistry. A  different anti- 
matrilysin antibody, RmAb which is a rat m onoclonal antibody, was considered for use 
in this procedure. To ascertain whether any non-specific binding would result with this 
antibody, another western blotting experiment was performed. 200  (ig o f  three o f the 
tissue isolates were loaded on a 12 % SD S-PA G E gel and the immunoblotting
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executed as before except that the primary antibody (RmAb) was used at a 1 : 200  
dilution while the secondary antibody, an HRP-labelled anti-rat IgG, was used at a 
dilution o f  1 : 5000. The blot was developed with D A B  and is shown in Figure 4.4.
Figure 4.4 W estern blot demonstrating presence o f matrilysin in breast tissue samples 
Ti, T2 and T3. A rat monoclonal anti-matrilysin antibody was used as the primary 
antibody. Lane 1 contains MW markers and the sizes (in kDa) are indicated. The 
tissue sam ples are loaded in lanes 2 - 4 .  A n arrow on the right o f  the figure points to 
the matrilysin band.
Non o f  the non-specific staining seen with the polyclonal antibody used previously was 
evident in this blot. Faint bands at 28 kD a indicated positive staining for matrilysin. 
This antibody (RmAb) does not detect the active form o f  the enzyme so low er bands 
were not expected. The apparent specificity o f  this antibody made it a suitable 
candidate for immunohistochemistry.
4.8 Immunohistochemistry
As with RT-PCR, positive results with western blotting give no indication o f  
whether tumour or normal cells within a particular tissue sample express the protein o f  
interest. The location o f  positively expressing cells within the tissue can be investigated  
using immunohistochemistry. Successful immunohistochemistry may be difficult to  
achieve as the suitability o f  the antibody used for detection is critical. The lack o f non­
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specific binding seen with RmAb in western blotting experiments suggested that this 
may be a suitable antibody to use, however, it w as not initially developed for this 
purpose.
5 (im sections were cut from the formalin-fixed, paraffin-embedded blocks o f  
the tumour samples (T - T 10) and the three samples o f  normal breast tissue (N i - N 3). 
Prior to probing with the antibody, the sections had first to be dew axed and rehydrated 
by passage through a series o f  graded alcohols. The actual immunohistochemistry 
procedure was performed exactly as outlined in section 2.2 .14. Follow ing developm ent 
with D A B , the sections were counterstained with haematoxylin, m ounted and view ed. 
Very little background staining w as seen in any o f  the sections. All control sections, on 
which rat pre-immune serum w as used in place o f  RmAb, showed no staining above 
background. Figures 4 .5  to 4.8 are photographs o f  four o f  the sections (three tumour 
and one normal), w hich show  exam ples o f  the staining patterns observed. The first two  
tumour sections, one poorly differentiated and one moderately differentiated, show  
intense staining for matrilysin protein in nests o f  tumour cells. N o  positive staining can 
be seen in the surrounding stromal cells. The last tw o sections, one tumour and one  
normal, show positive staining for matrilysin protein by normal ductal epithelial cells. 
This staining in normal ductal epithelium has previously been reported (Saarialho-Kere 
et al., 1995; Heppner et al., 1996). The intense staining associated with tumour cells 
has also been seen previously (Heppner et a l ,  1996).
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Figure 4.5 Tissue section T8, a poorly differentiated infiltrating ductal carcinoma. The 
top panel show s this section stained with haematoxylin and eosin. The middle panel 
shows the results obtained when this section was probed with the rat anti-matrilysin 
antibody RmAb. The bottom panel shows the control reaction when pre-immune 
serum was used in place o f the m onoclonal antibody. Specific staining for matrilysin is 
visible in the nests o f  tumour cells. [M agnification 400X ]
102
Figure 4.6 Tissue sample T4, an infiltrating ductal carcinoma. The top panel shows 
this section stained with haematoxylin and eosin. The m iddle panel contains a view  o f  
the section probed with the rat m onoclonal anti-matrilysin antibody, RmAb. The 
bottom panel is  the control reaction when pre-immune rat serum w as used in place o f  
the RmAb. Once again, specific staining for matrilysin is observed in tumour 
epithelium and not surrounding stromal cells. [M agnification 400X]
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Figure 4.7 Tissue section Ti, an infiltrating ductal carcinoma. The top panel shows 
this section stained with haematoxylin and eosin. The m iddle panel shows the results 
obtained when this section was probed with the rat m onoclonal anti-matrilysin 
antibody, RmAb. The bottom panel show s the control reaction when pre-immune 
serum was used in place o f  the m onoclonal antibody. Specific staining for matrilysin is 
observed in normal glandular epithelial cells present in this sample. [Magnification 
400X ]
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Figure 4.8 Tissue sample N i, normal breast tissue. The top panel show s this section  
with haematoxylin and eosin. The middle panel shows the results obtained when the 
section w as probed with the rat anti-matrilysin antibody, RmAb. The bottom panel 
shows the control reaction when pre-immune serum was used in place o f  the 
m onoclonal antibody, specific staining for matrilysin is observed in the glandular 
epithelium. [Magnification 400X]
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The results o f  the immunohistochemical analysis o f  the tissue sections are striking. 
Matrilysin protein was detected in all sections. Immunoreactivity appeared as a 
cytoplasmic, granular or diffuse staining in all cases. It was associated with both 
invasive tumour cells (Figures 4.5 and 4 .6) and with normal glandular epithelial cells 
(Figures 4.7  and 4 .8). A ll sections show ed areas without immunostaining. Table 4 .2  
summarises the results o f  the immunohistochemistry with all the sections examined.
T able 4 .2  Im m u n oh istoch em istry  Results
R elative
TUM OUR NORM AL
T, +++ ++
T2 +++ ++
t 3 +++ n.a.
I t 4 +++ +
t 5 ++ +
1 T<- ++ ++
t 7 ++ +
1 T* +++ +++
t 9 ++ +
H o ++ ++
N , n.a. +++
n 2 n.a. +
n 3 n.a. +
The relative intensity and amount o f  staining o f  either tumour cells ( ‘TU M O U R ’) or 
normal epithelium ( ‘N O R M A L ’) in each section was assessed by eye and scored  
accordingly. ‘+ 5 indicates low  levels o f  staining, *++’ indicates moderate staining and 
‘+ + + ’ indicates a high level o f  intense staining, ‘n .a .’ indicates that a particular 
classification was not applicable as no exam ple o f  that tissue was present in the section.
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Similar expression o f  matrilysin m R N A  in ductal epithelial cells o f  the mammary gland 
has been reported (Saarialho-Kere et al., 1995). The authors o f  that study suggested  
that, as matrilysin is constitutively expressed by the glandular epithelium, it must serve 
a critical function. One possibility is that it is responsible for degrading proteinaceous 
debris thus maintaining the viability o f  the gland. The production o f  matrilysin m RNA  
by breast tumour cells has also been reported (Heppner et al., 1996). It was localised  
to the epithelial com ponents o f  tumours and to the epithelium o f morphologically 
normal ducts, confirming exactly the results presented here. Therefore, matrilysin 
expression by normal and tumour cells o f  human breast tissue has now  been confirmed  
at both m R N A  and protein levels. An important consideration is that the antibody used  
recognises latent matrilysin only. It cannot be determined from these results if  active  
enzym e is associated with either normal or tumour tissue. The activity o f  the enzym e 
could possibly be investigated using the technique o f  in situ zymography whereby a 
suitable substrate for the enzym e (e.g. casein) is incorporated into a photographic 
emulsion and placed on a section (Galis et al., 1994). Alternatively an antibody which  
specifically recognises the active form o f  matrilysin could be utilised in 
immunohistochemistry. It w ould be interesting to ascertain if  the enzyme produced by 
the normal ductal cells was actively degrading proteinaceous material thus supporting 
the gland cleaning function suggested by Saarialho-Kere et al. (1995). Active enzym e 
produced by tumour cells could be directly involved in invasion or indirectly through, 
for exam ple, its possible role in activating urokinase (Marcotte et al., 1992)
Table 4.3 indicates the results for each tissue sample obtained with the various 
m ethods o f  detecting matrilysin used. A s can be seen, positive results were obtained  
for all tissue samples by at least one method and, in m ost cases, tissue samples were 
positive by all three methods.
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SP E C IM E N A N A L Y SIS M E T H O D
R T -P C R W . B L O T T IN G IM M U N O H IST .
T, neg pos pos
t 2 neg pos pos
t 3 pos pos pos
t 4 pos pos pos
t 5 pos pos pos
t 6 pos pos pos
t 7 pos pos pos
Tg pos pos pos
t 9 pos pos pos
T io pos pos pos
Ni N .D . N .D . pos
n 2 N .D . N .D . pos
n 3 N .D . N .D . pos
T ab le  4 .3  Results for each tissue section as determined by the three different methods 
for matrilysin detection. W . blotting =  western blotting, and immunohis. =  immuno- 
histochemistry. The results are positive (pos) or negative (neg). N .D . indicates that a 
particular sample was not analysed by that method.
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RT-PCR as a technique is relatively easy to perform although prevention o f  
R N A  degradation can be difficult to achieve. False positive results are often associated  
with this technique due to its extreme sensitivity, how ever, appropriate preventative 
methods should insure against this. The inclusion o f  primers for a constitutively 
expressed gene such as P-actin acts as an internal control and allows for comparisons 
to be made between samples. This can be important as starting the method with equal 
amounts o f  R N A  does not necessarily mean that direct comparisons o f  RT-PCR  
products can be made. Degradation o f  the RNA and also variations from tube to tube 
in the efficency o f  the reactions can influence the amount o f  product obtained.
The tw o protein m ethods, western blotting and immunohistochemistry, 
indicated positive expression o f  matrilysin in all samples analysed. These techniques 
were relatively easy to perform, although the requirements for suitable antibodies may 
limit their usefulness. Immunohistochemistry was the m ost informative method used as 
identification o f  the cells responsible for protein expression could be made. The 
antibody used in this study recognised only latent matrilysin enzyme, however, so  
determination o f  matrilysin activity in these breast tissue samples has not been 
achieved.
It should be mentioned that the ELISA for matrilysin was intended for use with 
the breast tumour study, how ever, as the quantity o f  tissue available was extremely 
small, the total amount o f  protein isolated was not enough for both western blotting 
experiments and the ELISA. It would be expected that the ELISA method would be 
suitable for large-scale analysis o f  clinical samples and it is hoped to use it in the future 
for this purpose. H ow ever, as the antibodies used in the ELISA only recognise latent 
matrilysin, additional information regarding the presence o f  active enzym e would not 
result from this method.
4.9 Evaluation of M ethods
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4.10 M atrilysin as a Prognostic M arker in Breast Cancer
The finding o f  matrilysin expression in all tissue samples - both normal and 
tumour and, indeed, in both normal and tumour com ponents o f  the samples - suggests 
that it would be o f  little use as an indicator o f  tumour presence or grade in breast 
tissue. Investigation o f  its expression in tumours o f  other tissues, however, may prove  
beneficial. It has previously been shown that matrilysin m R N A  expression is associated  
with colon tumour developm ent (M cD onnell et al., 1991; W itty et al., 1994; N ew ell et 
al., 1994) but, to date, few  other tumours have been investigated for matrilysin 
expression.
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Sum m ary
The aim in this chapter, was to analyse a small number o f  breast tumour samples for 
matrilysin expression using a variety o f  techniques. T issue samples were obtained from  
ten breast tumours. R N A  and protein w as extracted from these samples and used for 
RT-PCR and western blotting experiments, respectively. Matrilysin expression was 
found in eight o f  the R N A  isolates and all ten o f  the protein isolates. The slight 
disparity may be a result o f  R N A  degradation.
In order to determine tissue localisation o f  the positive expression, formalin- 
fixed, paraffin-embedded sections o f  the tumour samples were cut onto slides. A  rat 
monoclonal anti-matrilysin antibody RmAb, appeared to be a suitable reagent for 
immunohistochemistry and this technique was tried. A ll sections showed positive 
immunoreactivity in distinct areas. Staining w as, in all cases, localised to epithelial 
cells. These could be tumour-derived or normal glandular epithelium. Three tissue 
sections from histologically normal breast tissue were also examined by this technique. 
Positive staining was observed in ductal epithelial cells. The matrilysin protein 
expression seen in these samples, both in tumour and normal tissue, confirms results 
obtained by other groups for matrilysin m RNA expression (Saarialho-Kere et al., 1995; 
Heppner et al., 1996). Similar expression at the protein level has also been seen by at 
least one other group (Prof. Lynn Matrisian, pers. com m .) Determination o f  the 
activity o f  the matrilysin enzym e expressed by both normal and tumour cells would  
prove interesting and may help to confirm a suggested function for matrilysin in normal 
glands i.e. to clean the gland o f  proteinaceous debris.
O f the three techniques used for matrilysin detection, immunohistochemistry 
was considered the m ost informative. The presence o f  matrilysin in all sections, both 
tumour and normal, suggested it is o f  limited value as a tumour marker in breast tissue. 
Investigation o f  matrilysin expression in tumours o f  other tissues may, however, prove 
valuable.
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Chapter Five
Effects o f Cytokines on Expression of 
Matrilysin and Stromelysin-1 
in Human Tumour Cell Lines
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Introduction
The term ‘cytokine’ has generally been used to describe the signalling m olecules 
associated with the immune system, separating these from the m itogenic m olecules, the 
growth factors, which act on different cell types. A s the m olecules in question are 
better understood, this division has becom e redundant as m any so-called cytokines have 
growth factor activity and vice versa. For this reason, the term cytokine, as used here, 
defines a soluble polypeptide which acts nonenzymatically in picomolar to nanomolar 
concentrations to regulate cellular function (Nathan and Spom , 1991).
5.1 Historical Context
Cytokine research began in the 1930s when investigators demonstrated that 
macrophage migration w as inhibited in cultures o f  antigen-treated lymphoid tissues. 
The m olecule responsible for this antigen-induced inhibition o f  phagocyte migration 
was not identified for over thirty years when tw o groups independently demonstrated 
the presence o f  a soluble factor named migration inhibitory factor or M IF (Adelman et 
al, 1979). In the intervening period, other regulatory m olecules such as nerve growth  
factor and interferon had been discovered (Nathan and Spom , 1992). Over the 
follow ing years, similar types o f  experiments where different immune system  cells were 
isolated and treated with supernatants from other cells so modulating their function in 
som e way, were perfom ed (M izel, 1989). In this way, numerous activities were 
described and named for the responses they had produced. A s all the activities 
described had a connection with lym phocytes, the term ‘lymphokine’ was coined to 
describe them (Barth et al, 1987). A  large number (over 100) o f  different activities 
were described with names such as antibody inhibitory material (AIM ) or specific 
macrophage arming factor (SM AF) (M izel, 1989). A s som e o f  the m olecules 
responsible for these activities were purified, they were found to have a number o f  
different effects i.e. exhibited pleiotropic behaviour. In truth, however, the
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preparations were often impure so that som e activities ascribed to certain m olecules 
were due to the presence o f  contaminants. Only with the advent o f  recombinant D N A  
technology could the various activités be separated and definitely assigned to particular 
m olecules (Hamblin, 1988). In 1979, the term ‘interleukin’ was adopted to describe 
m olecules that served as communication links between leukocytes (M izel, 1989). The 
first tw o interleukins, interleukin-1 and -2  (IL-1, IL-2) w ere designated to the various 
activities affecting T -cell proliferation and activation, IL-1 being derived from  
macrophages and IL-2 from T -cells them selves. This refinement o f  terminology and 
reclassification o f  these m olecules began a period o f  intense research leading 
eventually to the use o f  recombinant IL-2 in a clinical setting for various cancers and 
AIDS (Kaplan et al, 1992). The actual number o f  cytokines characterised has also  
increased rapidly. There are now  15 known interleukins, each responsible for a specific 
set o f  activities and acting through a particular receptor.
The perception that other signalling m olecules from the fields o f  virology  
(interferons), haem atology (colony stimulating factors, CSFs) and cell biology (growth 
factors) were also important in im munology led to the gradual replacement o f  
‘lymphokine’ with ‘cytokine’. It is only recently that the diversity o f  activity and 
cellular origin demonstrated by m ost cytokines has been realised (Nathan and Spom , 
1992) It is this diversity that has prompted us to examine the effects o f  what were 
previously thought o f  as immune system  m olecules on other processes.
5.2 Cytokine Functions and M ode o f Action
In the immune system, where their activités have been m ost studied, the various 
cytokines act differently and synergistically in a hierarchical manner (Sedlacek and 
M oroy, 1995). The concentration and combination o f  cytokines acting on a cell are 
decisive for its proliferation, differentiation and function. In order to provoke a specific 
response, cytokines have to bind to and activate specific receptors on the membranes o f  
target cells. D ue to the large number o f  cytokine m olecules that have been 
characterised, it is impossible to describe them all in detail. The follow ing is a brief
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survey o f  the various cytokines used in the course o f  the investigations described later 
in this chapter, their receptors and activities.
Interleukin-1 : IL-1 was first discovered in the 1940s and named endogenous pyrogen  
for its ability to cause fever. It has also been known under various other names such as 
leukocyte endogenous mediator, lymphocyte activating factor, catablin, osteoclast- 
activating factor and haematopoitin-1 (Dewhirst et al, 1985; Dinarello, 1988; Akira et 
al, 1990). There are tw o distinct IL-1 m olecules, I L - la  and IL -lp , coded for by 
separate genes. Although they only share 25% hom ology at the amino acid level, both 
forms bind to the same receptor (Barth et al, 1987) and are, therefore, usually referred 
to as the one protein, IL-1. Both proteins are synthesized as 31 kD a inactive precursor 
m olecules which must be enzymatically cleaved to yield a 13 - 17.5 kD a mature protein 
(M izel, 1989). This cleavage is achieved intracellularly by interleukin-converting 
enzyme (ICE) or extracellularly by plasmin or elastase (Sedlacek and M ôrôy, 1995). 
A proportion o f  activated IL-1 remains membrane-bound and may explain its ability to  
participate in autocrine and paracrine events without inducing the systemic effects that 
occur when mature IL-1 gains access to the circulation. Although initially described as 
a product o f  activated phagocytes, IL-1 has since been shown to be produced by a w ide  
variety o f  cell types including synovial fibroblasts, keratinocytes, mesangial cells o f  the 
kidney, astrocytes and microglial cells o f  the brain, vascular endothelial and smooth  
muscle cells and corneal, gingival and thymic epithelial cells (Dinarello, 1988). This 
truly pleiotropic m olecule has a myriad o f  effects both in specific cells in vitro, and 
systemically in vivo. Som e o f  the more prominant activités are summarised in Table 
5.1.
The induction o f  fever is due to the effects o f  IL-1 on the hypothalamic 
thermoregulatory centre. The release o f  several hypothalamic and pituitary peptides 
such as endorphins and adrenocorticotrophin (ACTH) can also be induced by this 
cytokine. A s w ell as stimulating ACTH  production, IL-1 also acts directly on the 
adrenal gland to upregulate steroid synthesis. The results o f  IL-1 treatment on the liver 
include the depression o f  liver cytochrom e P450-dependent drug metabolism, reduction 
of hepatic albumin production with an increase o f  other hepatic proteins resulting in the
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acute phase response (Abbas et al, 1991). The ability o f  IL-1 to initiate prostaglandin 
synthesis is perhaps one o f  its m ost important biological properties, accounting for 
many local and systemic effects (Dinarello, 1988). The induction, by IL-1, o f  
prostaglandins, collagenase and collagen in synovial fibroblasts is  resposible for the 
pain, degradation and scar formation leading to restricted m ovem ent in arthritic joints.
T ab le  5 .1 : E ffects o f  IL-1
Type of Effect Examples
In  vitro : Cell Growth Fibroblast, keratinocyte, mesangial and glial cell 
proliferation
In v i t r o : Inflammation Increased synthesis of collagen and
procollagenase
Bone resorption
Prostaglandin E2 synthesis in synovial fibroblasts
In  v i tr o : Cytotoxic Causes cell death in tumour cells , P islet cells 
and erythrocytes
In v i tro : Metabolic Increases intestinal mucus production 
Decreases hepatic albumin transcription
In v i tro : Leukocytes Chemotaxis of B and T lymphocytes
Basophil histamine release
Neutrophil and monocyte thromboxane synthesis
Systemic : Central Nervous System Fever
Sleep
Decreases appetite 
Stimulates ACTH release
Systemic: Mctabolic Increases hepatic proteins 
Decreases cytochrome P450 activity
Systemic : Vascular wall Capillary leak syndrome 
Hypotension
Increases prostaglandin synthesis
Systemic: Haematologic Neutrophilia
Lymphopenia
Increases bone marrow growth factors
Compiled from Dinarello, 1988; Sedlacek and Moroy, 1995; Akira et al, 1990
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M odulation o f  IL-1 levels is achieved physiologically by down-regulation of  
receptor levels by IL-1 itself and by the presence o f  a natural antagonist, interleukin 
receptor antagonist (IL-RA). IL-RA is a 17.5 kD a protein produced by m onocytes, B 
lymphocytes, endothelial cells and keratinocytes which has no biological activity o f  its 
own (Sedlacek and M oroy, 1995). It binds to the same receptor as IL-1 although at a 
slower rate and m ust be present in 100-fold excess to interfere with IL-1 binding. A s a 
pure antagonist, IL-RA has been investigated as a therapeutic agent and is in clinical 
developm ent for use in septic shock, rheumatoid arthritis, graft versus host disease, 
asthma and inflammatory bow el diseases. Currently, the therapeutic modulators o f  IL- 
1 activity m ost often used in chronic inflammatory conditions are the corticosteroids 
(Sedlacek and M oroy , 1995).
A  high-affinity IL-1 receptor has been cloned from an expression library and 
characterised (Akira et al, 1990). The receptor has three domains : an extracellular o f  
319 amino acids; transmembrane o f  20  amino acids; and cytoplasmic o f  213 amino 
acids. The extracellular portion possesses three immunoglobulin-like motifs showing 
that the IL-1 receptor belongs to the immunoglobulin superfamily. The intracellular 
portion has no significant hom ology with any known proteins although there is 
evidence for intrinsic G protein activity (Sedlacek and M oroy, 1995).
Interleukin 2 : IL-2 is a 15 kDa protein exclusively produced by antigen-stimulated T  
lymphocytes (Sedlacek and M oroy, 1995). It would appear to be a true immune 
system m olecule resposible for the proliferation and differentiation o f  lymphocytes via 
specific cell surface receptors. These receptors are constitutively expressed by natural 
killer (NK ) cells whereas B and T cell receptor expression is dependent on antigenic 
and IL-1 stimulation (Barth et al, 1987). In addition to its cellular proliferative 
function, IL-2 stimulates the release o f  other cytokines, interferon (IFN)-y, GM -CSF  
and tumour necrosis factor (TNF) from N K  cells and IL-1, IL-6, IL-8 and TNF from  
m onocytes. It is also implicated in antibody production from activated B lymphocytes ( 
Abbas etal,  1992). D ue to its ability to stimulate cytotoxic T lymphocytes (CTLs) and 
NK  precursors resulting in lymphokine-activated killer (LAK) cells, IL-2 has been used 
in tumour immunotherapy (Rosenberg et al, 1987) and AIDS treatment (Kaplan et al,
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1992). W hen used alone in high doses, IL-2 appears associated with severe side-effects 
e.g. vascular leak syndrome, and few  beneficial clinical responses. A t low er doses and 
in combination with adoptive immunotherapy i.e. the administration o f  immune effector 
cells such as LAK s or CTLs, beneficial responses have been observed (Rosenberg et al, 
1987; W est et al, 1987) although som e adverse reactions still occur. Current 
developm ents include the use o f  tumour infiltrating lym phocytes (TILs) genetically 
manipulated to deliver IL-2 and other cytokines directly to the tumour (Russell, 1990; 
Rosenberg, 1992). IL-2 has also been used to treat severe com bined immunodeficiency 
(SCID) w hich may be the result o f  an IL-2 deficiency (Kaplan et al, 1992).
IL-2 interacts with target cells through binding o f  a specific receptor com plex  
(Smith, 1989). This high affinity receptor is com posed o f  at least two chains, one o f  75  
kDa molecular w eight which has a large cytoplasmic domain o f  286  amino acid 
residues and the other o f  55 kDa molecular w eight which has only a cytoplasmic 
‘anchor’ o f  13 amino acids (Kaplan et al, 1992). The tw o chains can function 
separately as low  or intermediate receptors although only the 75 kD a chain has an 
intracellular signalling domain. This suggests that similar biochemical results are 
obtained when IL-2 binds to the p75/p55 dimer as when it binds to the p75 chain alone. 
The important difference is the affinity w hich is 100-fold higher in the case o f  the dimer 
(Kaplan et al, 1992). The constitutively-expressed IL-2 receptor on N K  cells is 
com posed o f  the p75 chain alone, the high affinity dimer resulting only from antigenic 
stimulation (Hamblin, 1988).
Interleukin 6 : IL-6 is a glycoprotein with an o f  25 - 30 kDa, size  
differences being due to differential glycosylation (M izel, 1988). It is a multipotent 
cytokine exerting numerous biological activities. These include the regulation o f  
proliferation and differentiation o f  T and B lymphocytes, NK cells and normal 
haematopoietic progenitors as well as som e epithelial and neural cells (Blay et al,
1992). One o f  its major functions is the induction o f  antibody production by B cells 
(Hutchins et al, 1990) and, because o f  this, it is often used as a medium supplement for 
hybridomas. Other activities include promotion o f  angiogenesis, particularly in the 
ovary and uterus, weak antiviral activity (hence the alternative name interferon (3) and,
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synergistically with IL-1, induction o f  acute phase proteins from hepatocytes (Sedlacek  
and M oroy, 1995). It is produced principally by m onocytes but also by a wide range 
o f  other cells such as lym phocytes, fibroblasts, bone marrow stromal cells, endothelial 
cells, microglia cells, chondrocytes and osteocytes (M izel, 1989). Like IL-1 and TNF, 
IL-6 is found in the synovial fluid from joints o f  patients with rheumatoid arthritis 
(Akira et al, 1990). It is thought that IL-6 may participate with IL-1 in fine-tuning the 
catabolism o f  connective tissue com ponents by modulating the balance between  
degradative enzym es and their inhibitors (Ito et al, 1992).
IL-6 is constitutively produced by a variety o f  solid tumours. For this reason it 
has been examined as a prognostic indicator o f  m etastatic renal cell carcinoma (Blay et 
al, 1992). IL-6 levels were found to correlate with C reactive protein, an acute phase 
protein. Either or both o f  these factors were prognostic with high levels indicating 
poor survival and a poor response rate to IL-2, an experimental treatment for renal cell 
carcinoma. The same results were also obtained in a study o f  patients with metastatic 
melanoma (Tartour et al, 1994). A  study o f  patients with various lung carcinomas 
indicated that high levels o f  IL-6 along with G M -CSF, G -CSF or M -CSF were  
indicative o f  poor survival (Katsumata et al, 1996). Studies o f  the effects o f  IL-6 on  
tumour growth in cell lines have been contradictory. Serve et al (1991) tested the 
effect o f  different levels o f  exogenous IL-6 on the growth o f  twenty six different human 
cell lines derived from solid tumours and found no effect. To test the possibility o f  
autocrine growth stimulation by IL-6, neutralizing antibodies were used and, again, no 
effect on growth w as observed. Another study suggested that in cell culture, IL-6  
enhances, inhibits or has no effect on the proliferation o f  epithelial cells depending on 
the cell type examined (Krueger et al, 1991). The proliferation o f  keratinocytes was 
enhanced while breast carcinoma cell line growth w as inhibited. The breast carcinoma 
cells exhibited a major change in phenotype for as long as IL-6 was present in the 
culture medium. These researchers observed that the phenotypic changes resulting 
from IL-6 exposure were similar to the changes that particular groups o f  epithelial cells 
undergo during em bryogenesis and suggest a possible role for IL-6 in embryonic 
developm ent. The contradictory observations on the effects o f IL-6 on epithelial cell
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growth may be due to the different stages o f  tumours examined. A  study o f  melanoma 
lesions treated with IL-6 from dermal fibroblasts show ed that early stage, metastasis- 
incompetent lesions were growth inhibited by the cytokine whereas later, metastatic 
lesions were unaffected or even simulated by IL-6 (Lu et al, 1992). It is thought that 
as the tumour cells progress, they lose their dependence on IL-6 in a similar manner to 
the loss o f  oestrogen-dependence by breast cancer cells. Unlike the breast cancer cells 
however, the melanoma cells retain receptors and may exhibit proliferation in response  
to autocrine stimulation. Other studies have shown that breast cancer cells can also be 
inhibited by IL-6 (Danforth and Sgagias, 1993) perhaps due to down-m odulation o f  
ER. When transfected with int-2, a weakly transforming event, breast carcinoma cells 
can be stimulated by the cytokine, how ever this growth stimulatory effect is lost as the 
cancer progresses (B asolo et al, 1993). IL-6 upregulates expression o f  the adhesion 
m olecule ICAM-1 (CD 54) on breast cancer cells (Hutchins and Steel, 1994). A s this 
m olecule appears to be a marker o f  well-differentiated cells (Kaiserlian et al , 1991), 
investigators have suggested that the inhibitory effects o f IL-6 are mediated through it.
There is a network o f  cytokines whereby expression o f  a particular cytokine is 
influenced by the activity o f  others. IL-6 is potently induced by IL-1 and TNF, which 
are also pro-inflammatory cytokines. Production o f  IL-6, like IL-1 and TNF, can be 
super-induced by cyclohexim ide treatment suggesting that the regulation o f  cytokine 
production is under the control o f  labile repressor proteins (Akira et al, 1990). 
Dexam ethasone and other glucocorticoids can suppress production o f  these three 
cytokines. Many cytokines, including IL-6, contain AU-rich sequences in the 3 ’ 
untranslated regions o f  the transcribed genes which are thought to be involved in 
m RNA instability (Sen and Lengyel, 1992; Crawford and Matrisian, 1995). This 
ensures a short half-life which is important as cytokines are potent at extremely low  
concentrations.
The 80 kDa IL-6 receptor, like many other cytokine receptors, has four cysteine 
residues at the amino terminal region and a tryptophan-serine-X-tryptophan-serine 
m otif in the region just external to the plasma membrane (Abbas et al, 1992). 
Although conserved in members o f  the cytokine receptor family, the functional
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significance o f  these regions is unknown. The IL-6 receptor also has an 
immunoglobulin-like domain at the amino terminus, making it a member o f  the 
immunoglobulin superfamily. The relatively short, 82 amino acid, intracellular domain 
o f  the IL-6 receptor can be rem oved without affecting its activity (Akira et al, 1990). 
This has been found to be possible due to the presence o f  a 130 kD a membrane 
glycoprotein (g p l3 0 ) which associates with the IL-6 receptor and mediates the signal 
transduction via cellular tyrosine kinase and protein kinase activities (Sedlacek and 
M oroy, 1995). The IL-6 receptor and g p l3 0  do not form a dimer as such as they only 
becom e associated at their extracellular portions after the receptor is stimulated with 
IL-6 (Akira et al, 1990).
Interferon - y  : Interferon-y (IFN-y) is an antiviral and antiproliferative protein which 
also has potent immunoregulatory effects on a variety o f cells (Hamblin, 1988). It was 
first isolated in 1957 as a protein that protected cells from the effects o f viruses and 
w as named ‘interferon’ because it interfered with the replication o f  the viruses by 
som ehow changing the cells (Isaacs and Lindemann, 1957). Although the protein is 
only produced by activated T  cells and NK cells, IFN -y receptors are present on almost 
every cell type except erythrocytes (Sedlacek and M o ro y , 1995).
Mature IFN -y is a 166 amino acid protein with an M r o f  20  - 25 kD a depending 
on glycosylation (Hamblin, 1988). Although the detection o f  low  levels in the absence 
o f  a specific inducer has been reported (Sen and Lengyel, 1992), in vivo IFN -y  
synthesis results from antigenic stimulation while in vitro, non-specific T cell inducers 
such as concanavalin A can be used. IL-2 is also implicated in the synthesis o f  IFN-y  
from NK cells (Barth et al, 1987). Double-stranded R N A  is a potent inducer and is 
thought to be the IFN-y-inducing intermediate produced during virus replication (Sen  
and Langyel, 1992). IFN-y, like IL-6 and other cytokines, has destabilising sequences 
in its mRNA which ensure a short half-life.
IFN-y has also been known as ‘immune interferon’ due to its immunoregulatory 
functions. It is responsible for inducing the expression o f  major histocompatibility 
com plex (M HC) class I and class II encoded proteins involved in antigen recognition
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and presentation, increasing the cytotoxicity o f  N K  cells and macrophages, enhancing 
TNF cytotoxicity and regulating immunoglobulin isotypes secreted during the humoral 
immune response (Sedlacek and M oroy, 1995). IFN -y can selectively inhibit the 
expression o f  several mitochondrial genes which m ay contribute to the anti-proliferative 
effects o f  this cytokine (Sen and Lengyel, 1992). The anti-viral, immunomodulatory 
and anti-proliferative functions o f  IFN-y and its sister m olecule IF N -a , have led  to their 
use as therapeutic agents in a range o f  diseases including hairy cell leukaemia, K aposi’s 
sarcoma, hepatitis B and C infections and chronic granulamatous disease (Henderson,
1993).
The IFN -y receptor is a 90  kD a membrane-bound high affinity receptor which  
contains tw o cysteine-rich domains (Hamblin, 1988). U pon binding, IFN -y induces 
phosphorylation o f  serine-threonine residues on the receptor which begins the signal 
tranduction pathway (Sen and Lengyel, 1992). The ligand-receptor com plex is rapidly 
internalised (Hamblin, 1988), dissociated, dephosphorylated and recycled ensuring a 
constant presence o f  IFN -y receptors on cells  (Sedlacek and M oroy , 1995).
Epidermal Growth Factor : Epidermal growth factor (EGF) is a 6 kDa, 55 amino 
acid polypeptide produced by a wide range o f  cells (Sedlacek and M oroy, 1995). It is 
found in nearly all body fluids ( blood, milk, saliva, urine, sweat etc.) and in multiple 
organs and tissues. W hen first isolated from m ouse submaxillary glands, it w as shown  
to quicken the developm ent o f  newborn m ice and is now  implicated in growth and 
differentiation during foetal developm ent (W aterfield, 1985). It has a major role in 
angiogenesis and w ound healing and has even been developed as an ointment for use 
with bums victims (M utsaers and Laurent, 1995). EGF shares 40% hom ology with  
transforming growth factor (T G F )-a  and both proteins bind to the same cellular 
receptor (Waterfield, 1985). Growth factors such as EGF cause quiescent cells in the 
resting or G0 phase o f  the cell cycle to advance through the Gi and D N A  synthesis 
phases o f  the cycle resulting in mitosis and cell proliferation (Aaronson, 1991). 
Transition through the Gi phase requires sustained growth factor stimulation over a 
period o f  several hours.
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The EGF receptor (EGFr) is perhaps the best-characterised growth factor 
receptor due to the discovery that the A431 carcinoma cell line overexpresses large 
amounts o f  it making it easily available for study (W aterfield, 1985). It is a membrane- 
spanning glycosylated m olecule o f  Mr 170 kDa. U pon binding one m olecule o f  EGF, 
the receptor dimerizes and an intrinsic receptor tyrosine kinase is activated resulting in 
autophosphorylation (Sedlacek and M oroy, 1995). A  feedback mechanism which  
attenuates this tyrosine kinase activity results from the action o f  intracellular protein 
kinase C on a threonine residue o f  the EGFr (Hardie, 1991). This feedback mechanism  
is mediated by the second m essenger diacylglycerol generated through EGFr activity. 
A  second signal attenuation mechanism results from down-regulation o f  EGFr on the 
cell surface as a consequence o f  EGF binding (Gilligan et al, 1990). The EGFr is the 
product o f  the c -erbB2 proto-oncogene (Hardie, 1991). A  truncated form lacking an 
extracellular ligand-binding domain is the product o f  the \-erb  oncogene and results in 
constitutive EGF-like responses in transformed cells. The neu proto-oncogene product 
appears very similar to the EGFr and its oncogenic version which carries a single point 
mutation in the transmembrane region results in enhanced cellular transformation 
(Aaronson, 1991). The EGFr or c-erbB2/neu gene product is frequently overexpressed  
in tumours and has been proposed as a prognostic marker in breast and ovarian cancers 
(Cerra et al, 1995; Scambia et al, 1995). Other EGR-related peptides which bind the 
EGFr include T G F -a and amphiregulin. A  recent study showed that using antisense 
nucleotides directed against these peptides in conjunction with an EGFr-blocking 
antibody resulted in 80% growth inhibition o f  colon carcinoma cells (Normanno et al,
1996). Normally m ost epithelial cells express EGFr whereas cells o f  haematopoietic 
origin are EGFr-negative (Real et al, 1986), however, expression o f  EGFr is related to 
stage o f  cellular differentiation as w ell as cell lineage.
Fibroblast Growth Factors : The fibroblast growth factor (FGF) family presently 
consists o f  7 members: acidic FGF (a-FGF) or FG F -1, basic FGF (bFGF) or FGF-2 and 
five additional recently-discovered FGF-like proteins, hst/ks, int-2, FGF-5, -6 and -7 
(Mutsaers and Laurent, 1995). Acidic and basic FGF are very similar having the same 
M r o f  16-17 kDa and sharing 55% hom ology at the amino acid level (Sedlacek and
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M oroy, 1995). Their names result from differences in isoelectric points. bFGF is an 
ubiquitous protein while aFGF is more specifically associated with brain, retina and 
bone matrix. Apart from proliferative signals to fibroblastic cells, the major function o f  
a/bFGF is angiogenesis (V ile, 1995). This orderly migration and proliferation o f  blood  
vessels is important in embryonic developm ent, w ound healing and during the female 
reproductive cycle, all events where well-regulated neovascularization occurs. This is 
in contrast to the pathologic angiogenic activities associated with tumour developm ent 
and other disorders. B oth bFGF and aFGF are potent inducers o f  endothelial cell 
migration and proliferation and endothelial cells are the primary cell type involved in all 
forms o f  angiogenesis. In vitro, the FGFs are highly m itogenic for endothelial cells, 
while in vivo, picom olar concentrations only are required for angiogenesis (Vlodavsky  
et al, 1990). D espite bFGF being ubiquitous, endothelial cell proliferation is very low  
suggesting that bFGF is either inactive or sequestered. The latter suggestion appears to 
be the case with the ECM  being the major storage depot for bFGF (Vlodavsky et al, 
1990). This raises the possibility o f  invasive tumours being able to release bFGF as 
they degrade ECM  and so constantly provide them selves with new  sources o f  
angiogenic factors as they continue to invade. bFGF also appears able to stimulate the 
release o f  plasminogen activators from endothelial cells (Sedlacek and M oroy, 1995). 
Plasminogen activators along with heparanase can cause the degradation o f  heparan 
sulphate, the ECM  com ponent specifically responsible for binding or sequestering 
bFGF (Vlodavsky et al, 1990). Therefore as more bFGF is released, more plasminogen 
activator is released resulting in further release o f  bFGF and greater angiogenic and 
proliferative potential.
FGFs can induce either proliferation or differentiation in endothelial cells 
depending on the binding o f  cells to ECM  com ponents such as fibronectin and collagen  
(Ingber and Folkman, 1989). The different results appear to stem from the activation  
o f  stretch-sensitive ion channels in the endothelial cells which are activated as cells 
adhere to matrix proteins.
There are two high affinity receptors for the FGFs, receptor I binds aFGF better 
than bFGF and receptor II binds bFGF more strongly (Sedlacek and M oroy, 1995).
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Upon binding to either receptor, aFGF and bFGF are internalised and degraded in the 
lysosom al compartment. Both are slow ly degraded to low  molecular w eight peptides 
which may persist in the cell for up to 24 hours. Like the EGFr, the FGF receptors are 
coded for by proto-oncogenes [c-flg and c-bek] and both have intrinsic tyrosine kinase 
activity (Aaronson, 1991).
Insulin-like Growth Factors : The insulin-like growth factors IGF-I and IGF-II are 
single chain polypeptides with structural hom ology to proinsulin (Mutsaers and 
Laurent, 1995). They have similar molecular w eights (approximately 7 .5 kD a) and 
share 70% hom ology. In serum these growth factors are bound to specific IGF 
binding proteins, the IG FBPs, o f  which there are six known so far (Sedlacek and 
M oroy, 1995). As IGFs are inactive when com plexed, it is thought that these binding 
proteins are modulators o f  IGF activity (Mutsaers and Laurent, 1995). IGF-I and -II 
are also known as the som atom edins as they are secreted by the liver in response to the 
growth hormone somatotrophin (Hardie, 1991). The principal receptor for these 
factors, IGFrl is widely distributed on hepatocytes, fibroblasts, lymphocytes, 
erythrocytes, chondrocytes, adipocytes, pituitary and neural cells. This distribution 
reflects the function o f  the IGFs as paracrine and autocrine growth factors for 
parenchymal cells (Sedlacek and M oroy, 1995). Physiologically, IGF-I is a regulator 
o f cell proliferation while IGF-II appears to be important during foetal development 
(M acauley, 1992). IGF-I is apparently responsible for bone elongation during growth  
and serum levels o f  this cytokine in adolescent boys from pygmy races are only one  
third o f  the levels found in corresponding individuals from taller races (Hardie, 1991). 
IGF-II is widely expressed in m ouse embryos but expression is progressively halted in 
virtually all tissues after birth (Christofori et al, 1994). In humans, however, rather 
high levels o f  IGF-II persist in adult serum but its function is unclear (Rogler et al,
1994). Igf-II is an exam ple o f an imprinted gene, that is one in which one allele is 
silenced so that all transcription takes place from the allele contributed by one parent 
only. In the case o f Igf-II, the paternal allele only is active during developm ent in 
m ouse embryos (M acauley, 1992).
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As they are potent mitogens for a w ide variety o f  cell types, it is not suprising 
that the IGFs have been identified as major paracrine or autocrine growth factors in a 
number o f cancers (W estley and M ay, 1995). There is also evidence that the IGFs have 
a role to play in the actual transformation process itself. Transgenic m ice in which 
expression o f  IGF-II w as targeted to the mammary gland by placing it under the 
control o f  the tissue specific p-lactoglobulin promoter, developed an excess o f  
mammary tumours (Bates et al, 1995). Another group made transgenic m ice in which 
IGF-n expression w as targeted to the liver under the control o f  the major urinary 
protein promoter (R ogler et al, 1994). In this case, m ice developed diverse tumours 
with a preponderance o f  hepatocellular carcinoma. A  third study examined the 
oncogenic activity o f  the S V 40 large T antigen under the control o f  the insulin 
promoter in transgenic m ice (Christofori et al, 1994). A t first no aberrant proliferation 
was seen but by 14 w eeks o f  age, formation o f  highly vascularised solid tumours was 
observed in 1 - 2% o f  islets in the pancreas. The initial proliferative switch w as seen to  
correlate with local activation o f  IGF-II. In vitro, transfection o f  tumour cells with 
antisense oligonucleotides directed against IGF-II m R N A  interfered with tumour 
developm ent while transgenic m ice in which the IGF-II gene was ablated developed  
tumours with reduced malignancy. Similarly, in human breast tumours, expression o f  
IGF-II in stromal fibroblasts appears to correlate with malignancy (Cullen et al, 1991). 
A s a further test o f  the tumour developing function o f  the IGFs, Long et al (1995) 
directed antisense oligonucleotides against the IG Frl rather than the growth factors 
themselves. Tumour cells transfected with the antisense o ligos, when injected into 
m ice lost the ability to produce metastases compared to controls.
IGFs can bind to three different receptors : the insulin receptor, IGFrl and 
IGFr2. O f these IGFrl appears to be the receptor o f  highest affinity for these cytokines 
(Mutsaers and Laurent, 1995). Insulin can also bind to IGFrl although the affinity is 
100-fold less than between the receptor and the IGFs (Sedlacek and M oroy, 1995). 
IGFrl is a tetrameric PocaP structure with tw o transmembrane P chains joined via 
disulphide bridges to tw o extracellular a  domains also joined to each other by a 
disulphide link (Hardie, 1991). The P chains have intrinsic tyrosine kinase activity.
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although not identified as proto-oncogene products themselves, the P chains can act as 
substrates for the src oncogene product, an intracellular tyrosine kinase (W estley and 
M ay, 1995).
Transforming Growth Factor B : There are five known isoform s o f  TGF-P, 3 of 
which have been found in mammalian tissues (TG F-Pi( 2, 3), one in avian tissues (TGF- 
P4) and one in Xenopus (TG F-p5) (W alker et al, 1994). The mammalian isoform s share 
approximately 80% hom ology. TGF-P w as initially isolated from platelets but was 
subsequently found to be expressed by alm ost all cells and is secreted in a latent form  
which is unable to bind to its receptor (M utsaers and Laurent, 1995). Activation o f  
pro-TGF-P is achieved by proteinase [e.g. plasmin] action (Sedlacek and M oroy,
1995). TGF-P is a potent growth inhibitor for m ost cell types although proliferative 
effects have been observed in osteoblasts and uterine lining epithelial cells (Mutsaers 
and Laurent, 1995). It can effect entry into the differentiation pathways in many cell 
types including fibroblasts, mesenchymal cells into bone cells and chondrocytes and 
bronchial epithelia into squamous cells (Sedlacek and M oroy, 1995). In contrast it can 
inhibit differentiation o f  mucoblasts and adipose cells. TGF-P is a key regulator o f  the 
inflammation process, involved in both its initiation by stimulating m onocyte migration 
and growth factor production, and its resolution by inhibiting immune cell adhesion to  
the vascular endothelium, down-regulating macrophage functions and antagonizing the 
actions o f  the pro-inflammatory cytokine TN F (M auviel et al, 1993a). TGF-P has a 
major role in wound healing being associated with increased tensile strength o f  a 
healing w ound due primarily to its stimulating effect on ECM  production (Mutsaers 
and Laurent, 1995). Apart from its potent stimulatory effects on fibronectin, 
procollagen I and III, elastin and tenascin, TGF-P also induces the matrix proteoglycan  
decorin. Decorin can bind TGF-P and neutralise its biological activity suggesting that it 
is a natural regulator. Apart from stimulating ECM  formation directly, TGF-P also has 
an inhibitory effect on ECM  degradation by down-regulating proteinase production and 
upregulating proteinase inhibitor expression (Edwards et al, 1987).
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TGF-P w as named for its ability to induce the phenotypic transformation o f  
fibroblast cell lines (Derynck, 1994) so its role in cancer developm ent should not be 
suprising. The relationship o f  TGF-P to altered ECM  expression and its effect on 
disease progression has been examined in invasive breast carcinoma using immuno- 
histochemistry (Walker et al, 1994). Prominent immunoreactivity for TGF-P was 
associated with lymph node metastasis, increased cellular fibronectin, more prominent 
tenascin and the presence o f  tumour associated macrophages and T lymphocytes 
indicating that TGF-P m ay ahve a role in invasion and metastasis o f  breast carcinomas.
TGF-p binds with high affinity to m ost cell types and to date at least nine 
receptor/binding activities have been identified although m ost o f  the activity appears to 
be mediated through type I and type II receptors (Mutsaers and Laurent, 1995). These 
receptors belong to a family o f  serine/threonine kinase receptors and have a short 
extracellular domain and a long cytoplasm ic region that consists largely o f  the kinase 
domain (Derynck, 1994). An intrinsic tyrosine kinase activity has also been attributed 
to the type II receptor. Although very little is known about the intracellular events that 
follow  TGF-P treatment, it is thought the signalling mechanisms in cells stimulated to 
proliferate by this cytokine are different to those in cells that are growth arrested. In 
proliferating cells, TGF-P appears to upregulate other growth factors such as platelet 
derived growth factor (PDGF) or receptors such as EGFr whereas in epithelial cells 
which are growth inhibited, TGF-P appears to arrest the cell cycle in the Gi phase 
(Derynck, 1994).
The preceeding pages have served to introduce the general activities o f  a number o f  
different cytokines. The specific effects o f  som e o f  these m olecules on MMP and 
TIMP expression w ill now  be reviewed.
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5.3 Cytokines and M etalloproteinases
A s m entioned in chapter one, the expression o f  various members o f  the M M P and 
TIMP families can be m odulated by a w ide range o f  m olecules. Table 1.2 listed the 
inhibitory or stimulatory effects o f  a number o f  these m olecules on M M P expression. 
Am ongst those m olecules, the cytokines are perhaps the m ost important as they are 
physiologically relevant and their presence has been demonstrated in areas where MMP  
activity is  m anifested (Ito et al, 1992).
The proinflammatory cytokines IL-1, IL-6 and TN F are particularly associated with 
rheumatoid arthritis, an autoimmune disorder characterised by chronic inflammation 
(Abbas et al, 1991). It has been demonstrated that IL-1 in particular can upregulate 
interstitial collagenase and strom elysin-1, enzym es associated with this disease 
(M acNaul et al, 1990). The stimulatory effect o f  IL-1 could be further enhanced in a 
synergistic manner with TNF. The effects o f  IL-1 on stromelysin-1 and interstitial 
collagenase can also be improved by IL-6 which, on its ow n, has no effect on these 
M M Ps in synovial fibroblasts (Ito et al, 1992). IL-1 and TN F appear to have no effect 
on TIMP-1 levels and are thus responsible purely for an increase in degradation in 
rheumatoid synovium  (M acNaul et al, 1990). IL-6 on the other hand, does enhance the 
production o f  TIMP-1 by synovial fibroblasts (Ito et al, 1992). H ow ever the levels o f  
TIMP-1 stimulated by IL-6 were far low er than the levels o f  interstitial collagenase and 
stromelysin-1 induced by IL-1 in conjunction with IL-6. The induction o f  TIMP-1 by 
IL-6 has been demonstrated in other cell types also. In human dermal fibroblasts, 
TIMP-1 production w as enhanced by IL-6 whereas interstitial collagenase and 
stromelysin-1 were unaffected (Sato et al, 1990). The stimulation o f  TIM P-1 by EL-6 
in hepatocytes both in vitro and in vivo has also been demonstrated (Kordula et al, 
1992). A s IL-6 is the principal mediator o f  the acute phase response which results in 
the enhanced synthesis o f  various liver proteins including the general anti-proteinase 
a 2-macroglobulin, its effect on TIM P-1 should not be suprising. T o determine 
whether the effect o f  IL-1 on the arthritis-associated M M Ps was mediated through 
prostaglandins, the principal effectors o f  IL-1 activities, the direct effects o f  PGE2 on
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M M P production in fibroblasts has been examined (M auviel et al, 1994). Unlike IL-1, 
PGE2 did not affect stromelysin-1 expression although it did elevate levels o f  interstitial 
collagenase in a dose-dependent manner. The stimulatory action o f  PGE2 on interstitial 
collagenase showed no additive or synergistic effects with IL-1. A  previous study also 
showed that the IL-1-induced M M P expression could not be mediated through 
prostaglandins as the prostaglandin-inhibitory agent indomethacin had no effect on the 
stimulation attributed to IL-1 (M acNaul et al, 1990).
The effects o f  IL-1 and TNF as well as the potent tumour promoter 1 2 -0 -  
tetradecanoyl-phorbal-13-acetate (TPA) on M M P expression in a wide range o f  cell 
lines were com prehensively investigated by M ackay et al (1992). Gelatinase A  and 
TIM P-2 activities were not affected by the cytokines or TPA in m ost cell lines. 
Stromelysin-1, gelatinase B and TIMP-1 stimulation in response to IL-1 or TNF  
treatment was observed in many tumour cell lines and in normal human umbilical vein  
endothelial cells (H U V E C s). A s expected a greater stimulation was produced by TPA. 
In the case o f  A 549, a lung carcinoma cell line, TN F stimulated gelatinase B but not 
TIM P-1. This type o f  discoordinate induction is thought to cause the imbalance in 
proteinase and inhibitor activities which favours ECM  degradation by invasive tumour 
cells. TNF has also been shown to upregulate secretion o f  gelatinase B by a 
promyelocytic cell line, H L -60 (Ries et al, 1994). Basal secretion o f  the proteinase was 
reduced after a TNF-neutralizing antibody was added to the cells suggesting that the 
constitutive production o f  gelatinase B exhibited by these cells can be attributed to  
autocrine stimulation by TN F. This type o f  activity may be important in regulating the 
invasive ability o f  leukaemia cells.
The effects o f  TGF-J3 have previously been mentioned - it stimulates the 
synthesis o f  ECM  com ponents and appears to inhibit proteinases. This effect on  
proteinases has been demonstrated in cultures o f  human fibroblasts where levels o f  
interstitial collagenase decreased over a number o f  days as the cultures were exposed to 
TGF-p (Overall et al, 1989). In the same cultures, how ever, the synthesis o f  gelatinase 
A was increased alm ost two fold. T IM P-1 was also stimulated in these cultures. The 
authors o f  this study suggest that the gelatinase A may be required for ECM
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»remodelling after increased matrix protein deposition caused by TG F-p. TGF-P also  
increases T IM P-1 in hepatocytes in a similar manner to EL-6 in these cells (Kordula et 
al, 1992). In cervical epithelial cell lines which are growth inhibited by TG F-p, levels 
o f  both gelatinase A and B are upregulated in response to the cytokine (Agarwal et al,
1994).
The uterine endometrium is one o f  the few  areas in human adults where 
extensive tissue remodelling regularly occurs. This remodelling has been found to be 
principally due to the M M Ps stromelysin-1 and -2  and matrilysin (Osteen et al, 1994). 
W hile the stromally-produced stromelysins could be directly modulated by hormones, 
matrilysin, as an epithelial-specific M M P, w as found to require an additional factor to  
mediate its suppression by the hormone progesterone. TGF-P has been shown to be 
produced in response to progesterone and to inhibit matrilysin production by 
endometrial cells (Bruner et al, 1995). Matrilysin is also produced by developing  
phagocytes (Busiek et al, 1992). Its production by these cells does not appear to be 
affected by TGF-P or by the pro-inflammatory cytokines IL-1, IL-6 and TNF, however  
inhibitory effects have been attributed to IL-4, IL-10 and IFN-y, all inflammation- 
modulating cytokines (Busiek et al, 1995). It should be noted that IL-4 and IFN-y, 
although both inflammation-modulating, usually have antagonistic effects. In contrast, 
matrilysin produced by the mesangial cells o f  the kidney does appear to be stimulated 
by IL-1 and TNF (Marti et al, 1992). This variation in responsiveness suggests the 
activity o f tissue-specific factors within the various matrilysin-producing cell types.
EGF is stimulatory for a number o f  M M Ps in various cell types. In fibroblasts, 
the induction o f  stromelysin-1 by EGF has been shown to occur via the intracellular 
second messenger protein kinase C and specific nuclear transcription proteins Fos and 
Jun (M cDonnell et al, 1990). Stromelysin-1 and interstitial collagenase induction in 
fibroblasts by EGF is also due, in part, to increased stability o f  the M M P mRNA  
(Delaney and Brinckerhoff, 1992). The delineation o f  intra-cellular signalling pathways 
for M M Ps responding to various other cytokines has not, in many cases, been carried 
out. This topic will be further discussed in the introduction to chapter six. Oesphageal 
cell lines have also been shown to respond to EGF treatment by upregulating
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production o f  interstitial collagenase, stromelysin-1 and the gelatinases A  and B (Shima 
et al, 1993).
IFN-y can stimulate the production o f  interstitial collagenase and stromelysin-1 
but not TIMP-1 from cultured keratinocytes (Tamai et al, 1995).
From the above studies, it w ould  appear that interstitial collagenase and stromelysin-1 
are the m ost readily-inducible M M Ps that can be produced by a range o f  different cell 
types. Matrilysin show s a very variable stimulation pattern depending on the cell type. 
W hile the effects o f  a number o f  different cytokines on a number o f  different M M Ps in 
different cell types have been exam ined, there are not many studies where all these 
variables have been investigated together. The aim o f  the work presented in this 
chapter was to evaluate the effects o f  a range o f  different cytokines [EL-1, IL-2, IL-6, 
IGF-I, IGF-II, EGF, bFGF, TG F-p and IFN-y] on matrilysin and stromelysin-1 
production in a range o f  different cell lines. Stromelysin-1 represents an apparently 
readily-inducible M M P w hile matrilysin represents a tissue-specific M M P. This also  
serves as an introduction to our work o f  dissecting the control elements o f  the 
matrilysin promoter which is d iscussed further in chapter six.
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Results and Discussion
5.4 Cell Lines Used
A range o f  tumour cell lines representing different tissue types were used in this 
investigation. The cell lines used and their origins are outlined in Table 5.2.
¡¡Peli L in e - , '• ^  " 'N
| SW 480 Colon adenocarcinoma - primary tumour
! SW 620 Colon adenocarcinoma - lymph node metastasis
I L oV o Colon adenocarcinoma
! A 549i .........  ......... \ Lung carcinoma
\ K 562 Chronic m yeloid leukaemia
| EJ 1 Bladder carcinoma
) MCF-7 Breast carcinoma
I Go-GCCM Brain anaplastic astrocytoma
Table 5.2 C ell lines used and the tumours from w hich they were initially derived.
5.5  Basal Expression levels o f stromelysin-1 and matrilysin
Prior to examining the effects o f  cytokines on stromelysin-1 and matrilysin expression 
in these cell lines, their basal expression levels were determined. This was achieved by 
culturing the cell lines for at least tw o passages (see sections 2 .2 .9 .1 /2), before 
removing serum and culturing for 24 hrs in serum-free media. The cells were harvested 
and total R N A  extracted as outlined in section 2 .2 .11 .1 . The expression o f  specific 
matrilysin and stomelysin-1 m RNAs w as analysed using the Reverse Transcriptase -
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Polymerase Chain Reaction (RT-PCR) (section 2 .2 .12 ). Briefly, the m RNA was 
primed with o ligo  d(T) primers which bound specifically to the polyadenylated ‘tail’ o f  
mature m RNA. U sing a viral reverse transciptase enzym e, the primed m RNA was 
converted to cD N A . An aliquot o f  the cD N A  w as then m ixed with the enzym e Taq  
polymerase, specific primers recognising target genes and nucleotides. The reaction 
mixture was then subjected to thirty cycles o f  different temperatures chosen for optimal 
amplification o f  the target D N A .
In all PCR assays described here, tw o sets o f  primers were included in each  
reaction. One set recognised a region o f  the specific target gene, matrilysin or 
stromelysin-1, while the second set recognised a region o f  the constitutively-expressed  
gene, P-actin. The P-actin acted as an internal control for the actual reaction and also  
allowed normalisation o f  results between reactions. The expected size o f  the P-actin 
product was 225 bp. The stromelysin-1 product was 324  bp while the matrilysin 
product was 341 bp. Both the matrilysin and stromelysin-1 primers spanned an intron 
so that if  genom ic D N A  rather than cD N A  from the RT reaction were amplified, larger 
products would result.
The data in Table 5.3 represents the results obtained when R N A  from each o f  the cell 
lines mentioned was isolated and analysed for stromelysin-1 and matrilysin expression.
Cali L ine " : M aldJysm  ■ S tro m eh sm -I
| SW 480 - +
! SW 620: : + | +
| L oV o +++ -
j A 549 ++ +
| K562 ++ +
j EJ - -
| MCF-7 - ++
| Go-GCCM - +
1.............................................................. JTable 5.3 Expression o f  matrilysin and stromelysin-1 in human tumour cell lines. The 
relative levels o f each o f  the proteinases, determined by inspection, are indicated using 
a simple scoring system  where indicates no expression and ‘+ \  *++’ and *+++’ 
indicate increasingly higher levels.
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All cell lines used other than the leukaemia-derived K 562 cell line, were epithelial in 
origin. Matrilysin is regarded as as an epithelial-specific M M P (Crawford and 
Matrisian, 1995) while stromelysin, although usually associated with stromal cells, can 
also be produced by epithelial cells (Sato et al., 1992). The production o f  these 
proteinases by the K 562 cell line is more unusual. K ossakowska et al. (1993)  
examined 43 primary lymphomas for M M P expression and found matrilysin expressed  
in only a few  cases w hile strom elysin-1 expression w as not detected. Matrilysin is 
produced by developing m onocytes (Busiek et al., 1992) so its detection in a cell line 
derived from a blood cell lineage is, perhaps, not very suprising. It should also be 
borne in mind, as with all cell line work, that the cell lines may no longer fully resemble 
their cellular origins.
5.6 Cytokine Treatments
The cytokines used in this study represent a range o f  different activities 
including mediators o f  inflammation, classic growth factors, a growth-inhibitor and 
immunomodulators. T o assess their effects on matrilysin and strom elysin-1 steady- 
state m RNA levels, cell lines were cultured overnight in serum-free media prior to  
treatment for 8 hrs with a specific cytokine. The choice o f  8 hrs as the treatment time 
w as suggested by literature (M cD onnell et al., 1990; Gaire et al., 1994). The cells were 
then harvested, total R N A  isolated and analysed as above. In order to demonstrate that 
the ‘mini-preparation’ R N A  isolation m ethod used was indeed suitable, aliquots o f  the 
isolated R N A  were electrophoresed on agarose gels in the presence o f  the reducing 
agent, formaldehyde (section 2 .2 .11 .3 ). The presence o f  bands representing the 28S  
and 18S ribosomal R N A  subunits demonstrated successful RNA isolation with minimal 
degradation. The appearance o f  one o f  these gels is shown in Figure 5.1.
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Figure 5.1 Agarose gel electrophoresis o f  total R N A  isolated from the A 549 cell line 
follow ing cytokine treatment. Each lane contains R N A  isolated from a flask o f  A549  
cells treated with a specific cytokine. The white bands represent the 28S (upper band) 
and 18S (lower band) ribosomal subunits. The almost com plete lack o f  smearing 
indicates minimal degradation o f  the RNA.
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Satisfied that the R N A  isolation procedure yielded R N A  o f  high quality, the R N A  from 
all 8 cell lines treated with the 9 different cytokines was analysed using RT-PCR. The 
D N A  products for each cell line w ere run on 3 % agarose gels, stained with ethidium  
bromide and photographed. The gels obtained after RT-PCR analysis o f  one cell line
(A 549) are shown in Figure 5.2.
M W
(b p )
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Figure 5.2  Agarose gels o f  RT-PCR products from the total R N A  isolates obtained  
from the cell line A 549 follow ing treatment with different cytokines, (a) shows bands 
representing (3-actin (lower band at 225 bp) and stromelysin-1 (higher band at 324 bp), 
w hile (b) show s bands representing (J-actin and matrilysin (341 bp) products. The right 
hand lane(12) in each gel contained a 100 bp ladder as size markers and the lane 
im m ediately to the left o f  it ( l  1) contained the negative control reaction (RT-PCR with 
R N A  template replaced by water). The other lanes represented (1) control, (2) IL -ip , 
(3) IL-2, (4) IL-6, (5) IGF-I, (6) IGF-II, (7) EGF, (8) bFGF, (9) TG F-p and (10) IFN- 
Y-
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To assess the specific effect o f  each cytokine and to normalise for equivalent P-actin 
yields thus eliminating any variations between reactions, densitometric scanning o f  the 
gels was performed. Each pair o f  bands (P-actin and matrilysin or stromelysin-1) was 
analysed separately and a plot o f  light intensity versus band position w as obtained. An 
exam ple o f  one such plot is presented in Figure 5.3.
Band Position
Figure 5.3 Plot obtained from densitometric scanning o f  the ethidium bromide stained 
bands in a 3 % agarose gel. The pair o f  bands resulting from RT-PCR analysis o f  TGF- 
P treated A 549 cells were scanned and the data obtained plotted as above.
The area under the curve for each peak in these plots was then calculated. Ratios o f  
matrilysin or stromelysin-1 to P-actin were obtained and compared for each cytokine in 
every cell line. Figures 5 .4  - 5 .12  indicate in graphical format the effect o f  each 
cytokine in a particular cell line as determined by this analysis. The plots are obtained 
from one set o f  experiments and are representative o f  the results obtained when these 
experiments were repeated.
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Figure 5.4 Effects o f  IL -ip  on matrilysin and stromelysin-1 expression by a range o f  
cell lines. L evels o f  expression were determined by RT-PCR analysis and have been 
normalised relative to P-actin expression. The levels are represented as fold increase 
over control, with a baseline o f  1 representing control (i.e. untreated) levels. Neither 
MCF-7 or Go-GCCM  cells expressed matrilysin. The L oV o cell line expresses 
matrilysin at the same level as control follow ing treatment with IL -ip .
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Figure 5.5 Effects o f  IL-2 on matrilysin and stromelysin-1 expression in a range o f cell 
lines. L evels o f  expression were analysed by RT-PCR and have been normalised 
relative to P-actin expression. The levels are represented as fold  increase over control, 
with a baseline level o f  1 representing control (i.e. untreated) levels. Matrilysin was not 
expressed by the MCF-7 or Go-G CCM  cell lines. The level o f  matrilysin expressed by 
both the L oV o and EJ ce lls  fo llow in g  treatment with IL-2 w as similar to control.
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F igure 5 .6  Effects o f  IL-6 on matrilysin and stromelysin-1 expression in a range o f  cell 
lines. L evels o f expression were analysed by RT-PCR and have been normalised 
relative to (J-actin expression. The levels are represented as fold increase over control, 
with a baseline level o f  1 representing control (i.e. untreated) levels. The M CF-7, Go- 
GCCM and EJ cell lines did not express matrilysin. The levels o f matrilysin expressed  
by the A 549 cells follow ing treatment with IL-6 were similar to control.
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Figure 5.7 Effects o f  IGF-I on matrilysin and stromelysin-1 expression in a range o f  
cell lines. L evels o f  expression were analysed by RT-PCR and have been normalised 
relative to (3-actin expression. The levels are represented as fold increase over control, 
with a baseline level o f  1 representing control (i.e. untreated) levels. The MCF-7 cell 
line does not express matrilysin. A nalysis o f  the effect o f  IGF-1 on the Go-GCCM  cell 
line was not done.
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F igu re 5 .8  Effects o f  IGF-II on matrilysin and stromelysin-1 expression in a range o f  
cell lines. L evels o f  expression were analysed by RT-PCR and have been normalised 
relative to (3-actin expression. The levels are represented as fold  increase over control, 
with a baseline level o f  1 representing control (i.e. untreated) levels. Neither M CF-7 or 
G o-GCCM  cells expressed matrilysin. N o  result w as obtained for stromelysin-1 
expression by the EJ cell line.
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F igure 5 .9  Effects o f  EGF on matrilysin and stromelysin-1 expression in a range o f  cell 
lines. Levels o f  expression were analysed by RT-PCR and have been normalised 
relative to P-actin expression. The levels are represented as fold increase over control, 
with a baseline level o f  1 representing control (i.e. untreated) levels. The M CF-7 cell 
line does not express matrilysin and its level o f  stromelysin-1 expression was 
unchanged from control levels follow ing treatment with EGF. N o results were  
obtained for the G o-G CCM  cell line.
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F igure 5 .10  Effect o f  bFGF on matrilysin and stromelysin-1 expression in a range o f  
cell lines. L evels o f  expression were analysed by RT-PCR and have been normalised 
relative to P-actin expression. The levels are represented as fold  increase over control, 
with a baseline level o f  1 representing control (i.e. untreated) levels. Matrilysin was 
not expressed by the EJ, M CF-7 or Go-G CCM  cell lines. bFGF had no effect on 
stromelysin-1 expression in the SW 480 cell line as levels were similar to control. The 
effects o f  bFGF on K 562 cells  were not analysed.
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Cell Line
SW 480 SW 620 LoVo A549 K562 EJ MCF-7Go-GCCM
F igure 5 .11 E ffects o f  TGF-(3 on matrilysin and stromelysin-1 expression in a range o f  
cell lines. L evels o f  expression were analysed by RT-PCR and have been normalised 
relative to (3-actin expression. The levels are represented as fold  increase over control, 
with a baseline level o f  1 representing control (i.e. untreated) levels. Matrilysin was 
not expressed by either the M CF-7 or G o-G CCM  cell lines. L oV o matrilysin 
expression w as unchanged from control levels.
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F igure 5 .12  E ffects o f  IFN -y on matrilysin and stromelysin-1 expression in a range o f  
cell lines. L evels o f  expression were analysed by RT-PCR and have been normalised 
relative to (i-actin expression. The levels are represented as fold increase over control, 
with a baseline level o f  1 representing control (i.e. untreated) levels. Neither the MCF- 
7 or G o-GCCM  cell lines expressed matrilysin. N o result was obtained for matrilysin 
expression in K 562 cells. IFN -y had no effect on matrilysin expression in the L oV o cell 
line, or stromelysin-1 expression by either the A 549 or EJ cell lines, with levels similar 
to control.
147
5.6.1 Discussion of Cytokine Results
Effects o flL -lp
IL-lp is known as a pro-inflammatory cytokine responsible, amongst other 
functions, for the upregulation of interstitial collagenase and stromelysin-1 produced by 
synovial cells in rheumatoid arthritis (MacNaul et al., 1990; Ito et al., 1992). Its 
effects on MMP secretion by epithelial tumour cells are less well-characterised. 
Macakay et al., (1992) reported that stromelysin-1 and gelatinase B as well as TIMP-l 
could be stimulated in some tumour cell lines and normal human vein endothelial cells 
(HUVECs). Gelatinase A and TIMP-2 were refractory to IL-ip treatment in all cell 
lines tested. Their study did not include matrilysin and was limited to 4 tumour cell 
lines. The data presented in Figure 5.4 demonstrates that IL-ip has a stimulatory effect 
on stromelysin-1 production by almost all the cell lines tested ranging from a 4.5-fold 
increase in the bladder carcinoma line, EJ to a 1.3-fold increase in the colon cell line, 
SW620. Stromelysin-1 expression was inhibited by IL-ip in one cell line, the breast 
carcinoma MCF-7. Although not as dramatic as with stromelysin-1, the effects of IL- 
ip  on matrilysin expression were also generally stimulatory. Two cell lines, MCF-7 
and Go-GCCM, could not be induced to express matrilysin and the expression by the 
LoVo cell line remained unchanged from control. In 4 of the other cell lines examined, 
matrilysin expression was stimulated between 1.8- and 2.8-fold. There was a minor 
inhibitory effect on matrilysin expression by the A549 cell line. It is possible that 
matrilysin and stromelysin-1 could act synergistically to increase the invasive abilities of 
tumours if secreted by the one cell type. This may be of particular importance in 
tumours with a large amount of tumour-associated macrophages, as phagocytes are 
important producers of this cytokine.
Effects of IL-2
IL-2 is generally regarded as an immune system-associated cytokine so it is 
quite suprising to find it has stimulatory effects on stromelysin-1 production in 
particular by tumour cells. The stimulatory effect of IL-2 on both matrilysin and 
stromelysin-1 is strongest in the colon adenocarcinoma-derived SW480 cell line. In
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fact, stromelysin-1 expression is upregulated in all of the colon-derived cell lines 
following IL-2 treatment. It is possible that this in vitro effect is of little relevance in 
vivo, as it is thought that responses to cytokines are markedly affected by the ECM 
(Nathan and Spom, 1991) which is lacking in cell cultures. It is also possible, however, 
that the influence of the ECM could be affected by MMP release from tumour cells in 
response to cytokines.
Effects of IL-6
IL-6, like EL-lp, is a proinflammatory cytokine, although its effects are not so 
widespread. The almost complete lack of response by the majority of the cell lines 
tested was expected as previous studies of IL-6 have shown it to be stimulatory for 
TIMP-1 but not MMP expression (Sato et al., 1990; Kordula et al., 1992; Ito et al., 
1992). The 8-fold increase in matrilysin expression by the promyelocytic K562 cell 
line following IL-6 treatment is quite dramatic. There are few reports of matrilysin 
expression by leukaemias (Kossakowska et al., 1993) and none investigating cytokine 
effects on these types of cells. Matrilysin is produced by promonocytes (Busiek et al., 
1992) and there is a possibility that cytokines such as IL-6 are responsible for 
regulating that production.
Effects of IGF-I
There are no previous reports of IGF-I affecting MMP expression, however, it appears 
to be stimulatory for both matrilysin and stromelysin-1 in a range of cell lines. It has 
been reported that IGF-I can enhance proliferation of colon carcinoma cells (Lahm et 
al., 1994) and matrilysin production by colon carcinomas has also been previously 
documented (McDonnell et al., 1991; Newell et al., 1994; Witty et al., 1994). The role 
of matrilysin in colon tumour development is unclear but it is thought that it is linked to 
tumour cell proliferation. It is possible that the proliferative effects of IGF-I are 
mediated through matrilysin by an unknown mechanism. The greatest effect of IGF-I, 
however, is seen in the K562 cell line.
Effects of IGF-II
As is the case with IGF-I, there have been no previous reports of the effects of IGF-II 
on MMP expression. The strong effect of IGF-II on matrilysin expression by K562
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cells is similart to that seen with IGF-I and, as both IGF-I and II can act through the 
same receptor, this is not very surprising. The fact that the effects of IGF-I in other 
cell lines are not repeated by IGF-II may be due to the apparently limited function of 
IGF-n in foetal development. Human tumour cells derived from adult tissues may not 
have the ability to respond to IGF-II whereas the blood cell precursor cell line, K562, 
may represent foetal cells.
Effects of EGF
The stimulatory effects of EGF on MMP production, particularly stromelysin-1 and 
interstitial collagenase, have been well-documented (Kerr et al., 1988; McDonnell et 
al., 1990; Delaney and Brinckerhoff, 1992; Gaire et al., 1994). The similarity of MMP 
genes , almost all of which contain an AP-1 element in their promoter regions, is 
thought to be responsible for the widespread effects of EGF. There is, however, 
evidence for cell-type specific stimulation (Mauviel, 1993b) perhaps explaining the 
different levels of stimulation seen in the various cell lines used here. The lack of 
response in the MCF-7 cell line may be due to aberrant EGF receptors as changes in 
these receptors as a result of oncogenic transformation are often found in breast cancer 
cells (McGuire and Clark, 1992).
Effects of bFGF
The stimulatory effects of bFGF on matrilysin production are most evident in the colon 
carcinoma-derived cell lines. These effects have not previously been reported. The 
almost complete lack of effect on stromelysin-1 expression in these cell lines suggests 
bFGF is a matrilysin-specific cytokine. As matrilysin has been suggested to have a role 
in proliferation particularly of colon carcinomas (Witty et al., 1994), interfering with 
bFGF-induced stimulation of matrilysin may provide a mechanism of reducing the 
tumourigenicity of these cells.
Effects of TGF-p
TGF-P has previously been reported as having an inhibitory effect on stromelysin-1 and 
interstitial collagenase expression (Edwards et al., 1987; Kerr et al., 1990). These 
previous reports, however, examined stromelysin-1 expression by fibroblastic cells. It 
is interesting to see that in other cell types, TGF-P appears to be stimulatory for
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stromelysin-1 expression in 2 cell lines ( LoVo and K562) and to have little or no effect 
on stromelysin-1 expression by most other epithelial cell lines. Matrilysin expression 
was not observed to be inhibited in any cell lines either and, was actually stimulated in 3 
cell lines.
Effects of IFN-y
The immunomodulatory cytokine IFN-y did not appear to have a large effect on 
matrilysin expression by any cell line, although some stimulation was seen in the 
SW480, SW620 and EJ cell lines. Stromelysin-1 expression has previously been shown 
to be down-regulated by IFN-y treatment (Mauviel, 1993b), although, as is the case 
with most previous studies, fibroblastic cells were studied. IFN-y appeared to 
upregulate stromelysin-1 expression in a number of tumour cell lines examined here, 
including K562, LoVo and SW480.
Taking all the results together, it may be seen that the various cell lines respond quite 
differently to the different cytokines. There are a number of possible explanations :
• Presence or absence of specific cytokine receptors;
• Different levels of specific receptors;
• Cell-type specific secondary and tertiary messengers for signal transduction;
• Differences in mRNA processing.
Information regarding expression of specific cytokine receptors on particular cell lines 
is scarce. An investigation into EGF receptor (EGFr) by Real et al. (1986) revealed 
the presence of moderate amounts of EGFr on both SW480 and MCF-7 cells. 
However, this study also found no EGFr expression by K562 cells which is contrary to 
the observed effects of EGF on both matrilysin and stromelysin-1 expression. This 
disparity may be due to an alternative form of the EGFr protein not recognised by the 
monoclonal antibody used in the receptor expression study. The IGF receptor, through 
which both IGF-I and IGF-II can act, has been found to be expressed on all colorectal 
carcinoma cell lines tested (Lahm et al., 1994). The cell lines studied included SW480, 
SW620 and LoVo. Studies on how cytokines affect other cellular functions provide 
more information on receptor presence. The upregulation of the adhesion molecule,
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ICAM-1, in a number of breast cancer cell lines following treatment with either EL-1(3 
or IL-6 (Hutchins and Steel, 1994) suggests that receptors for these cytokines are 
present on MCF-7 cells. TGF-p, IFN-y and the IGFs have also been shown to 
influence the growth and behaviour of breast cell lines (Lippman et al., 1986; Cullen et 
al., 1991). The lack of response by any cell line to a particular cytokine may, therefore, 
suggest a lack of receptor. For example EJ, Go-GCCM or MCF-7 cells show no 
response to IL-2 and this may be due to a lack of a receptor for IL-2. Although the 
expression of matrilysin is apparently not affected by IL-2 in LoVo cells, stromelysin-1 
expression is enhanced suggesting a functioning receptor and signalling pathway.
Many gene-expression controlling elements are cell-type specific so that, 
although the regulatory message is transduced from the cell surface to the nucleus, 
gene activation cannot proceed. This may be the reason for the stimulatory effect of a 
particular cytokine in cell lines derived from certain tissues while no effect is seen in 
other cell lines. An example is the effect of EGF on stromelysin-1 expression. All the 
colon carcinoma cell lines (SW480, SW620 and LoVo) respond similarity while no 
response is seen in the lung (A549) or bladder (EJ) cell lines. Alternatively, the specific 
gene being investigated, may lack appropriate elements to respond to signals generated 
through the binding of a cytokine. bFGF, for example, has very little effect on 
stromelysin-1 expression in any cell line. The control elements of genes responsible for 
mediating signalling events are discussed further in chapter six.
A final possibility is that the effects seen are not actually due to interactions 
with matrilysin or stromelysin-1. As RT-PCR gives an indication of steady-state 
mRNA levels, increased levels may reflect mRNA of greater stability than usual. Some 
MMP genes, like some cytokine genes, appear to contain AU-rich destabilising 
sequences in the 3’ untranslated region of the mRNA (Delaney and Brinckerhoff, 
1992). It has been suggested that MMP-specific ribonucleases are required to degrade 
MMP mRNA (Brenner et al., 1989). The regulation of these ribonucleases may be 
affected by cytokine treatment thus having an effect on MMP mRNA stability resulting 
in an apparent increase in steady-state levels.
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Overall, these results indicate that, depending on tissue type, many cytokines 
can influence expression of matrilysin and stromelysin-1 mRNA. Previous studies have 
tended to concentrate on the effects of cytokines on MMP levels in fibroblastic cells. 
This investigation demonstrates that MMP expression by epithelial cells, also, can be 
modulated by cytokines. Whether there are specific control elements within the 
matrilysin gene responsible for these effects will be further investigated in chapter six.
5.7 In situ hybridisation
As further evidence of matrilysin expression in specific cell types, an alternative 
approach to demonstrating the presence of specific mRNA was used. In situ 
hybridisation shows specific mRNA localised within cells. The technique was used 
with the LoVo and K562 cell lines as these were to be further investigated for control 
of matrilysin expression (chapter six). A specific digoxigenin-labelled riboprobe for 
matrilysin was prepared and used as outline in section 2.2.13. The cells were grown in 
special chamber slides to allow ease of processing. Results obtained are shown in 
Figure 5.13.
The presence of specific matrilysin mRNA can be clearly seen. The lack of staining 
within the nucleus demonstrates that the probe bound only to RNA and not DNA. It 
was attempted to show cytokine effects on matrilysin expression using this technique, 
however, no clear differences between treated and untreated cells could be discerned.
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(C) (d)
Figure 5.13 In situ hybridisation of matrilysin mRNA in K562 [(a) & (b)] and LoVo 
[(c) & (d)] cells. Detection with the antisense probe is seen in (a) and (c) while the 
sense probe (negative control) was used in (b) and (d).
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5.8 Effects of cytokines on levels of matrilysin protein
While specific mRNA is present only in cells actively expressing a gene, post- 
transcriptional and translational regulation may affect expression of the actual protein 
coded for by the gene. To examine the levels of matrilysin protein produced by cell 
lines, an ELISA for matrilysin was developed. The development and validation of this 
assay is outlined in chapter three.
Conditioned media (CM) was collected from cell lines following 24 hr culturing in 
serum-free media. The medium was clarified by centrifugation and used directly in the 
ELISA. Results for matrilysin protein levels in different cell lines are shown in Figure 
5.14.
SW 480 SW 620 K562 LoVo A549 EJ
Cell Line
Figure 5.14 Matrilysin protein levels in CM from cell lines as determined by ELISA.
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From the matrilysin mRNA analysis in different cell lines (Table 5.3), it would have 
been expected that the LoVo cell line would produce most protein with A549 and 
K562 lines producing moderate amounts and SW620 producing least. The actual 
values for protein production indicate that the A549 cell line is the most potent 
producer. This disparity may be due to the longer incubation time used for protein 
analysis (24hrs as compared to 8 hrs for mRNA). The extra time was considered 
necessary as both transcription and translation processes had to be completed for 
protein formation while only transcription was necessary for mRNA production. An 
alternative explanation relates to post-transcriptional processing of mRNA. A549 
mRNA may have a longer half-life within the cell allowing more protein to be made 
from each transcript.
The ELISA was also used to assess the effects of cytokines on protein 
production by two cell lines, K562 and LoVo. The cells were treated with cytokines 
exactly as before but for a longer time period - 24 hrs rather than 8 hrs. The CM was 
collected from each flask, clarified by centrifugation and assayed for matrilysin using 
the sandwich ELISA. The ratio of cytokine-treated level to control (untreated) level 
was determined and the results plotted. The graphs obtained are shown in Figures 5.15 
(A) and (B)
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I  0-6-11
£  0 .4  -
Control IL-1 IL-2 IL-6 IGF-I IGF-II EG F bFGF TGF IFN
Cytokine
Control IL-1 IL-2 IL-6 IGF-I IGF-II EG F TGF IFN
Cytokine
Figure 5.15 Effects of cytokines on matrilysin protein production by (A) K562 and (B) 
LoVo cell lines. Results, determined by sandwich ELISA, are expressed as fold 
increase over control.
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As with the data from different cell lines, the results for cytokine treatments do not 
correlate well with the RT-PCR results for mRNA. The stimulatory effect of IL-6 in 
K562 cells is seen both at the mRNA and protein level, however, the other strong 
stimulating agent at the mRNA level, IGF-II, does not appear to have the same effect 
on expression of the protein. Further investigations will be required to determine if this 
is due to differences in post-transcriptional processing of the mRNA. In the LoVo 
cells, stimulatory effects on protein production were seen with a wider range of agents 
than were seen at the mRNA level. IGF-I is stimulatory for both mRNA and protein, 
however, other cytokines such as TGF-P and IL-6 also appear to have a strong up- 
regulating effect on protein production.
Another possible explantion for all the inconsistancies seen with the ELISA 
results may be due to its detection of the zymogen (28 kDa) form of matrilysin only. If 
this is rapidly being converted to the active (19 kDa) form in the culture medium from 
any of the cell lines, the actual levels assayed will be very low. This could be the case 
with the K562 cell line where the lowest levels of protein were detected despite the 
mRNA levels being relatively high.
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Summary
A range of cell lines were assessed as to their ability to produce matrilysin at both the 
mRNA and protein levels. mRNA analysis was accomplished using RT-PCR and, in 
the case of the LoVo and K562 cell lines, in situ hybridisation. Protein levels were 
assayed using the sandwich ELISA for matrilysin developed and validated as described 
in chapter three. Matrilysin production was seen at both mRNA and protein levels in 
the SW620, LoVo, A549 and K562 cell lines. Some disparity between the mRNA and 
protein data was evident. This may have been due to post-transcriptional modifications 
of the mRNA within the cells, or the generation of active matrilysin protein which was 
not detected by the ELISA.
The cell lines were treated with a range of cytokines to determine the possible effects of 
these molecules on matrilysin and stromelysin-1 production by epithelial cells. The 
breast cell line MCF-7, and the brain cell line Go-GCCM did not express matrilysin 
under any circumstances. The colon cell line SW480 and the bladder cell line EJ, 
although not normally producers of the enzyme, could be induced to express matrilysin 
mRNA after treatment with certain cytokines. The cytokines IL-ip, IL-6, bFGF, IGF- 
I and IGF-II up-regulated matrilysin in a number of cell lines. Stromelysin-1 up- 
regulation resulted in many cases, from treatment with IL-ip, IL-2, EGF, TGF-P and 
IFN-y. Some of the effects appeared to be tissue-specific. Further analysis of cytokine 
effects on the matrilysin promoter is presented in chapter six.
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Chapter Six
Matrilysin Promoter Studies
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Introduction
This chapter is concerned with the analysis of the matrilysin promoter. The 
promoter regions for both the human and mouse genes have previously been cloned 
and sequenced (Gaire et al., 1994; Prof. Lynn Matrisian, pers comm.). The direct 
effects of cytokine treatment on these regions were examined using the promoter 
sequences subcloned into reporter gene vectors. To do this, an appropriate cell line 
was selected and transfected (using a suitable method) with the promoter-reporter gene 
constructs, the cells were treated with the cytokines and the specific reporter gene 
assays used to quantify any effects. An introduction to control of gene expression is 
first presented.
6.1 Control of gene expression
For a specific protein to be manufactured by a cell, the gene that encodes it 
must first be transcribed from DNA to messenger RNA (mRNA). This then travels 
from the cell nucleus to the cytoplasm where it acts as a template from which the 
protein can be generated. The act of transcribing is subject to regulation by factors 
within the nucleus. These factors are in turn controlled by second messengers, for 
example cAMP or protein kinase C, changes in the activity of which result from cell 
signalling events such as may occur when a cytokine binds to its receptor on the cell 
surface.
The enzyme responsible for transcription of structural (i.e. coding) genes is 
RNA polymerase II. For transcription to take place, the enzyme must be aligned at the 
correct position on the gene. RNA polymerase II attaches to promoter regions, 
however the enzyme itself appears to lack any inherent ability to recognise promoters 
(Dynan and Tjian, 1985; Rothwell, 1993). Short DNA sequence elements located near 
the transcriptional start site (+1), play an important role in regulating gene expression. 
Such sequences mediate transcriptional activation by binding specific proteins known as 
transcription factors (Latchman, 1990). Almost all promoters that interact with RNA 
polymerase II contain a conserved sequence known as the TATA box (consensus
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sequence TATAAAA). It is located 20 - 30 bp upstream, i.e. 5’, of the transcriptional 
start site. Up to six different transcription factors bind in the vicinity of the TATA box 
(Hawley, 1991). These core transcription factors are also known as RNA polymerase II 
- associated proteins or RAPs (Greenblatt, 1991). One of these, TFIID known as the 
TATA-binding protein, actually recognises the TATA box and must bind to it before 
any other molecule can do so. Once TFIID binds, it is then followed by TFIIA and 
TFIIB to which a complex composed of RNA polymerase II, TFIIE and TFilF 
(RAP30 / 74) can bind (Roeder, 1991). Another common promoter sequence is the 
CAT box (consensus sequence CCA AT) about 80 bp upstream from +1 (Rasko and 
Downes, 1995). TATA and CAT are promoter sequences for RNA polymerase II and 
are found in many, but not all, coding genes. Those genes lacking a TATA box do not 
all have fixed sites for the start of transcription and depend on certain transcription 
factors acting along with RNA polymerase II (Rothwell, 1993) In other promoters 
lacking a TATA box, a discrete element overlying the start site helps to fix the place of 
initiation (Dynan, 1989). Apart from the transcription factors mentioned above that 
interact with the TATA box, there are many other nuclear proteins that bind other 
specific DNA sequences upstream of the +1 site e.g. the CAT box or GC elements 
(consensus sequence GGGCGG). Specific transcription factors and their recognition 
sequences will be discussed in section 6.2.
Some promoters are greatly influenced by DNA sequences named enhancers or 
activators. Figure 6.1 illustrates the possible arrangement of these elements.
GGGCGG CCAAT
-120 -80
A TATAAAA I—^l---------  +i
mRNA
->
-30
Enhancer/Repressor
Figure 6.1 Arrangement of DNA sequence elements controlling transcription of a 
typical eucaryotic protein-coding gene. The enhancer may be located upstream or 
downstream of the site of transcriptional initiation.
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Enhancers are not necessary for transcription and, by themselves, are not sufficient to 
initiate it, but they can greatly increase the efficiency of promoters. These sequences 
have a number of properties :
(i) An enhancer element can activate a promoter when placed up to several 
thousand bases from the promoter;
(ii) An enhancer can activate a promoter when placed in either orientation 
relative to the promoter;
(iii) An enhancer can activate when placed upstream or downstream of the 
transcribed region, or within an intervening sequence which is removed from 
the mRNA by splicing (Latchman, 1990).
Enhancers can be general or tissue-specific. For example, the enhancer element of 8 
nucleotides recognised by the DNA-binding protein OCT-2 is responsible for enhancing 
the transcription of immunoglobulin (Ig) genes. Its unique presence in B lymphocytes 
was shown by experiments in which the Ig gene promoter was placed in different cell 
types (Gillis et al., 1983). Transcription above basal level could only be seen in this 
one cell type. Experiments in which enhancers are moved about also reveal that an 
enhancer will increase the rate of transcription of any promoter that is placed nearby, 
showing that a given enhancer is not limited in its effect to just one promoter of a given 
gene (Rothwell,1993).
Elements that operate to decrease transcription also exist. These are termed 
silencers or repressors. Much like enhancers or upstream promoter elements, binding 
of specific proteins to these DNA sequences affects the way in which RNA polymerase 
II binds and functions. The complexes formed by enhancers/repressors and the basal 
transcriptional machinery are responsible for drawing RNA polymerase II to specific 
genes at specific rates.
6.2 Transcription factors
The promoters and enhancers that control the transcription of protein-coding 
genes are composed of multiple genetic elements or modules. Studies have shown that 
promoters are composed of discrete functional modules, each consisting of
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approximately 7 - 20 bp DNA and containing one or more recognition sites for 
transcriptional activator proteins (Dynan, 1989). Enhancers and promoters appear to 
have a very similar modular organisation. In fact, there are instances such as the Ig 
octamer motif, where the same module can occur in the context of either a promoter or 
enhancer. This suggests that DNA-binding proteins bound to either of these types of 
regulatory element, may interact with the cellular transcriptional machinery in 
functionally the same way.
To activate or repress transcription, transcription factors must be located in the 
nucleus, bind DNA and interact with the basal (or core) transcriptional apparatus. 
Interactions between transcription factors or between a transcription factor and a DNA 
sequence are mediated through structural domains present in the transcription factors 
(Hill and Treisman, 1995). One of the most common of these structural motifs used for 
DNA binding is known as the zinc finger (Rasko and Downes, 1995). It consists of a 
sequence of 20 - 30 amino acids with a pair of cysteines near the amino end and a pair 
of histidines or a pair of cysteines or a histidine and a cysteine near the carboxy end of 
the sequence. These residues bind to a zinc atom which is essential for the activity of 
the protein. Between the zinc-bound elements, the protein forms a loop or finger 
which can enter the major groove of DNA and bind to approximately 5 bp. The zinc 
finger DNA-binding proteins characterised so far, exhibit a variety of DNA sequence 
specificities probably dictated by the particular amino acid residues which comprise the 
finger (Mitchell and Tjian, 1989).
The structural motif predominandy responsible for joining DNA-binding 
proteins to each other, is known as the leucine zipper (McKnight, 1991). This consists 
of an a-helical region in which every seventh amino acid is a leucine. This ‘heptad 
repeat’ causes the leucines to be aligned in a plane along the length of the helix. It was 
first suggested that if two such helices lay side-by-side, their leucines would fit together 
like a zipper. More recently, it has been shown that, although the leucines are adjacent 
to each other, they do not ‘zip’ together (Rasko and Downes, 1995). The zippers do 
not form part of the DNA-binding domains; rather they allow pairs of DNA-binding 
proteins to join together to form a ‘scissors-grip’ structure. In this the two a-helices of
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the zipper domains lie together forming the blades of the scissors while the DNA- 
binding domains protrude at the end like handles, fitting into the major groove of DNA.
A different mode of DNA binding involves the helix-tum-helix or homeodomain 
motif. This domain encompasses approximately 60 amino acids with the most 
conserved positions between homeodomains of different proteins being occupied by 
basic and hydrophobic residues (Mitchell and Tjian, 1989).
Following is a brief introduction to some specific transcription factors or DNA- 
binding proteins which appear to play a role in the regulation of transcription of MMP 
genes:
SP-1
Specificity protein-1 (SP-1) was the first transcription factor to be isolated (Dynan and 
Tjian, 1985). All SP-1 binding regions contain one or more perfect copies of the GC 
box hexanucleotide GGGCGG, which may be present in either orientation relative to 
the direction of transcription. However, not all GC boxes bind SP-1 equally well as the 
bases outside the core hexanucleotide sequence appear to modulate the efficiency of 
binding. The SP-1 protein molecule has 3 zinc finger motifs at one end which attach to 
the DNA sequences and, at the other end, a glutamine-rich domain which appears to be 
responsible for protein.protein interactions (Tjian, 1995). No shared regulatory feature 
is evident among the diverse promoters in which SP-1 binding sites have been found 
(Dynan and Tjian, 1985). It is possible that SP-1 provides a basal, constitutive level of 
transcription which can then be modulated by other positive or negative regulatory 
factors (Dynan, 1989).
The C/EBP family
The CAT/Enhancer binding protein, C/EBP, was isolated by McKnight and colleagues 
from rat liver extracts (Landschulz et al., 1988). This protein has affinity not only for 
the CAT motif in promoters, but also for a motif called the core homology, common to 
many enhancers. The protein is not found in all tissues and is, therefore, a possible 
contributor to tissue-specific gene expression. C/EBP is a 369-amino acid molecule 
which, in certain regions, has homology to the protein products of the proto-oncogenes 
jun, fos  and myc (McKnight, 1991). These regions of homology have since been 
identified as leucine zipper domains and are primarily responsible for the dimer
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formation associated with these proteins (known as basic zipper (bZIP) proteins). 
These proteins can only bind to DNA in the form of dimers and most can do so in the 
form of homo- or hetero-dimers (Jones, 1990)
Nuclear factor for IL6 (NF-IL6), also known as IL-6DBP ( EL-6-dependent 
DNA binding protein) is a member of the C/EBP family of transcription factors (Akira 
et al., 1990; Poli et al., 1990). NF-IL6 is strongly homologous to C/EBP in the region 
of the basic (DNA binding) domain and in the leucine zipper region. The 
transcriptional activation of the IL-6 gene by IL-1 is dependent on a 15 bp palindromic 
sequence ACATTGCCACAATCT located at position -150 which can be bound by NF- 
IL6 (Akira et ah, 1990). NF-IL6 not only activates this gene but is also responsible for 
the regulation of genes encoding other inflammatory cytokines, acute phase proteins, 
serum albumin, c-Fos and some other genes. NF-IL6 and C/EBP can interact in vitro 
to form heterodimers that bind to DNA with the same specificity as the respective 
homodimers. NF-IL6 can also interact with the p50 subunit of another transcription 
factor NF-kB (LeClair et al., 1992; Matsusaka et al., 1993). Analysis of promoters of 
genes which respond to the inflammatory cytokines IL-6 and IL-1, reveals that binding 
sites for both NF-IL6 and NF-kB are frequently present. It is thought, therefore, that 
the interaction of subunits of these two transcription factors could be highly important 
in regulating gene expression.
Another member of the C/EBP family, NF-IL6P, also appears responsible for 
mediating effects of IL-6 on transcription. NF-IL6P is a 269-amino acid protein with a 
potential leucine zipper structure (Kinoshita et ah, 1992). It can, like C/EBP and NF- 
IL6, bind to the CAT box as well as the enhancer core sequence. The gene for NF- 
IL6(3 is expressed at an undetectable level in normal tissues but is induced by 
inflammatory cytokines such as IL-1 or IL-6. NF-IL6p easily forms a heterodimer with 
NF-IL6 and this heterodimer can bind the same DNA sequences as the respective 
homodimers. In fact, NF-IL6P is a stronger activator of transcription than NF-IL6 and 
appears to show a synergistic effect with it.
The ets family
The first member of this family to be discovered was v-ets, which was named 
for the virus of its origin, E-twentysix. It is quite a large family of related genes with 9
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identified human genes (MacLeod et al., 1992). In most of the proteins encoded by 
family members, a DNA binding domain (the ETS domain) is localised at the carboxyl 
terminus of the protein. This ETS domain, which covers approximately 85 amino 
acids, has no structural homology to other DNA-binding motifs such as the zinc finger, 
leucine zipper or homeodomain motifs. The p68ce<i'y protein binds to the PEA3 
element of the polyoma virus enhancer which has the sequence AGCAGGAAGT 
(Wasylyk et al., 1990). All eta-family members bind to DNA regions which contain the 
purine-rich core sequence GGAA/T (MacLeod et al., 1992). Trawi-activation by p68c' 
e‘s'] from the PEA3 site of the polyoma virus enhancer is cooperative with activation by 
the transcription factor AP-1 bound to an adjacent PEA1 site (Wasylyk et al., 1990). 
This cooperativity is mediated by protein:protein interactions. The capacity of Ets 
proteins to interact with other transcriptional regulatory factors suggests a role in 
coordinating changes in gene expression in response to second messenger and 
extracellular signals.
AP-1
The AP-1 DNA binding protein is actually a dimer of two proteins. It can be 
either a Jun-Jun homodimer or a Jun-Fos heterodimer. Both Jun and Fos are products 
of proto-oncogenes, jun and fos respectively (Chiu et al., 1989). The DNA sequence 
to which AP-1 binds is known as the TPA (12-0-tetradecanoyl-phorbal-13-acetate) 
responsive element or TRE (consensus sequence TGAC/GTCA). The binding of AP-1 
to the TRE is over 1000-fold more efficient when a heterocomplex of Jun and Fos, 
rather than the Jun-Jun homodimer, forms the AP-1 (Sassone-Corsi et al.,1988). The 
differences in binding reflect differences in dimerisation stability with Jun-Fos forming 
at least 500-times more efficiently than Jun-Jun dimers (Jones, 1990). Fos proteins 
cannot form stable homodimers. Both Jun and Fos have leucine zipper motifs and this 
is how they interact with each other (Schiitte et al., 1989). Mutant versions of bZIP 
proteins containing altered basic domains can act as dominant/negative regulators of 
transcriptional activation (Jones, 1990). This is illustrated by the effects of JunB ( a 
member of the Jun family which also contains c-Jun and JunD) on activation of AP-1 
responsive genes. c-Jun is an efficient activator of genes containing a single TRE while 
JunB is not (Chiu et al., 1989). In fact, JunB actually inhibits activation of these
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promoters by e-Jun. JunB, c-Jun and JunD share significant sequence homology. They 
are coexpressed in many tissues, although at different levels (Schiitte et al., 1989). 
The transcription of c-jun and junB genes reveals different responses to some 
extracellular stimuli. These variations in the different Jun proteins may contribute to 
the regulatory effects of AP-1.
The TIE
The existence of a TGF-(3l inhibitory element (TIE), consensus sequence 
GnnTTGGnGn, has been demonstrated in a number of promoters (Kerr et al., 1990). 
Binding of the TIE appears to repress positive regulatory signals supplied by other 
transcription factors. The c-Fos protein has been demonstrated as the DNA binding 
element associated with the TIE.
6.3 Regulatory elements in MMP genes
Sequencing of the promoter regions of MMP genes has yielded some surprising 
information. Gelatinase A has been shown to have no TATA or CAT boxes (Huhtala 
et al., 1990). As mentioned previously, genes without TATA boxes can have variable 
transcriptional start sites. Gelatinase A appears to have two such sites, 9 bp apart. The 
lack of a TATA box is often associated with so-called ‘housekeeping’ or constitutively- 
expressed genes and the 72 kDa gelatinase A protein is, perhaps, the most widely 
expressed of the MMPs (Crawford and Matrisian, 1995). The gelatinase A promoter 
does have some regulatory elements; there are two GC boxes at positions -69 and -89 
and an AP-2 potential binding site within the first exon at position +157 (Huhtala et al., 
1990). The AP-2 protein appears to mediate transcriptional activation through the 
second messengers protein kinase C and cAMP-dependent protein kinase A (Imagawa 
etal., 1987).
Other MMPs, for which promoter sequences are available, have TATA boxes 
and AP-1 binding sites (TREs) (Angel et al., 1987; Quinones et al., 1989; Huhtala et 
al., 1991; Gaire et al., 1994). A comparison of the promoter sequences of the MMP 
genes is shown in figure 6.2.
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Figure 6.2 A comparison of regulatory elements found in the promoters of MMP 
genes. Transcriptional start sites are indicated by +1. TATA boxes, AP-1 binding 
sites, PEA3 elements, AP-2 recognition sites, GC boxes and TIEs have been marked. 
The orientations of the PEA3 elements relative to transcription are indicated by arrows. 
The diagram is not to scale. (Taken from Gaire et al., 1994).
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Stromelysin-1, stromelysin-2, interstitial collagenase and matrilysin also contain PE A3 
sites which bind members of the c-ets family of proteins. C-ets proteins can be induced 
by the activation of the proto-oncogenes ras and src, while AP-1 is composed of the 
protein products of the fos and jun proto-oncogenes. Such responsiveness to proto­
oncogenes suggests that the MMP genes are linked to cellular growth and control 
(Crawford and Matrisian, 1995). It also suggests that the expression of these genes 
can be easily affected by cellular transformation. Inhibition of expression by TGF-fi 
would also appear to be a common feature of MMP genes given the frequency with 
which the TIE appears in MMP promoters. The matrilysin promoter, for example, has 
three apparent TIE regions upstream of other regulatory elements (Gaire et al., 1994).
The fact that particular sequences are present in the promoter region of a given 
gene does not necessarily mean that the transcriptional regulatory elements they 
represent are functional. Figure 6.3 illustrates potential transcriptional elements present 
in the mouse and human matrilysin promoters based on sequence information. The 
work presented in this chapter is intended to demonstrate their potential activity. Proof 
that these elements are indeed functioning as thought will require further 
experimentation.
Figure 6.3 Potential transcriptional elements within the human and mouse matrilysin 
promoters. This diagram represents approximately 500 bases of 5’ sequence of the (A) 
human and (B) mouse matrilysin gene. +1 represents the transcription inititation site. 
TATA boxes, AP-1 binding sites, PEA3 elements TIE and NF-IL6 consensus binding 
motifs are indicated. The diagram is not drawn to scale.
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RESULTS AND DISCUSSION
6.4 Preparation of Plasmids
A number of different plasmids were used in the course of this work. 
Restriction digests were used in order to identify particular plasmids (section 2.2.8.6). 
The expected sizes corresponding to each plasmid cut with a specific enzyme are 
presented in Table 6.1.
friction Enzyme Expected Size of Fragmenis t hp.J !
pCHllO Pvu II 360, 700, 2600, 3500
pFLCAT Eco R1 + Bam HI 751, 1382, 2400
pCMVCAT Pvu II 333,1727, 2054, 2567
p295HPCAT Pvu II 535,1728,2567
p933HPCAT Pvu II 1278, 1728, 2567
pGL2-Control Bam HI + Hind III 2900,3146
pGU-MMP Pvu II 2500,4000
Table 6.1 The expected sizes (in bp) of fragments resulting from digesting specific 
plasmids with the enzymes mentioned. The different patterns obtained when these 
digest products were run on agarose gels were used to confirm identities of the 
plasmids.
pCHllO carries the gene for the bacterial enzyme (3-galactosidase. The gene is under 
the control of a promoter from the simian virus, SV40, so any cells which are 
successfully transfected with this plasmid should produce P-galactosidase. This 
enzyme is easily detected using either an in situ staining technique which utilises the 
synthetic substrate X-gal, or by assaying cell lysates with CPRG (see sections 
2.2.10.1/3). The ease of detection makes this a suitable enzyme for assessing 
transfection efficiencies. The in situ staining technique was used in early experiments
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when cell lines and transfection methods were being screened to find the most suitable 
combination. The CPRG assay was used in later transfections when the plasmid 
pCHllO was co-transfected with a matrilysin promoter construct. This allowed 
corrections to be made for variations in transfection efficiency observed among 
experiments.
The pCAT group of plasmids (kindly donated by Prof. Lynn Matrisian, 
Vanderbilt University) all contain the gene for the bacterial enzyme chloramphenicol 
acetyl transferase (CAT). The positive control plasmid, pCMVCAT, contains this gene 
under the control of a promoter from the cytomegalovirus (CMV). Any cells 
successfully transfected with this plasmid should express CAT protein. The negative 
control plasmid, pFLCAT, contains the CAT gene with an SV40 promoter attached to 
the 3’ end. This orientation of promoter should not activate transcription of the CAT 
gene and so cells transfected with this plasmid wil not express CAT protein. 
p295HPCAT and p933HPCAT are matrilysin promoter-reporter gene constructs. 
They contain various lengths of the human matrilysin promoter (designated by the 
figures in the plasmid names) attached to the CAT gene. By using different lengths of 
the promoter, various combinations of transcriptional elements could be examined as to 
their effect on transcriptional activation of the attached CAT gene.
The pGL2 plasmids contain the gene for the firefly luciferase enzyme. The 
pGL2-control plasmid contains SV40 promoter and enhancer regions so that the 
luciferase enzyme should be efficiently produced by cells successfully transfected with 
this plasmid. pGL2-MMP (obtained from Prof. Lynn Matrisian, Vanderbilt University) 
contains the luciferase gene attached to 2.7 Kb of the mouse matrilysin promoter. No 
other promoter or enhancer sequences are present.
Figure 6.4 is an agarose gel showing the products obtained when these plasmids 
are digested with the appropriate restriction enzymes. On comparison with the data in 
Table 6.1, it may be seen that the plasmids, when digested, give the expected fragments 
thus confirming their identity.
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Figure 6.4 Plasmids cut with restriction digests (as detailed in Table 6.1) and run on a 
1.2 % agarose gel. The sizes of the fragments obtained correspond to those expected. 
Lane 1 : 1 kb ladder - DNA size markers 
Lane 2 : pCHl 10 - Pvu II digest 
Lane 3 : pCMVCAT - Pvu II digest 
Lane 4 : pFLCAT - Bam HI + Eco RI digest 
Lane 5 :
Lane 6 : p295HPCAT - Pvu II digest
Lane 7 : p933HPCAT - Pvu II digest
Lane 8 : pGL2-Control - Bam HI + Hind III digest
Lane 9 : pGLrMMP - Pvu II digest
Lane 10 : 100 bp ladder - DNA size markers
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6.5 Optimisation of Transfections
For genes to be transcribed, control regions in their promoters must be bound 
by appropriate transcription factors. Some transcription factors are cell-type specific, 
therefore some genes may only be expressed in specific cell types under normal 
circumstances [aberrations may occur as a result of the transformation process]. To 
examine the transcription factors required for activation of a particular gene therefore, 
it is necessary that the study be carried out in cells where those transcription factors are 
present. For this reason, promoter studies of a given gene are usually undertaken in 
cells which normally express the gene as the necessary transcription factors are 
definitely present. Based on this reasoning, and using the results obtained by RT-PCR 
presented in chapter 5, the cell lines K562, SW620 and LoVo, all of which express 
basal levels of matrilysin, were chosen for transfection studies. A fourth cell line, 
SW480, which does not normally express matrilysin unless induced to do so by specific 
treatments, was also used in early experiments. This cell line had previously been 
shown to be transfectable and so was used as a positive control for some optimisation 
experiments.
Three different transfection methods were investigated. Calcium-phosphate 
mediated transfection was first described by Graham and Van der Eb (1973). The 
method is based on the formation of a crystalline precipitate produced when calcium 
ions interact with the negatively charged phosphate groups of DNA in the presence of 
soluble phosphate ions. The exact mechanism of this transfection technique is unclear, 
but it is thought that the precipitate attaches to the cell surface and is then taken into 
the cell by endocytosis.
DEAE-dextran-mediated transfection is quite similar. The positively charged DEAE- 
dextran binds to the negatively charged phosphate groups of the DNA. This complex 
then binds to the negatively charged cell surface. Uptake into the cells is also thought 
to be by endocytosis. Lipofection, that is transfection mediated by cationic liposomes, 
is a relatively new tool. Cationic lipids, such as DOTAP, form liposomes in aqueous 
solution. These can then interact spontaneously with negatively charged DNA to form
174
stable complexes. The complexes adhere to the cell surface, fuse with the phospholipid 
cell membrane and release the DNA into the cytoplasm of the cell.
The DEAE-dextran method is generally recommended for use with small amounts of 
DNA and is only suitable for transient transfections where the exogenous DNA is not 
incorporated into the target cell’s genome. Calcium phosphate-mediated transfection 
and transfection with liposomes such as DOTAP, can be either transient or stable. In 
the case of stable transfections, exogenous DNA is incorporated into the genome of the 
target cell. This is usually achieved using a selective pressure such as antibiotic (e.g. 
neomycin) resistance by co-transfecting a gene coding for such resistance together with 
the desired gene.
All the transfection techniques investigated have a number of variables 
associated with them. Firstly, not all techniques are suitable for all cell lines. In fact 
there appear to be a number of cell lines which are extremely difficult to transfect for 
unknown reasons. Secondly, any cell line which can be transfected by a given technique 
will have an optimal DNA concentration suitable for transfection. With some cell lines, 
amounts of DNA above 10 |ig may prove toxic to the cells, whilst in other cell lines, 50 
(ig of DNA may be required for transfection. Thirdly, in the case of lipofection 
reagents, the optimal ratio of liposome to DNA for efficient transfection of a given cell 
line must be determined empirically. Other points which should be considered include 
the amount of time following transfection for which the DNA precipitate is left in 
contact with the cells, the use of glycerol or other ‘shocking’ agents to stimulate 
cellular uptake of exogenous DNA, and the period of time following transfection for 
which the cells are left prior to harvesting for analysis. Varying the cell line, the 
amount of DNA and the ratio of transfection reagent to DNA were all investigated. 
The amount of time precipitates were left in contact with cells, the use of glycerol and 
the harvest time were fixed for all transfections. Precipitates of either calcium 
phosphate and DNA or DOTAP and DNA were left in contact with cells for 5 hours in 
all experiments. Glycerol was used in the calcium phosphate-mediated transfections 
following removal of the DNA precipitate to briefly shock the cells and stimulate 
uptake of DNA. In DEAE-dextran transfections, the drug chloroquine may be used 
for similar reasons, however, it was not used in these experiments. All transfected cells
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were left for 48 hours prior to harvesting. This was to allow the cells to recover and to 
give enough time for cytokine stimulations if they were used.
Using 6-well culture plates containing 5 x 1 0s - 5 x 1 06 cells per well 
(dependent on cell line used) and a range of concentrations of the plasmid pCHllO, 
each of the transfection methods was tried with each of the cell lines. 48 hrs following 
transfection, the plates were fixed and stained for J3-galactosidase activity (section 
2.2.10.1). Blue cells, indicating the presence of the enzyme and hence successful 
transfection, were visible only in the SW480 and K562 cell lines following calcium 
phosphate or DOTAP-mediated transfections. No successfully transfected cells were 
observed in those plates transfected using DEAE-dextran. This information is 
presented in Table 6.2. The appearance of successfully transfected cells is shown in 
Figure 6.5. In SW480 cells, the enzyme appears to be produced in large amounts 
throughout the cell so that transfected cells are deep blue in colour. In contrast, the 
K562 cells that have been transfected only appear to produce small amounts of the 
enzyme in localised regions within the cells. The actual blue stain is quite difficult to 
observe.
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‘ Transfection CefiLin* Posi tit? *  .{.¡¡(il um> «r sion
Calcium Phosphate SW480 +++
! K562 +++: LoVo -
SW620 -
DEAE-dextran SW480 -
K562 -■
LoVo -
SW620 -
DOTAP SW480 ++
| K562 ++++
LoVo -
SW620 -
Table 6.2 Results of various transfection methods on different cell lines. The presence 
of blue stain resulting from the action of the enzyme (3-galactosidase (carried on the 
plasmid pCHl 10) on the substrate X-gal demonstrated the success of the transfection 
method. The degree of staining is indicated using a scoring system where indicates 
no blue cells apparent, ‘+’ indicates minimal staining, and *++’, *+++’ and ‘++++’ 
indicate increasing levels of staining relative to each other.
Figure 6.5 In situ staining for production of the enzyme P-galactosidase. (a) SW480 
cells magnified 200X. The positively staining cells are deep blue in colour and can be 
clearly seen, (b) K562 cells magnified 200X. The positively staining cells contain 
regions within them which are blue in colour.
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At this stage, it was decided to concentrate with only one cell line, K562, and one 
transfection method, DOTAP-mediated transfection, as results obtained with other 
methods and suitable cell lines were disappointing.
6.5.1 Optimisation of DOTAP transfections in K562
As stated previously, the amount of DNA and the ratio of DNA to transfection 
reagent can affect the efficiency of a DOTAP-mediated transfection. To determine the 
optimal ratio of DOTAP to DNA and total amount of DNA, an experiment was 
conducted where various amounts of DNA were mixed in two different ratios with 
DOTAP. Following transfection and a 48 hr recovery period, the cells were harvested, 
lysed and the lysates assayed for p-galactosidase activity using a CPRG assay. The 
results are presented in Figure 6.6.
0 1 2 3 4 5 6 7 8
Amount of DNA (^g)
Figure 6.6 Optimisation of DOTAP-mediated transfection of K562 cells. The effects 
of varying both the total amount of DNA and the DOTAP to DNA ratio were 
examined by assaying for (3-galactosidase activity using a CPRG assay and measuring 
absorbances at 574 nm. The two DOTAP to DNA ratios examined were 3 |ig/|ig DNA 
and 4 p.g/|ig DNA. The three amounts of DNA examined at these two ratios, were 3 
i^g, 5 ng and 7 |ig.
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The optimum DOTAP : DNA ratio was thus taken to be 4 |ig DOTAP / |ig DNA while 
a total amount of 5 |ig of DNA was used in further experiments.
The actual efficiency of transfection when these amounts of DNA and DOTAP 
were used was then calculated. This was done by setting up a tissue culture plate with 1 
x 106 K562 cells and the following day, transfecting the cells with 5 |ig of pCHllO 
DNA using DOTAP at a ratio of 4 |ig /  |ig DNA. 48 hrs later, the cells were fixed and 
stained for (3-galactosidase activity using the in situ staining technique. The positively 
staining (blue) cells were counted and the percentage transfected cells calculated. 
26,988 blue cells were counted. This approximates to a transfection efficiency of 2.7% 
which is a suitable transfection efficiency for transient transfections.
6.6 Analysis of the human matrilysin promoter
Two different lengths of the human matrilysin promoter attached to the reporter 
gene, CAT, were available for study. The plasmid p295HPCAT contained 295 bp of 
the 5’ flanking region of the human matrilysin gene. On examination of Figure 6.3, it 
may be seen that within this region there are two potential PEA3 elements, an NF-IL6 
consensus sequence, an AP-1 binding sequence and a TATA box. The mitogenic 
tumour promoting agent, TPA, would be expected to activate transcription therefore 
through the AP-1 binding motif (otherwise known as the TPA responsive element) 
while the cytokines IL-1 and IL-6 could also potentially activate transcription through 
the NF-IL6 sequence. Other factors may activate transcription through the PEA3 
elements. p933HPCAT contains 933 bp of the 5’ flanking region of the human 
matrilysin gene. This length of promoter has all those elements present in the 295 bp 
region in addition to 2 TGF-(5 inhibitory elements or TIE sequences.
K562 cells were transfected with these plasmids and positive and negative 
controls - pCMVCAT and pFLCAT-using the DOTAP method as previously outlined. 
The plasmid pCHllO was cotransfected with each of the CAT plasmids to allow for 
correction of variations in transfection efficiencies. Following transfection, the cells 
were treated with various cytokines and TPA (see section 2.2.9.6). 48 hrs after
transfection, the cells were harvested and lysed. A portion of each lysate was used for
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the CPRG assay to determine levels of p-galactosidase resulting from transfection of 
pCHl 10. Significant values indicating enzyme activity were obtained with all samples 
of transfected cells indicating successful transfections. The presence of CAT protein 
was determined using a commercially available CAT ELISA (section 2.2.10.4). The 
amount of CAT protein in each sample was determined from a set of CAT standards 
also assayed using the ELISA. The results are presented in Table 6.3.
None
m m  v
0 .....
... 2
w f i w m  1 1
0
IL-lp 2 21 0 0
IL-6 0 15 4 0
EGF 0 N.D. 0 0
TGF-P 0 N.D. 13 0
IGF-1 0 70 4 0
TPA 2 N.D. 0 4
Table 6.3 Results of CAT ELISA following DOTAP-mediated transfection of K562 
cells and cytokine/TPA treatment. The results given are pg of CAT protein in each 
lysate determined from a calibration set of CAT standards assayed using the CAT 
ELISA. The values have been corrected for equivalent (3-galactosidase activity as 
determined from a CPRG assay. ‘N.D.’ signifies that a particular sample was not 
assayed.
All values are extremely low, possibly due to the lysate preparation technique used. 
Although the claims from the manufacturer are that the lysis buffer is suitable for use in 
assays for CAT, (3-galactosidase and luciferase reporter genes, it has been optimised for 
use with luciferase assays. Also, the actual amount of lysate that was available for use 
in the assay was very small - equivalent to 3 x 104 cells. The presence of CAT protein, 
albeit in small amounts, in the pCMVCAT transfected cells does indicate that 
transfections were successful. IGF-1 appears to stimulate the viral CMV promoter as 
the increase in levels of CAT over untreated pCMVCAT transfected cells is 
approximately 4-fold. The only other significant result is the slight stimulatory effect of
TGF-P seen with the shorter promoter construct p295HPCAT. This length of 
promoter does not contain any TIE sequences and it is not known what elements are 
resposible for mediating a TGF-p stimulatory effect.
Previous work carried out in this laboratory (O’Shea, M.Sc. Thesis, 1996) also 
demonstrated little activity with the human matrilysin promoter - CAT constructs. 
Recent results from our collaborators in Vanderbilt University corroborate these 
findings (Prof. Lynn Matrisian, pers. comm.). It is thought that the constructs may 
have been originally prepared with 5’ flanking regions of the CAT gene included 
between the matrilysin promoter and the actual CAT coding gene. Another possibility 
is an error in the human matrilysin promoter sequence. The constructs are currently 
been remade with a different reporter gene and it is hoped to use these in the near 
future.
As another matrilysin promoter construct was available - 2.7 Kb of the mouse 
matrilysin promoter linked to the luciferase reporter gene - it was decided to conduct 
further transfection experiments with it.
6.7 Analysis of the mouse matrilysin promoter
The plasmid pGLrMMP contains 2.7 Kb of the 5’ flanking region from the 
mouse matrilysin promoter. Sequence information is available for the first 500 bp only. 
From Figure 6.3, it can be seen that there are a number of potential regulatory elements 
within this region. These include a TATA box, an AP-1 binding site, two PEA3 
elements, an NF-IL6 consensus sequence and a TIE sequence. From these sequences, 
it would be expected that cytokines such as EGF, IL-1, EL-6 and TGF-P as well as the 
mitogen TPA, would have effects on transcriptional activation of the mouse matrilysin 
gene. In the pGL2-MMP plasmid, the matrilysin gene has been replaced with a 
luciferase gene and transcriptional activity can, therefore, be easily measured using 
luminescence.
Initially, the pGL2-control plasmid was used to check that luciferase activity 
could be detected. All cells were co-transfected with pCHllO and lysates analysed for 
both luciferase and p-galactosidase activity. Using increasing amounts of both
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plasmids (up to a total of 6 (ig of DNA), K562 cells were transfected with pGL2- 
control and pCHllO and harvested 48 hrs later. The lysates were assayed as outlined 
in section 2.2.10.5 and the results obtained are presented in Table 6.4.
Table 6.4 Luminescence and absorbance values for K562 cell lysates following 
transfection with various amounts of the plasmids pCHl 10 and pGL2-control.
These results proved that the luciferase assay was valid for determining activity of a 
transfected luciferase gene. In all further transfections with luciferase constructs, 6 [ig 
total DNA was used which included equal amounts of pCHllO and the luciferase 
construct.
6.7.1 Effects of cytokines and TPA
Transfection experiments in which K562 cells were transfected using the 
reagent DOTAP, with plasmids encoding (3-galactosidase (pCHllO) and the mouse 
matrilysin promoter attached to the luciferase reporter gene (pGL2-MMP), were 
performed. 40 hrs after transfection, the cells were treated with various cytokines or 
TPA. After a further 8 hrs incubation, the cells were harvested, lysed and analysed for 
both luciferase and (3-galactosidase activities using luminescence and CPRG assays, 
respectively. The luciferase values were corrected for equivalent amounts of (3- 
galactosidase, and the results expressed as fold-increase over control. The data 
obtained from 3 such experiments was averaged and is presented in Figure 6.7.
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Figure 6.7 Transcriptional activity of mouse matrilysin promoter in K562 cells 
following treatment with cytokines and TPA. The data represented is averaged from 
three experiments.
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EGF, TPA, IL-6, IGF-I, IGF-II and TGF-(3 all appear to upregulate gene expression. 
TPA is a synthetic analogue of the cellular second messenger diacylglycerol wich 
activates protein kinase C (Pohl et al., 1988). Other molecules which use the same 
signal transduction pathway would be expected to have similar effects to TPA. Binding 
of the EGF receptor by EGF activates diacylglycerol (Hardie, 1991). The similarity of 
the effect seen with both EGF and TPA is, therefore, not surprising.
Stimulation of endogenous matrilysin mRNA in K562 cells by IL-6 and the IGF 
molecules was previously demonstrated (Figures 5.6 - 5.8, Chapter five). The 
promoter elements responsible for mediating these effects are apparently present within 
the first 2.7 Kb of the promoter. As these cytokines have not previously been shown to 
have an effect on matrilysin expression, analysis of the promoter regions responsible is 
certainly warrented. The stimulatory effect of IL-6 seen with this promoter construct is, 
however, less than the effect seen with matrilysin mRNA. It is possible that an 
additional NF-IL6 or similar element lies upstream of the promoter region examined 
here. In contrast, the lack of response to EGF seen with endogenous matrilysin mRNA 
could be due to repressor elements upstream of the promoter region. Another possible 
explanation for the lower levels of stimulation seen with the transfected promoter 
construct compared to endogenous matrilysin, is a difference in copy number. The 
transcription factors necessary to mediate a particular response may be present in 
limiting amounts so that when a gene is transfected with a high copy number per cell, 
lower transcriptional activation than usual can result (Frisch and Ruley, 1987).
The stimulatory effect of TGF-p was not anticipated. Most previous studies have 
shown that, in fibroblasts, TGF-p inhibits production of MMPs such as interstitial 
collagenase and stromelysin-1 (Overall et al., 1989; Kordula et al., 1992). A 
stimulatory effect on gelatinases A and B in uterine epithelial cells was observed in one 
study, however, stromelysin-1 was also down-regulated (Agarwal et al., 1994). The 
mechanism by which TGF-P exerts its inhibitory activity on levels of interstitial 
collagenase has been elaborated (Mauviel et al., 1993). It upregulates production of 
the proto-oncogene product, JunB, which is a negative regulator of the AP-1 
component, c-Jun. JunB has, however, been shown to be inhibitory only in promoters
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containing a single AP-1 binding site (Chiu et al., 1989). In promoters with multimeric 
TRE regions, JunB is an efficient transcriptional activator. It is possible that more TRE 
or similar elements are present as enhancer elements and this may explain the 
stimulatory effect of TGF-P.
There is very little data available concerning the matrilysin promoter. The 
results obtained here greatly increase our knowledge of the factors which can 
transcriptionally activate the matrilysin gene. However, much more work is required. 
The next step in this analysis will be to determine minimal promoter lengths necessary 
to obtain particular responses. It would be expected that a short region of the 
promoter containing just the TATA and AP-1 boxes would be sufficient for the 
stimulatory effects of EGF and TPA. It will be more interesting to determine the 
regions responsible for mediating effects of the IGFs and IL-6, as these cytokines have 
not previously been linked with activation of an MMP gene. Once the regions 
responsible have been isolated to within 20 - 40 bp of DNA, site-directed mutagenseis 
and DNase I footprinting can be used to identify exactly the DNA sequences to which 
regulatory proteins can bind. The regulatory proteins themselves can then be purified 
from nuclear extracts using the DNA sequences as affinity isolation reagents. It is 
hoped eventually to define the signal transduction pathway by which binding of a 
particular cytokine such as IGF-I or -II results in upregulation of matrilysin gene 
expression. This could result in the design of matrilysin-specific inhibitors which, it is 
envisaged, could be therapeutic in certain tumours, particularly colorectal.
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Summary
Four cell lines were investigated as to their suitability for transfection studies using 
three different transfection methods. One of these, SW480, did not express matrilysin 
and was used only as a control as it had previously been transfected by methods used in 
this study. Only the K562 cell line could be easily transfected by the methods 
examined. The DOTAP-mediated transfection method was demonstrated to be the 
most suitable method for this cell line. The optimal amounts of DNA used for 
transfection and the ratio of DOTAP to DNA were empirically determined prior to 
proceeding with promoter studies.
K562 cells were transfected with plasmids containing lengths of the human matrilysin 
promoter linked to the reporter gene CAT. The transfected cells were then treated 
with cytokines and TPA, harvested and lysed. Levels of CAT protein, as determined 
by a CAT ELISA, were very low and no discemable difference from control was found 
in the cytokine- or TPA-treated cells. This was thought to be due to problems with the 
manufacture of the promoter constructs. These promoter constructs are cuiTently 
being remade and it is hoped to repeat the transfection experiments with them.
A 2.7 Kb length of mouse matrilysin promoter linked to the luciferase reporter gene 
was then transfected into K562 cells and the cells treated with cytokines and TPA. 
Stimulatory effects were observed in cells treated with TPA, EGF, IL-6, IGF-I, IGF-II 
and TGF-(3 suggesting that the transcriptional control elements responsible for 
mediating effects of these molecules, lie within this region of the matrilysin promoter. 
This is the first report of transcriptional activation of the matrilysin gene by many of 
these factors. Only TPA and EGF had previously been investigated and shown to have 
an effect (Gaire et al., 1994). Further investigations will be required to determine 
precisely which regions are linked with specific cytokines.
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Chapter Seven
Final Summary and Conclusion
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Summary
The research presented in this thesis is centred on the MMP, matrilysin. 
Four related but distinct areas were covered. Firstly, a sensitive and specific one- 
step, sandwich ELISA for matrilysin was developed. The monoclonal antibodies 
used in this assay were provided by our collaborators from Syntex Research, 
California and Vanderbilt University, Tennessee. The ELISA was validated for use 
with cell culture medium and was shown to have excellent reproducibility. The 
linear range was 5 - 5 0  ng/ml with a limit of detection of 0.45 ng/ml. Although this 
ELISA was not useful for the breast tumour study presented in this thesis, it is 
expected that it could be used for determination of matrilysin levels in other tumour 
types. Matrilysin expression has been particularly associated with colon tumour 
development (Witty et al., 1994; Yamamoto et al., 1995). Specific mRNA for 
matrilysin was not found in normal colon tissue but was seen in adenomas although 
at lower levels than in invasive carcinomas (Newell et al., 1994). A sensitive and 
specific ELISA for matrilysin will be useful to determine if matrilysin protein levels 
can be correlated with stage of tumour development. The only previously described 
ELISA for matrilysin requires 3 days before results can be obtained (Ohuchi et al., 
1996). In order to assess possible correlations between tumour stage and matrilysin 
level, large numbers of patient samples should be analysed. Obviously, this can be 
achieved more easily with a faster assay. Our matrilysin ELISA is a significant 
improvement on that previously available as it requires only 7 hours before results 
can be obtained.
Matrilysin expression has previously been demonstrated in gastrointestinal 
carcinomas (McDonnell et al., 1991). Its expression by tumour cells only and not 
in adjacent normal tissue or other non-tumour tissue samples, suggested a role for 
matrilysin in gastrointestinal tumour development. In order to analyse its 
expression in breast tissue, ten tissue samples from patients with infiltrating ductal 
carcinoma were studied using three different detection methods. One of these 
methods, RT-PCR, examined mRNA expression. Eight out of the ten samples were
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positive for matrilysin mRNA expression using this method. The cell types 
responsible for the positive result were, however, unknown.
Two protein detection methods, western blotting and immunohisto- 
chemistry, were also used. It was not known if any of the available antibodies 
would be suitable for immunohistochemistry. The first antibody used for western 
blotting, pAt>2, although the only available reagent for detecting both the zymogen 
and active forms of matrilysin, demonstrated non-specific binding to a high 
molecular weight component of the tumour tissue. All of the tissue samples were 
positive for expression of at least one of the two forms of the matrilysin enzyme 
when this antibody was used. A second antibody, RmAb, detected only the 
zymogen form of the enzyme but showed no non-specific binding. This antibody 
was then used for immunohistochemistry. The ten tumour samples as well as three 
samples of histologically-normal breast tissue, were analysed using this technique. 
Positive immunostaining was seen in all samples. The staining was associated only 
with epithelial cells, both tumour-derived and normal ductal cells. In a study of 
matrilysin expression in the normal mouse, the mammary gland was one of the few 
tissue types in which positive expression was demonstrated (Wilson et al., 1995). It 
would appear that the human mammary tissue also expresses this protein. In breast 
tumours, therefore, the expression of matrilysin is not linked with tumour 
development. It would be interesting to investigate tumours of other tissues as 
constitutive expression of matrilysin by normal tissue would not appear to be 
widespread.
The regulation of MMP expression by cytokines is an area of great interest 
(Mauviel, 1993b). The demonstration that tumour-associated expression of these 
invasion-linked proteinases may be controlled by polypeptide factors released by 
tumour or adjacent stromal cells (Borchers et al., 1994), suggests new possibilities 
in tumour immunotherapy. Information concerning cytokine regulation of 
matrilysin is limited. Of the cytokines investigated here, only EGF, TGF-p and 
IFN-y have previously been shown to have any effect on matrilysin expression 
(Gaire et al., 1994; Bruner et al., 1995; Busiek et al., 1995). Most previous studies 
of cytokines and MMPs have concentrated on fibroblastic cells which do not 
express matrilysin. In this study, eight tumour cell lines representing diverse tissue
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origins, were analysed for matrilysin expression following treatment with a range of 
cytokines. Expression of another MMP, stromelysin-1, by these cytokine-treated 
cell lines was also examined. Matrilysin is apparently expressed in a tissue-specific 
manner although cytokines such as IL-1(3, IL-6, bFGF, IGF-I and IGF-II can 
modulate levels, even inducing expression in cell lines which are normally negative 
such as SW480 and EJ. Stromelysin-1 was expressed in a wider range of cell lines 
but again, levels could be modulated by IL-1J3, EL-2, EGF, TGF-(3 and IFN-y. The 
demonstration that IL-6, in particular, is an inducer of matrilysin expression may 
serve to explain the levels of the enzyme present in normal breast tissue. A recent 
report shows that IL-6 is expressed in normal breast tissue but that levels decrease 
in invasive tumours (Basolo et al., 1996). It has been previously demonstrated that 
IGF-I, IGF-n and bFGF are autocrine and paracrine growth factors for breast 
tumours (Lippman et al., 1986; Cullen et al., 1992). These factors may upregulate 
matrilysin expression by breast tumour cells. IGF-I and IGF-II are of particular 
interest as they have been shown to be important stimulators of tumour cell 
proliferation in colorectal carcinomas (Lahm et al., 1994).
Transfection analysis of matrilysin promoter constructs in a suitable cell line 
was also performed. Human matrilysin promoter regions linked to the CAT 
reporter gene were shown to have little activity. Similar results have been reported 
by other groups (Prof. Lynn Matrisian, Dr T. Bowden, pers. comm.). It is thought 
that these results are due to an excess of 5’ flanking sequence of the CAT gene in 
the constructs. The constructs are currently being remade and will be analysed as 
soon as they are available. A 2.7 Kb mouse matrilysin promoter region linked to 
the luciferase reporter gene was successfully transfected into the K562 cell line 
using a lipofection reagent, DOTAP. Following transfection, the cells were treated 
with cytokines and TPA. EGF and TPA were the strongest stimulatory agents and 
it is thought that they both act through the AP-1 binding site present in the 
matrilysin promoter. As similar results were not seen with EGF when endogenous 
matrilysin expression by K562 cells was examined, the presence of repressor 
regions upstream of the 2.7 Kb promoter region used in transfection analysis must 
be considered. Alternatively, differences between mouse and human matrilysin 
genes may explain the results. An investigation of rat matrilysin showed little
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difference from the human form (Abramson et al., 1995) so it is unlikely that the 
mouse version would deviate to a large degree. IL-6 and IGF-I and -II were shown, 
as in the previous section, to be stimulatory. The presence of an NF-IL6 element 
within the promoter may explain the IL-6 effect, however, it is not known which 
elements are responsible for effects of IGF-I and -II. These cytokines have not 
previously been shown to regulate MMP gene expression so a more detailed 
investigation of their effects would be recommended.
The data concerning the effects of cytokines on matrilysin expression 
particularly at the transcriptional level is very interesting. There are no previous 
studies of matrilysin transcriptional regulation using a mouse promoter and no 
reports of IL-6, IGF-I or IGF-II being linked to matrilysin expression. There is a 
growing body of evidence to suggest that matrilysin is especially important in the 
early development of colorectal cancer (McDonnell et al., 1991; Witty et al., 1994; 
Newell et al., 1994; Yamamoto et al., 1995). The most recent data links matrilysin 
expression with the APC gene which is implicated in colorectal tumourigenesis 
(Fearon and Vogelstein, 1990). Approximately 90 % of adenomas arising in mice 
carrying a mutation in the APC gene predisposing to multiple intestinal neoplasias 
(Min mice) express matrilysin. A cross between Min mice and mice in which the 
matrilysin gene has been ablated by homologous recombination results in progeny 
with a 60 % reduction in the number of intestinal neoplasias (Matrisian et al., 
1996). The significance of this link between matrilysin and early events in 
colorectal tumourigenesis remains to be elucidated. Some of the data presented in 
this thesis may contribute to our understanding of matrilysin in tumourigenesis. Of 
the three colon tumour cell lines examined, two, SW620 and LoVo, have been 
shown to produce and respond to IGF II in an autocrine manner (Lahm et al., 
1994). These cell lines constitutively produce matrilysin. The third colon cancer 
cell line, SW480, although expressing an IGF receptor, does not itself appear to 
produce IGF-I or II (Lahm et al., 1994). SW480 cells do not produce matrilysin 
although they can be induced to do so by addition of exogenous IGF-I or II. This 
suggests that the matrilysin expression associated with colorectal tumourigenesis 
may be regulated by the IGFs. Investigation of the specific mechanism of IGF 
induction of matrilysin could lead to the development of a specific matrilysin
191
inhibitor which could then be used therapeutically for colorectal cancer. Our 
results also show that another cytokine, bFGF, is apparendy associated specifically 
with matrilysin induction and should be further investigated.
The transcriptional activation of matrilysin by IL-6 has not previously been 
reported. Sequence analysis of the matrilysin promoter suggests the existence of 
possible IL-6 responsive elements but their activity has not been demonstrated. The 
next step in our work will be to determine minimal promoter lengths which respond 
to IL-6 and other specific cytokines and then to identify the specific DNA 
sequences involved. Ultimately, it is hoped to delineate the signal transduction 
pathways which result in matrilysin gene expression following cytokine treatment. 
This knowledge could increase our understanding of the tumour development 
process thus leading to the development of specific therapeutic agents, and could 
also be of benefit in understanding the regulatory effects of cytokines on many other 
genes.
192
Chapter Eight
Bibliography
193
Aaltonen, M., Lipponen, P., Kosma, V., Aaltomaa, S. and Syrjanen, K. (1995) 
Prognostic value of cathepsin D expression in female breast cancer. Anti Cancer Res 15 
1033 - 1037.
Aaronson, S. A. (1991) Growth Factors and Cancer. Science 254 1146-115.
Abbas, A. K., Lichtman, A. H. and Pober, J. S. (1991) Cellular and Molecular 
Immunology. WB Saunders Co., Philadelphia, pp 234
Abramson, S. R., Conner, G. E., Nagase,H., Neuhaus, I. and Woessner, J. F. Jr. (1995) 
Characterisation of rat uterine matrilysin and its cDNA. J Biol Chem 270 16016 - 16022
Agarwal, C., Hembree, J. R., Rorke, E. A. and Eckert, R. L. (1994) Transforming growth 
factor ß l regulation of metalloproteinase production in cultured human cervical epithelial 
cells. Cancer Res 54 943-949.
Adelman, N.E., Hammond, M.E., Cohen, S and Dvorak, H.F. (1979) Lymphokines as 
inflammatory mediators. In : Biology of the Lymphokines. Pick, E., Cohen S. and 
Oppenheim J.J. eds. Academic, New York, pp 13 - 58.
Akira, S., Hirano, T., Taga, T. and Kishimoto, T. (1990) Biology of multifunctional 
cytokines : IL-6 and related molecules (IL-1 and TNF). FASEB J 4 2860-2867.
Albini, A., Melchiori, A., Santi, L., Liotta, L.A., Brown, P.D. and Stetler-Stevenson, 
W.G. (1991) Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83 775 - 779.
Alvarez, O.A., Carmichael, D.F. and De Clerck, Y.A. (1990) Inhibition of collagenolytic 
activity and metastasis of tumor cells by a recombinant tissue inhibitor of 
metalloproteinases. J Natl Cancer Inst 82 589 - 595.
Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R. J., Rahmsdorf, H. J., Jonat, C., 
Herrlich, P. and Karin, M. (1987) Phorbal ester-inducible genes contain a common cis 
element recognised by a TPA-modulated trans-acting factor. Cell 49 729-739.
Bae, S., Arand, G., Azzam, H., Pavasant, P., Torn, J., Frandsen, T. L. and Thompson, 
E. W. (1993) Molecular and cellular analysis of basement membrane invasion by human 
breast cancer cells in matrigel-based in vitro assays. Breast Cancer Res Treat 24 241 -
255.
Baker, T., Tickle, S., Wasan, H., Docherty, A., Isenberg, D. and Waxman, J. (1994) 
Serum metalloproteinases and their inhibitors : markers for malignant potential. Br J 
Cancer 70 506 - 512.
Barth, N. M., Galazka, A. R. and Rudnick, S. A. (1987) Lymphokines and cytokines. In 
Principles of Cancer Biotherapy, ed by R.K. Oldham, Raven Press Ltd., New York.
194
Basolo, F., Calvo, S., Fiore, L., Conaldi, P. G., Falcone, V. and Toniolo, A. (1993) 
Growth-stimulating activity of interleukin-6 on human mammary epithelial cells
transfected with the int-2 gene. Cancer Res 53 2957-2960.
Basset, P., Bellocq, J.P., Wolf, C., Stoll, I., Hutin, P. Limacher, J.M., Podhajcer, O.L., 
Chenard, M.P., Rio, M.C. and Chambon, P. (1990) A novel metalloproteinase gene 
specifically expressed in stromal cells of breast carcinomas. Nature 348 699- 704.
Bates, P., Fisher, R., Ward, A., Richardson, L., Hill, D J. and Graham, C.F. (1995) 
Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J 
Cancer 72 1189 - 1193.
Bergmann, U., Michaelis, J., Oberhoff, R., Knauper, V., Beckmann, R. and Tschesche, H.
(1989) Enzyme-linked immunosorbent assays (ELISAs) for the quantitative determination 
of human leukocyte collagenase and gelatinase. J. Clin. Chem. Clim. Biochem. 27 351- 
359.
Bernhard, E.J., Gruber, S.B. and Muschel, RJ. (1994) Direct evidence linking MMP-9 
(92 kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo 
cells. Proc Natl Acad Sci USA 91 4293 - 4297.
Bevilacqua, G., Sobel, M. E., Liotta, L. A. and Steeg, P. S. (1989) Association of low 
nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node 
involvement and other histopathological indicators of high metastatic potential. Cancer 
Res 49 5185-5190.
Bishop, J. M. (1991) Molecular themes in oncogenesis. Cell 64 235 - 248.
Blasi, F. (1993) Molecular mechanisms of protease-mediated tumor invasiveness. J Surg 
Oncol Suppl. 3 21-23.
Blay, J., Negrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., 
Ravault, A., Tourani, J., Moskovtchenko, J., Philip, T. and Favrot, M. (1992) Serum 
level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 
52 3317-3322.
Boone, K., Johnson, M.J., De Clerck, Y.A. and Langley, K.E. (1990) cDNA cloning 
and expression of a metalloproteinase inhibitor related to tissue inhibitor of 
metalloproteinases. Proc Natl Acad Sci (USA) 87 2800 - 2804.
Borth, W. (1992) a 2-macroglobulin, a multifunctional binding protein with targeting 
characteristics. FASEB J 6 3345 - 3353.
Bouchet, C., Spyratos, F., Martin, P., Hacene, K., Gentile, A. and Oglobine J. (1994) 
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen 
activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69 398 - 405.
195
Boudreau, N., Sympson, C. J., Werb, Z. and Missell, M. J. (1995) Suppression of ICE 
and apoptosis in mammary epithelial cells by extracellular matrix. Science 267 891-893.
Borchers, A. H., Powell, M. B., Fusenig, N. E. and Bowden, G..T. (1994) Paracrine 
factor and cell-cell contact-mediated induction of protease and c-ets gene expression in 
malignant keratinocyte / dermal fibroblast co-cultures. Exp Cell Res 213 143-147.
Bramhall, S.R., Stamp, G.W.H., Dunn, J., Lemoine, N.R. and Neoptolemos, J.P.
(1996) Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of 
the metalloproteinases (TIMP-1) in pancreatic and ampullary disease. Br J Cancer 73 
972 - 978.
Brenner, D.A., O’Hara, M., Angel, P., Chojkier, M. and Karin M. (1989) Prolonged 
activation of jun and collagenase genes by tumour necrosis factor-a. Nature 337 661 - 
663.
Brinckerhoff, C. E., Suzaki, K., Mitchell, T. I., Oram, F., Coon, C. I., Palmiter, R. D., and 
Nagase, H. (1990) Rabbit procollagenase synthesized and secreted by a high yield 
mammalian expression vector requires stromelysin for maximal activation. J Biol Chem 
265 22262-22269.
Brown, P. T., Levy, A. T., Margulies, I. M.K., Liotta, L. A. and Stetler-Stevenson, W. G. 
(1990) Independent expression and cellular processing of Mr72,000 type IV collagenase 
and interstitial collagenase in human tumorigenic cell lines. Cancer Res 50 6184-6191.
Brown, P.D., Bloxidge, R.E., Anderson, E. and Howell, A. (1993) Expression of 
activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis JL1183 - 
189.
Brown, P.D. (1996) Synthetic matrix metalloproteinase inhibitors : From cancer models to 
cancer patients. Proc Am Assoc Cancer Res 37 633 - 634.
Bruner, K. L., Rodgers, W. H., Gold, L. I., Hargrove, J. T., Matrisian, L. M. and Osteen, 
K. G. (1995) Transforming growth factor (3 mediates the progesterone suppression of an 
epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl 
Acad Sci USA 92 7362 - 7366.
Burrin, J. and Newman, D. (1991) Production and assessment of antibodies. In : 
Principles and Pracice of Immunoassay, Christopher P. Pierce and David J. Newman 
(eds). Macmillan Publishers, U.K. pp 20 - 25.
Busiek, D. F., Ross, F. P., McDonnell, S., Murphy, G., Matrisian, L. M. and Welgus, H.
G. (1992) The matrix metalloproteinase matrilysin (Pump) is expressed in developing 
human mononuclear phagocytes. J Biol Chem 267 9087-9092.
196
Busiek, D. F., Baragi, V., Nehring, L. C., Parks, W. C. and Welgus, H. G. (1995) 
Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines 
and hormones. J Immunol 154 6484 - 6491.
Carlsson, R. and Glad, C. (1989) Monoclonal antibodies into the ‘90s : the all-purpose 
tool. Bio/Technology 7 567 - 573.
Carmichael, D.F., Sommer, A., Thompson, R.C., Anderson, D.C., Smith, C.G.,
Welgus, H.G. and Stricklin, G.P. (1986) Primary sequence and cDNA cloning of human 
fibroblast collagenase inhibitor. Proc Natl Acad Sci (USA) 83 2407 - 2411.
Carter, C.L., Allen, C. and Henson, D.E. (1989) Relation of tumor size, lymph node 
status and survival in 24,740 breast cancer patients. Cancer 63 181 - 187.
Catty, D. and Raykundalia, C. (1989) ELISA and related immunoassays. In : Antibodies 
Vol II - A Practical Approach, D. Catty (ed). IRL Press, Oxford, pp 97 - 154.
Cawston, T.E., Galloway, W.A., Mercer, E., Murphy, G. and Reynolds, JJ. (1981) 
Purification of rabbit bone inhibitor of collagenase. Biochem J. 195 159 - 165.
Cerra, M., Cecco, L., Montella, M., Tuccillo, F., Bonelli, P. and Dotti, C. (1995) 
Epidermal growth factor receptor in human breast cancer: comparison with steroid 
receptors and other prognostic factors. Int J Biol Markers 10 136- 142.
Chiu, R., Angel, P. and Karin, M. (1989) Jun-B differs in its biological properties from, 
and is a negative regulator of, c-Jun. Cell 59 979 - 986.
Chomcynski, P. and Sacchi, N. (1987) Single-step metod of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 156 - 159.
Christofori, G., Nalk, P. and Hanahan, D. (1994) A second signal supplied by insulin­
like growth factor II in oncogene-induced tumorigenesis. Nature 369 414 - 417.
Clark, G. M., Dressier, L. G., Owens, M. A., Pounds, G., Oldaker, T. and McGuire, W. 
L. (1989) Prediction of relapse or survival in patients with node-negative breast cancer 
by DNA flow cytometry. N Engl J Med 320 627 - 633.
Clark, R.A.F. (1988) Overview and general considerations in wound repair. In : The 
Molecular and Cellular Biology of Wound Repair, RAF Clark and PM Henson, eds. 
Plenum Press, New York, pp 3 - 33.
Collier, I.E., Wilhelm, S.M., Eisen, A.Z., Marmer, B.L., Grant, G.A., Seltzer, J.L., 
Kronherger, A., He, C., Bauer, E.A. and Goldberg, G.I. (1988) H-ras oncogene- 
transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase 
capable of degrading basement membrane collagen. J Biol Chem 263 6579 - 6587.
197
Cooksley, S., Hipkiss, J. B., Tickle, S. P., Holmes-Ievers, E., Docherty, A. J.P., 
Murphy, G. and Lawson, A. D.G. (1990) Immunoassays for the detection of human 
collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme- 
inhibitor complexes. Matrix 10 285 - 291.
Crawford, H. C. and Matrisian, L. M. (1995) Tumor and stromal expression of matrix 
metalloproteinases and their role in tumor progression. Invasion Metastasis 14 234 - 245.
Cross, J. C., Werb, Z. and Fisher, S. J. (1994) Implantation and the placenta : key pieces 
of the development puzzle. Science 266 1508- 1518.
Cullen, K. J., Smith, H. S., Hill, S., Rosen, N. and Lippman, M. E. (1991) Growth 
factor messenger RNA expression by human breast fibroblasts from benign and malignant 
lesions. Cancer Res 514978 - 4985.
Daidone, M. G., Silverstrini, R., D’Errico, A., DiFronzo, G., Benini, E., Mancini, A. M., 
Garbisa, S., Liotta, L. A. and Grigioni, W. F. (1991) Laminin receptors, collagenase IV 
and prognosis in node negative breast cancers. Int J Cancer 48 529 - 532.
Danforth, D. A. and Sgagias, M. K. (1991) Interleukin l a  blocks estradiol-stimulated 
growth and down-regulates the estrogen receptor in MCF-7 breast cancer cells in vivo. 
Cancer Res 51 1488 - 1493.
Davies, B., Brown, P. D., East, N., Crimmin, M. J. and Balkwill, F. R. (1993a) A 
synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival 
of mice bearing human ovarian carcinoma xenografts. Cancer Res 53 2087 - 2091.
Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, 
D., Hanby, A. and Balkwill, F.. (1993b) Levels of matrix metalloproteinases in bladder 
cancer correlate with tumor grade and invasion. Cancer Res 53 5365 - 5369.
Davies, B., Miles, D.W., Hepperfield, L.C., Naylor, M.S., Bobrow, L.G., Rubens, R.D. 
and Balkwill, F.R. (1993c) Activity of type IV collagenases in benign and malignant 
breast disease. Br J Cancer 67 1126- 1131.
De Clerck, Y.A., Yean, T.D., Ratzkin, B.J., Lu, H.S. and Langley, K.E. (1989) 
Purification and characterisation of two related but distinct metalloprtoeinase inhibitors 
secreted by bovine aortic endothelial cells. J Biol Chem 264 17445 - 17453.
De Clerck, Y.A., Yean, T., Lu, H.S., Ting, J and Langley, K.E. (1991a) Inhibition of 
autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase 
inhibitor MI / TIMP-2. J Biol Chem 266 3893 - 3899.
De Clerck, Y.A., Yean, T.D., Chan, D., Shimada, H. and Langley, K.E. (1991b) 
Inhibition of tumor invasion of smooth muscle cell layers by recombinant human 
metalloproteinase inhibitor. Cancer Res 512151 - 2157.
198
De Clerck, Y.A., Shimada, H., Boone, T.C., Langley, K.E. and Taylor, S.M. (1992) 
Inhibition of invasion and metastasis in cells transfected with an inhibitor of 
metalloproteinases. Cancer Res 52 701 - 708.
Delany, A. M. and Brinckerhoff, C. E. (1992) Post-transcriptional regulation of 
collagenase and stromelysin gene expression by epidermal growth factor and 
dexamethasone in cultured human fibroblasts. J Cell Biochem 50 400 - 410.
Diaz-Meco, M. T., Quinones, S., Municio, M. M., Sanz, L., Bernal, D., Cabrero, E., Saus, 
J. and Moscat, J.. (1991) Protein kinase-C-independent expression of stromelysin by 
platelet-derived growth factor, ras oncogene and phosphotidylcholine-hydrolysing 
phospholipase C. J Biol Chem 266 22597 - 22602.
Derynck, R. (1994) TGF-p-receptor mediated signaling. Trends Biochem Sci 19 548- 
553.
Dewhirst, F. E., Stashenko, P. P., Mole, J. E. and Tsuramachi, T. (1985) Purification 
and partial sequence of human osteoclast activating factor: identity with interleukin ip. J 
Immunol 135 2562 - 2568.
Dinarello, C. A. (1988) Biology of Interleukin-1. FASEB J 2 108 - 115.
Docherty, A. J.P., Lyons, A., Smith, B., Wright, E. M., Stephens, P. E. and Harris, 
J.R. (1985) Sequence of human tissue inhibitor of metalloproteinases and its identity to 
erythroid potentiating activity. Nature 318 66 - 69.
Docherty A.J.P., Cockett, M.I., Birch, M.L. et al., (1994) Gelatinase inhibitors for the 
treatment of cancer. Clin Exp Metastasis 12 12-15.
Dodge, G.R. and Poole, A.R. (1989) Immunohistochemical detection and 
immunohistochemical analysis of type II collagen degradation in human normal, 
rheumatoid and osteoarthritic articular cartilages and in explants of bovine articular 
cartilage treated with interleukin-1. J Clin Invest 83 647 - 661.
Dorudi, S., Hanby, A.M., Poulsom, R., Northover, J. and Hart, I.R. (1995) Level of 
expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. 
Brit J Cancer 71 614 - 616.
Duffy, M. J., Reilly, D., O’Sullivan, C., O’Higgins, N., Fennelly, J. J. and Andreasen, P.
(1990) Urokinase-plasminogen activator, a new and independent prognostic marker in 
breast cancer. Cancer Res 50 6827 - 6829.
Duffy, M.J. (1992) Urokinase plasminogen activator : a protease implicated in cancer 
invasion and metastasis. Cancer Topics 9 30 - 31.
199
Duffy, M.J., Blaser, J., Duggan, C., McDermott, E., O’Higgins, N., Fennelly, JJ . and 
Tschesche, H. (1995) Assay of matrix metalloproteinases types 8 and 9 by ELIS A in 
human breast cancer. Brit J Cancer 71 1025 - 1028.
Dynan, W. S. and Tjian, R. (1985) Control of eukaryotic messenger RNA synthesis by 
sequence-specific DNA-binding proteins. Nature 316 774 - 779.
Dynan, W. S. (1989) Modularity in promoters and enhancers. Cell 58 1-4.
Edwards, D.R., Murphy, G., Reynolds, J.J., Whitman, S.E., Docherty, A.J.R, Angel,
P. and Heath, J.C. (1987) Transforming growth factor beta modulates the expression of 
collagenase and metalloproteinase inhibitor. EMBO J 6 1899 - 1904.
Edwards, R. (1985) Immunoassay. An Introduction. William Heinemann Medical Books, 
London, pp 55 - 73
Engvall, E. and Perlmann P. (1971) ELISA quantitative assay of immunoglobulin G. 
Immunochemistry 8 871- 875.
Engvall, E. (1980) Enzyme immunoassay - ELISA and EMIT. MethsEnzymol 20 419-
439.
Fearon, E. R. and V., Bert. (1990) A genetic model for colorectal tumorigenesis. Cell 61 
759 - 767.
Femandez-Resa, P., Mira, E. and Quesada, A. R. (1995) Enhanced detection of casein 
zymography of matrix metalloproteinases. Anal Biochem 224 434 - 435.
Fidler, I. J. (1993) Role of the organ environment in the pathogenesis of cancer 
metastasis. Proc Am Assoc Cancer Res 34 570.
Fisher, G.J., Datta, S. C., Talwar, H. S., Wang, Z., Varani, J., Kang, S. and Voorhees, J.
J. (1996) Molecular basis of sun-induced premature skin ageing and retinoid antagonism. 
Nature 379 335 - 339.
Fisher, S.J. and Damsky, C.H. (1993) Human cytotrophoblast invasion. Semin Cancer 
Biol 4 183 - 188.
Freije, J. M.P., Diez-Itza, I., Balbin, M., Sanchez, L. M., Blasco, R., Tolivia, J. and 
Lopez-Otin, C. (1994) Molecular cloning and expression of collagenase-3, a novel 
human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269 16766 
- 16773.
Frisch, S. M. and Ruley, H. E.. (1987) Transcription from the stromelysin promoter is 
induced by interleukin-1 and repressed by dexamethasone. J Biol Chem 262 16300 - 
16304.
200
Frisch, S.M., Reich, R., Collier, I.E., Genrich, L.T., Martin, G. and Goldberg, G.I.
(1990) Adenovirus El A represses protease gene expression and inhibits metastasis of 
human tumour cells. Oncogene 5 75 - 83.
Fujimoto, N, Mouri, N., Iwata, K., Ohuchi, E., Okada, Y. and Hayakawa, T. (1993) A 
one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa 
gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 221 91- 
103.
Gaffney, E.V., Halpin, D.P. and Blakemore, W.S. (1995) Relationship between low 
estrogen receptor values and other prognostic factors in primary breast tumours. Surgery 
117 241 -246.
Galis, Z. S., Sukhova, G. K., Lark, M. W. and Libby, P. (1994) Increased expression of 
matrix metalloproteinases and matrix degrading activity in vulnerable regions of human 
atherosclerotic plaques. J Clin Invest 94 2493 -2503.
Gaire, M., Magbanua, Z., McDonnell, S., McNeil, L., Lovett, D. H. and Matrisian, L. 
M. (1994) Structure and expression of the human gene for the matrix metalloproteinase 
matrilysin. J Biol Chem 269 2032 - 2040.
Ganesh, S., Sier, C. F.M., Griffioen, G., Vloedgraven, H. J.M., De Boer, A., Welvaart, 
K., Van De Velde, C.J.H., Van Krieken, H.J.M., Verheijen, J. H., Lamers, C. B.H.W. 
and Verspaget, H. W. (1994) Prognostic relevance of plasminogen activators and their 
inhibitors in colorectal cancer. Cancer Res 54 4065 - 4071.
Garbisa, S., Pozzatti, R., Muschel, R.J., Saffioti, U., Ballin, M., Goldfarb, R.H., 
Khoury, G. and Liotta, L.A. (1987) Secretion of type IV collagenolytic protease and 
metastatic phenotype : induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2- 
Ela. Cancer Res 47 1523 - 1528.
Giavazzi, R., Garofalo, A., Valoti, G., Valla, R., Rossi, R., Bone, E. andLucchini, V. 
(1996) Baltimastat (BB-94) in combination with cisplatin inhibits human ovarian 
carcinoma xenografts. Proc Am Assoc Cancer Res 32. 90.
Gilligan, A., Prentki, M. and Knowles, B. B. (1990) EGF-receptor down-regulation 
attenuates ligand-induced second messenger formation. Exp Cell Res 187 134- 142.
Gillis, S.D., Morrison, S.L., Oi, V.T. andTonegawa, S. (1983) A tissue-specific 
transcription enhancer element is located in the major intron of a rearranged 
immunoglobulin heavy chain gene. Cell 33 717 - 728.
Gipson, I.K. and Kiorpes, T.C. (1982) Epithelial sheet movement: protein and 
glycoprotein synthesis. Dev Biol 92 259 - 262.
201
Girard, M. T., Matsubaru, M., Kublin, C., Tessier, M. J., Cintron, C. and Fini, M. E. 
(1993) Stromal fibroblasts synthesize collagenase and stromelysin during long term tissue 
remodeling J CellSci 104 1001 - 1011.
Goldberg, G.I., Marmer, B.L., Gregory, G.A., Eisen, A.Z., Wilhelm, S and He, C. 
(1989) Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor 
of metalloproteases designated TIMP-2. Proc Natl Acad Sci (USA) 86 8207 - 8211.
Goldberg, G. I., Strongin, A., Collier, I. E., Genrich, T. and Marmer, B. L. (1992) 
Interaction of 92kDa type IV collagenase with the tissue inhibitor of metalloproteinases 
prevents dimerization, complex formation with interstitial collagenase and activation of the 
proenzyme with stromelysin. J Biol Chem 267 4583 - 4591.
Graham, C. H. and Lala, P. K. (1992) Mechanisms of placental invasioh of the uterus 
and their control. Biochem Cell Biol 70 867 - 874.
Graham, F.L. and Van der Eb, A J . (1973) A new technique for the assay of infectivity of 
human adenovirus 5 DNA. Virology 52 456 -
Gravallese, E. M., Darling, J. M., Ladd, A. L., Katz, J. N., and Glimacher, L. H.
(1991) In situ hybridization studies of stromelysin and collagenase messenger RNA 
expression in rheumatoid synovium. Arth Rheum 34 1076 - 1084.
Grant, G. A., Eisen, A. Z., Marmer, B. L., Roswit, W. T. and Goldberg, G, I. (1987) 
The Activation of human skin fibroblast procollagenase. J Biol Chem 262 5886 -5889.
Greenblatt,. (1991) RNA polymerase-associated transcription factors. Trends Biochem 
Sci 16 408-411.
Greene, J., Wang, M., Xiao, G., Liu, Y.E. and Shi, Y.E. (1996) Loss of expression of 
TIMP-4, a novel human tissue inhibitor of metalloproteinase, in human breast cancer 
malignant progression. Proc Am Assoc Cancer Res 37 91.
Hamblin, A. S. (1988) Lymphokines. IRL Press, Oxford, pp 13 - 32
Hanemaaijer, R., Koolwijk, P., Le Clercq, L., De Vree, W.J. and Van Hinsbergh, V.W. 
(1993) Regulation of matrix metalloproteinase expression in human vein and 
microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and 
phorbal ester. Biochem J 296 803 - 809.
Hardie, D.G. (1991) Biochemical Messengers. Hormones, Neurotransmitters and 
Growth Factors. Chapman and Hall, London, pp 225 - 295.
Hasty, K. A., Reife, R. A., Kang, A., H., and S., John M. (1990) The role of 
stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arth 
Rheum 33 388 - 397.
202
Hawley, D. (1991) Transcriptional activation : enter TFIIB. Trends Biochem Sci 16 317 - 
318.
Hayes, D. F. (1996) Breast Cancer. In : Atlas of Diagnostic Oncology 2nd Edition,
Arthur T. Skarin (ed). Mosby Wolfe, London, pp 239 - 275.
He, C., Wilhelm, S.M., Pentland, A.P., Marmer, B.L., Grant, G.A., Eisen, A.Z. and 
Goldberg, G.I. (1989) Tissue cooperation in a proteolytic cascade activating human 
interstitial collagenase. Proc Natl Acad Sci USA 86 2632 - 2636.
Hembry, R.M., Bagga, M.R., Murphy, G., Henderson, B. and Reynolds, JJ . (1993) 
Rabbit models of arthritis : Immunolocalisation of matrix metalloproteinases and tissue 
inhibitor of metalloproteinase in synovium and cartilage. Am J Pathol 143 628 - 642.
Henderson, J. (1993) Whatever happened to interferon? J Biol Ed 27 12 - 16.
Heppner, K. J., Matrisian, L. M., Jensen, R. A. and Rodgers, W. H. (1996) Expression 
of most matrix metalloproteinase family members in breast cancer represents a tumor- 
induced host response. Am J Pathol 149
Hicks, N.J., Ward, R.V. and Reynolds, JJ . (1984) A fibrosarcoma model derived from 
mouse embryo cells : Growth properties and secretion of collagenase and 
metalloproteinase inhibitor (TIMP) by tumor cell lines. Int J Cancer 33 835 - 844.
Higashiyama, M., Doi, O., Yokouchi, H., Kodama, K., Nakamori, S., Tateishi, R. and 
Kimura, N. (1992) Immunohistochemical analysis of nm23 gene product/NDP kinase 
expression in pulmonary adenocarcinoma: lack of prognostic value. Brit J Cancer 66 533 
-536.
Hill, C. S. and Treisman, R. (1995) Transcriptional regulation by extracellular signals: 
mechanisms and specificity. Cell 80 199 - 211.
Himelstein, B.P., Canete-Soler, R., Bernhard, E.J. and Muschel, R.J. (1994) Induction 
of fibroblast 92 kDa gelatinase/ type IV collagenase expression by direct contact with 
metastatic tumor cells. J Cell Sci 107 477 - 486.
Howard, E.W., Bullen, E.C. and Banda, M.J. (1991) Preferential inhibition of 72- and 92- 
kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem 266 13070 - 
13075.
Hudson, L. and Hay, F.C. (1980) Practical Immunology 2nd Edition. Blackwell 
Scientific Publishers, Oxford, pp 8 - 11.
Huhtala, P., Chow, L. T. and Tryggvason, K. (1990) Structure of the human type IV 
collagenase gene. J Biol Chem 265 11077 - 11082.
203
Hunt, L.T., Barker, W.C. and Chen, H.R. (1987) A domain structure common to 
hemopexin, vitronectin, interstitial collagenase and a collagenase homolog. Protein Seq 
Data Anal 1 21 - 26.
Hutchins, D., Cohen, B. B. and Steel, C. M. (1990) Production and regulation of 
interleukin 6 in human B lymphoid cells. Eur J Immunol 20 961 - 968.
Hutchins, D. and Steel, C. M. (1994) Regulation of ICAM-1 (CD54) expression in 
human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer 
58 80 - 84.
Imai, K., Yokohama, Y., Nakanishi, I., Ohuchi, E., Fujii, Y., Nakai, N. and Okada, Y. 
(1995) Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. J Biol 
Chem 270 6691 -6697.
Ingber, D.E. and Folkman, J. (1989) Mechanochemical switching between growth and 
differentiation during fibroblast growth-stimulated angiogenesis in vitro : role of 
extracellular matrix. J Cell Biol 109 317 - 330.
Ishikawa, E., Imagawa, M., Hashida, S., Yoshitake, S., Hamaguchi, Y. andHeno, T. 
(1983) Enzyme-labelling of antibodies and their fragments for enzyme immunoassay and 
immunohistochemical staining. J Immunoassay 4_ 209 - 327.
Ito, A., Itoh, Y., Sasaguri, Y., Morimatsu, M. and Mori, Y. (1992) Effects of 
interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial 
fibroblasts. Arth Rheum 35 1197 - 1201.
Ito, A., Nakajima, S., Sasaguri, Y., Nagase, H. and Mori, Yo (1995) Co-culture of 
human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the 
production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Brit J Cancer 21 1039 
- 1045.
Jacobson, S.G., Cideciyan, A.V., Regunath, G., Rodriguez, F.G., Vandenburgh, K., 
Sheffield, V.C. and Stone, E.M. (1995) Night blindness in Sorsby’s fundus dystrophy
reversed by vitamin A. Nat Genet H  27 - 32.
Johansson, S. and Smedsrod, B. (1986) Identification of a plasma gelatinase in 
preparations of fibronectin. J Biol Chem 261 4363 - 4366.
Jones, N. (1990) Transcriptional regulation by dimerization : Two sides to an incestuous
relationship. Cell 61 9-11.
Kaiserlian, D., Rigal, D., Abello, J. and Revillard, J. (1991) Expression, Function and 
regulation of the intercellular adhesion molecule-1 (ICAM-1) on human intestinal 
epithelial cell lines. Eur J Immunol 21 2415 - 2421.
204
Kaplan, G., Cohn, Z. A. and Smith, K. A. (1992) Rational immunotherapy with 
interleukin-2. Bio/Technology 10 157 - 162.
Kataoka, H., DeCastro, R., Zucker, S. and Biswas, C. (1993) Tumor-cell derived 
collagenase stimulatory factor increases expression of interstitial collagenase, stromelysin 
and 72kDa gelatinase. Cancer Res 53 3154-3158.
Katsumata, N., Eguchi, K., Fukuda, M., Yamamoto, N., Ohe, Y., Oshita, F., Tamura, 
T., Shinkai, T. and Saijo, N. (1996) Serum levels of cytokines in patients with untreated 
promary lung cancer. Clin Cancer Res 2 553 - 559.
Kawami, H., Yoshida, K., Ohsaki, A., Kuroi, K , Nishiyama, M. andToge, T. (1993) 
Stromelysin-3 mRNA expression and malignancy : comparison with clinicopathological 
features and type IV collagenase mRNA expression in breast tumors. Anticancer Res 13 
2319-2324.
Kemler, R. (1993) From cadherins to catenins : cytoplasmic protein interactions and 
regulation of cell adhesion. Trends Gens 9 317 - 321.
Kerr, L.D., Holt, J.T. and Matrisian, L.M. (1988) Growth factors regulate transin gene 
expression by c-fos dependent and c-fos independent pathways. Science 242 1424 - 1427.
Kerr, L. D., Miller, D. B. and Matrisian, L. M. (1990) TGF-(5l inhibition of 
transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell 61 
267 - 278.
Kinoshita, S., Akira, S. and Kishimoto, T. (1992) A member of the C/EBP family NF- 
IL6p, forms a heterodimer and transcriptionally synergises with NF-IL6. Proc Natl Acad 
SciUSA 89 1473 - 1476.
Khokha, R., Waterhouse, P., Yagel, S., Lala, P.K., Overall, C.M., Norton, G. and 
Denhardt, D.T. (1989) Antisense RNA-induced reduction in murine TIMP levels confers 
oncogenicity on Swiss 3T3 cells. Science 244 947 - 950.
Knudson, A. G. Jr. (1985) Hereditary cancer, oncogenes and antioncogenes. Cancer Res. 
45 1437 . 1443.
Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody 
of defined specificity. Nature 256 495 - 497.
Kohn, E. C. and Liotta, L. A. (1995) Molecular insights into cancer invasion : strategies 
for prevention and intervention. Cancer Res 55 1856- 1862.
Kolkenbrock, H., Orgel, D., Hecker-Kia, A., Noack, W. and Ulbrich, N. (1991) 
Complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72 kDa 
progelatinase is a metalloproteinase inhibitor. Eur J Biochem 198 775 - 781.
205
Kordula, T., Guttegemann, I., Rose-John, S., Roeb, E., Osthues, A., Tschesche, H., 
Koj, A., Heinrich, P. C. and Graeve, L. (1992) Synthesis of tissue inhibitor of 
metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2). FEBS 313 143 - 147.
Kossakowska, A. E., Urbanski, S. J., Watson, A., Hayden, L. J. and Edwards, D. R. 
(1993) Patterns of expression of metalloproteinases and their inhibitors in human 
malignant lymphomas. Oncol Res 5 19-28.
Krueger, J., Ray, A., Tamm, I. and Sehgal, P. B. (1991) Expression and function of 
interleukin-6 in epithelial cells. J Cell Biochem 45 327 - 334.
Lahm, H., Amstad, P., Wyniger, J., Yilmaz, A., Fischer, J. R., Schreyer, M. and Givel, 
J. (1994) Blockade of the insulin-like growth factor I receptor inhibits growth of human 
colorectal cancer cells : Evidence of a functional IGF-II-mediated autocrine loop. Int J 
Cancer 58 452-459.
Landschulz, W.H., Johnson, P.F., Adashi, E.Y., Graves, B.J. and McKnight, S.L. (1988) 
Isolation of a recombinant copy f  the gene encoding C/EBP. Genes Dev 2 786 -800.
Latchman, D. (1990) Gene Regulation : A Eukaryotic Perspective. Unwin Hyman, 
London, pp 138 - 227.
Leader, M., McDermott, N. and Al-Sader, M. (1995) A review of in situ and early 
invasive breast carcinoma. J Ir Coll Phys Surg 24 179 - 184.
LeClair, K. P., Blanar, M. A. and Sharp, P. A. (1992) The p50 subunit of NF-kB 
associates with the NF-IL6 transcription factor. Proc Natl Acad Sci USA 89 8145 - 
8149.
Lebfevre, O., Wolf, C., Limacher, J., Hutin, P., Wendling, C., LeMeur, M., Basset, P. 
and Rio, M. (1992) The breast cancer -associated stromelysin-3 gene is expressed during 
mouse mammary gland apoptosis. J Cell Biol 119 97 - 1002.
Leone, A., Flatow, U., Richter, K. C., Sandeen, M. A., Margulies, I. M.K., Liotta, L. 
A. and Steeg, P. S. (1991) Reduced tumor incidence, metastatic potential, and cytokine 
responsiveness of nm23-transfected melanoma cells. Cell 65 25 - 35.
Lerner, R. A. (1982) Tapping the immunological repertoire to produce antibodies of 
predetermined specificity. Nature 299 592 - 596.
Levy, A.T., Cioce, V., Sobel, M.E., Garbisa, S., Grigoni, W.F., Liotta, L.A. and 
Stetler-Stevenson, W.G. (1991) Increased expression of the Mr 72,000 type IV 
collagenase in human colonic adenocarcinoma. Cancer Res 51 439 - 444.
Linder, M. E. and Gilman, A. G. (1992) G Proteins Sci Am 267 36 - 43.
206
Liotta, L., Kleinerman, J. and Saider, G. (1974) Quantitative relationships of 
intravascular tumor cells, tumor vessels and pulmonary metastases following tumor 
implantation. Cancer Res. 34 997 - 1004.
Liotta, L.A., Tryggvason, K. and Garbisa S. (1980) Metastatic potential correlates with 
enzymatic degradation of basement membrane collagen. Nature 284 67-68.
Liotta, L.A., Roa, C.N. and Barsky, S.H. (1983) Tumor invasion and the extracellular 
matrix. Lab Invest 49 636 - 649.
Liotta, L.A., Steeg, P.S., and Stetler-Stevenson, W.G. (1991a) Cancer metastasis and 
angiogenesis: an imbalance of positive and negative regulation. Cell 64 327 - 336.
Liotta, L. A., Stetler-Stevenson, W. and Steeg, P. S. (1991b) Metastasis suppressor 
genes. Import Adv Oncol 6 85 - 100.
Lippman, M. E., Dickson, R. B., Bates, S., Knabbe, C., Huff, K., Swain, S., McManaway, 
M., Bronzert, D., Kasid, A. and Gelmann, E. P. (1986) Autocrine and paracrine growth 
regulation of human breast cancer. Breast Cancer Res Treat 7 59 - 70.
Lippman, M.E. and Dickson, R.B. (1989) Mechanisms of growth control in normal and 
malignant breast epithelium. Rec Prog Horm Res 45 383 - 439.
Long, L., Rubin, R., Baserga, R. and Brodt, P. (1995) Loss of the metastatic phenotype 
in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor 
receptor. Cancer Res 55 1006 - 1009.
Lu, C., Vickers, M. F. and Kerbel, R. S. (1992) Interleukin 6 : a fibroblast-derived 
growth inhibitor of human melanoma cells from early but not advanced stages of tumor 
progression. Proc Natl Acad Sci USA 89 9215-9219.
Lyons, J. G., Birkedal-Hansen, B., Pierson, M. C., Whitelock, J. M. and Birkedal- 
Hansen, H. (1993) Interleukin-1 (3 and transforming growth factor-al epidermal growth 
factor induce expression of Mr 95,000 type IV collagenase/ gelatinase and interstitial 
fibroblast-type collagenase by rat mucosal keratinocytes. JBiolChem 268 19143 - 
19151.
Macauley, V.M. (1992) Insulin-like growth factors and cancer. Br J Cancer ^ 5 311 - 320.
Macleod, K., Leprince, D. and Stehelin, D. (1992) The ets gene family. Trends Biol Sci 
17 251 -256.
MacNaul, K. L., Chartrain, N., Lark, M., Tocci, M. J. and Hutchinson, N. I. (1990) 
Discoordinate expression of stromelysin, collagenase and tissue inhibitor of 
metalloproteinases-1 in rheumatoid human synovial fibroblasts.J Biol Chem 265 17238 - 
17245.
207
Mackay, A. R., Ballin, M. P., Farina, A. R., Nason, A. M., Hartzler, J. L. and 
Thorgeirsson, U. P. (1992) Effect of phorbal ester and cytokines on matrix 
metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal 
cell lines. Invasion Metastasis 12 168- 184.
Majmudar, G., Nelson, B. R., Jensen, T. C., Vorhees, J. J, and Johnson, T. M. (1994) 
Increased expression of stromelysin-3 in basal cell carcinomas. Molec Carcinogenesis 9 
17 - 23.
Mandai, M., Konishi, L, Komatsu, T., Mori, T., Arao, S., Nomura, H., Kanda, Y„ 
Hiai, H. and Fukumoto, M. (1995) Mutation of the nm23 gene, loss of heterozygosity at 
the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumor 
progression and nm23 gene expression. Brit J Cancer 72 691 - 695.
Marti, H., McNeil, L., Thomas, G., Davies, M. and Lovett, D. H. (1992) Molecular 
characterization of a low-molecular-mass matrix metalloproteinase secreted by glomerular 
masangila cells as PUMP-1. BiochemJ 285 899-905.
Marx, J. (1993a) New role for gene linked to metastasis suppression? Science 261 428 - 
429.
Marx, J. (1993b) Cellular changes on the route to metastasis. Science 259 626 - 629.
Mast, A. E., Enghild, J. J., Nagase, H., Suzuki, K , Pizzo, S. V. and Salvesen, G.
(1991) Kinetics and physiologic relevance of the inactivation of ai-proteinase inhibitor, 
oti-antichymotrypsin, and antithrombin HI by matrix metalloproteinases-1,-2 and -3. J 
Biol Chem 266 15810- 15816.
Matrisian, L.M., Bowden, G. T. Krieg, P. Fürstenberger, G. Briand, J. Leroy, P. and 
Breathnach, R. (1986) The mRNA coding for the secreted protease transin is expressed 
more abundantly in malignant than in benign tumors. Proc Nad Acad Sci USA 83 9413 - 
9417.
Matrisian, L.M. (1990) Metalloproteinases and their inhibitors in matrix remodelling. 
Trends Gens 6 121-125.
Matrisian, L.M., McDonnell, S. Miller, D.B., Navre, M. Seftor, E.A. and Hendrix, 
M.J.C. (1991) The role of the matrix metalloproteinase stromelysin in the progression of 
squamous cell carcinomas. Am J Med Sci 302 157 - 162.
Matrisian, L.M. (1992) The matrix degrading metalloproteinases. Bioessays 14 455 - 
463.
Matrisian, L. M., Heppner, K.J. and Wilson, C.J. (1996) Matrilysin and stromelysin in 
tumor progression. Proc Am Assoc Cancer Res 37 632 - 633.
208
Matsusaka, T. Fujikawa, K. Nishio, Y. Mukaida, N. Matsushima, K. Kishimoto, T.and 
Akira, S. (1993) Trsnscription factors NF-IL6 and NF-kB synergistically activate 
transcription of the inflammatory cytokines interleukin6 and interleukin 8. Proc Natl 
Acad Sci USA 90 10193 - 10197.
Mauviel, A. Chen, Y.Q. Dong, W. Evans, C.H. and Uitto, J. (1993a) Transcriptional 
interactions of transforming growth factor-(3 with pro-inflammatory cytokines. Curr Biol 
3 822 - 831.
Mauviel, A. (1993b) Cytokine regulation of metalloproteinase gene expression. J Cell 
Biochem 53 288 - 295.
Mauviel, A. Halcin, C. Vasiloudes, P., Parks, W.C., Kurkinen, M. and Uitto, J. (1994) 
Uncoordinate regulation of collagenase, stromelysin, and tissue inhibitor of 
metalloproteinases genes by prostaglandin E2 : selective enhancement of collagenase gene 
expression in human dermal fibroblasts in culture. J Cell Biochem 54 465 - 472.
McCachren, S.S. (1991) Expression of metalloproteinases and metalloproteinase inhibitor 
in human arthritic synovium. Arth Rheum 34 1085 - 1092.
McCarthy, G. M., Mitchell, P. G., Struve, J. A. and Cheung, H. S. (1992) Basic 
calcium phosphate crystals cause coordinate induction and secretion of collagenase and 
stromelysin. JCellPhys 153 140- 146.
McDonnell, S. E., Kerr, L. D. and Matrisian, L. M. (1990) Epidermal growth factor 
stimulation of stromelysin mRNA in rat fibroblasts requires induction of proto-oncogenes 
c-fos and c-jun and activation of protein kinase C. Molec Cell Biol 10 4284 - 4293.
McDonnell, S., Navre, M., Coffey, R. J. Jr and Matrisian, L. M. (1991) Expression and 
localization of the matrix metalloproteinase Pump-1 (MMP-7) in human gastric and colon 
carcinomas. Molec Carcinogenesis 4 527 - 533.
McGuire, W. L. and Clark, G. M. (1992) Prognostic factors and treatment desicions in 
axillary node-negative breast cancer. N Engl J Med 326 1756 - 1761.
McGuire-Goldring, M.K., Murphy, G., Gowen, M., Meats, J.E., Ebsworth, N.M., Poll, 
C., Reynolds, JJ . and Russell, R.G. (1983) Effects of retinol and dexamethasone on 
cytokine-mediated control of metalloproteinases and their inhibitors by human articular 
chondrocytes and synovial cells in culture. Biochem Biophys Acta 763 129- 139.
McKnight, S. L. (1991) Molecular zippers in gene regulation. Sci Am April 32 - 39.
Mink, D., Hollaender, M., Von Tongelen, B., Villena-Heinsen, C. and Schmidt, W. 
(1995) Demonstration of estrogen and progesterone receptors in breast cancers with 
monoclonal antibodies. Different results with enzyme immunoassay and immuno- 
histochemical methods. Eur J Gynaecol Oncol 16 81 - 91.
209
M itchell, P. J. and Tjian, R. (1989) Transcriptional regulation in mammalian cells by 
sequence specific D N A  binding proteins. Science 245 371 - 378.
M izel, S. B. (1989) The interleukins. FASEB J 3 2379 -2 3 8 8 .
M onteagudo, C., M erino, M. J., San-Juan, J., Liotta, L. A . and Stetler-Stevenson, W.
G. (1990) Immunohistochemical distribution o f  type IV collagenase in normal, benign and 
malignant breast tissue. A m  J Pathol 136 585 - 592.
M outsiakis, D ., M ancuso, P., Krutzch, H., Stetler-Stevenson, W . and Zucker, S. (1992) 
Characterization o f  m etalloproteinases and tissue inhibitors o f  metalloproteinases in human 
plasma. Conn Tiss Res 28 213 - 230.
M uller, D ., Breathnach, R ., Engelm ann, A ., M illon, R., Brenner, G., Flesch, H., 
Dumaont, P., Eber, M. and A becassis, J. (1991) Expression o f  collagenase-related  
metalloproteinase genes in human lung or head and neck tumours. Int J. Cancer 48 5 50  - 
556.
Muller, D ., W olf, C., A becassis, J., M illon, R., Engelm ann, A ., Brenner, G., Rouyer, 
N ., Rio, M. C., Eber, M ., M ethlin, G ., Chambon, P. and Basset, P. (1993) Increased  
stromelysin-3 gene expression is associated with increased local invasiveness in head and 
neck squamous cell carcinomas. Cancer Res 53 165 - 169.
Murphy, G., McGuire, M .B ., R ussell, R.G. and R eynolds, J.J. (1981) Characterisation 
o f collagenase, other m etalloproteinases, and an inhibitor (TIM P) produced by human 
synovium  and cartilage in culture. Clin Sei 6 1 7 1 1  - 716.
Murphy, G ., Cockett, M. I., Stephens, P. E., Smith, B. J. and Docherty, A. J.P. (1987) 
Stromelysin is an activator o f  procollagenase. B iochem  J 248 265 - 268.
Murphy, G., W illenbrock, F., Ward, R. V ., Cockett, M. I., Eaton, D . and Docherty, A. 
J.P. (1992) The C-terminal dom ain o f  72kD a gelatinase A  is not required for catalysis, 
but is essential for membrane activation and modulates interactions with tissue inhibitors 
o f  metalloproteinases. B iochem  J 283 6 3 7 - 6 4 1 .
Murphy, G., Cockett, M. I., Ward, R. V. and D ocherty, A . J.P. (1991) Matrix 
metalloproteinase degradation o f  elastin, type IV collagen and proteoglycan. B iochem  J 
277 277 - 279.
Murphy, G., Segain, J., O ’Shea, M ., Cockett, M ., Ioannou, C., Lefebvre, O.,
Chambon, P. and Basset, P. (1993) The 28kDa N-terminal domain o f  mouse stromelysin- 
3 has the general properties o f  a weak m etalloproteinase.J B iol Chem 268 15435 - 
15441.
Mutsaers, S. and Laurent, G. (1995) W ound healing: from entropy to integrins. The 
Biochem ist 17 32 - 38.
210
Nagase, H ., Enghild, J.J., Suzuki, K. and Salvesen, G. (1990) Stepw ise activation  
m echanism s o f  the precursor o f  matrix metalloproteinase (strom elysin) by proteinases and 
(4-aminophenyl) mercuric acetate. Biochem istry 29 5 7 8 3 - 5 7 8 9 .
N agle, R. B., Knox, J. D ., W olf, C., Bow den, G. T. and Cress, A. E, (1994) A dhesion  
m olecules, extracellular matrix and proteases in prostate carcinoma. J Cell B iochem  
(Supplement )19 232 - 237.
Nakaon, A ., Tani, E., M iyazaki, K., Yamamoto, Y . and Furuyama, J. (1995) Matrix 
metalloproteinases and tissue inhibitors o f metalloproteinases in human gliom as. J 
Neurosurg 83 298 - 307.
Nakagawa, T., Kubota, T., Kabuto, M ., Sato, K., K awano, H ., Hayakawa, T. and 
Okada, Y. (1994) Production o f  matrix m etalloproteinases and tissue inhibitor o f  
m etalloproteinases-1 by human brain tumors. J Neurosurg 81 69 - 77.
Nakayama, H ., Yasui, W ., Y okozaki, H. and Tahara, E. (1993) Reduced expression o f  
nm23 is associated with m etastasis o f  human gastric carcinomas. Jap J Cancer R es 84  
1 8 4 -  190.
Nathan, C. and Spom , M. (1991) Cytokines in context. J C ell B io l 113 981 - 986.
Naylor, M .S., Stamp, G .W ., D avies, B .D . and Balkw ill, F.R. (1994) Expression and 
activity o f  M M Ps and their regulators in ovarian cancer. Int J Cancer 58 . 50  - 56.
Netzel-Arnett, S., Sang, Q., M oore, W ., G.I., Navre, M ., Birkedal-Hansen, H. and Van  
Wart, H. E. (1993) Comparative sequence specificities o f  human 72- and 92-kD a  
gelatinases (type IV collagenases) and PUM P (matrilysin). Biochem istry 32 6427 -
6432.
N ew ell, K ,  W itty, J, Rodgers, W .H . and Matrisian, L.M . (1994) Expression and 
localisation o f  matrix-degrading metalloproteinases during colorectal tumorigenesis. M ol 
Cacrinogenesis 10 199 - 206.
N icolson, G.L. (1991) G ene expression, cellular diversification and tumor progression to 
the metastatic phenotype. B ioessays 13  337 - 342.
N issim , A ., H oogenboom , H. R., Tom linson, I. M ., Flynn, G., M idgeley, C., Lane, D. 
and Winter, G. (1994) Antibody fragments from a “single pot” phage display library as 
immunochemical reagents. EM BO  J 13 692  - 696.
Nomenclature Committee o f  the International Union o f  Biochem istry and M olecular 
B iology (1992) In : W ebb, E.C. (ed) Enzym e Nom enclature, Academ ic Press Inc , N ew  
York, p 412.
211
Nomura, H., Sato, H., Seiki, M ., M ai, M. and Okada, Y . (1995) Expression o f  
membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55
3263 - 3266.
Normanno, N ., Bianco, C., Dam iano, V ., D e  A ngelis, E ., Selvam , M. P., Grass, M ., 
M agliulo, G., Tortora, G., B ianco, A. R., M endelsohn, J., Salom on, D . S. and 
Ciardiello, F. (1996) Growth inhibition o f  human colon carcinoma cells by combinations 
o f  anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clin 
Cancer Res 2 601 - 609.
Obata, K ., Iwata, K., Okada, Y ., Kohrin, Y ., Ohuchi, E ., Y oshida, S., Shinm ei, M . and 
Hayakawa, T. (1992) A  one-step sandwich enzym e im m unoassay for human matrix 
metalloproteinase-3 (strom elysin-1) using m onoclonal antibodies. Clin Chim Acta 211 59  
-7 2 .
Ohuchi, E., Azum ano, I., Y oshida, S., Iwata, K., Okada, Y . (1996) A  one-step  
sandwich enzyme im m unoassay for human matrix metalloproteinase 7 (matrilysin) using  
monoclonal antibodies. Clin Chim Acta 244  181 - 198.
O ’Shea, H. (1996) Transcriptional regulation o f  matrilysin gene expression. M .Sc. Thesis, 
Dublin City University, Dublin, Ireland.
Osteen, K. G., Rodgers, W . H ., Gaire, M ., Hargrove, J. T., Gorstein, F. and Matrisian, 
L. M. (1994) Stromal-epithelial interaction m ediates steroidal regulation o f  
metalloproteinase expression in  human endometrium. Proc Natl Acad Sci U SA  91 10129  
-1 0 1 3 3 .
Overall, C. M. and Sodek, J. (1990) Concanavalin A  produces a matrix-degradative 
phenotype in human fibroblasts. J B iol Chem 265 21141 - 1151.
Overall, C. M., Wrana, J. L. and Sodek, J. (1989) Independent regulation o f  collagenase, 
72kDa progelatinase and m etalloendoproteinase inhibitor expression in human fibroblasts 
by transforming growth factor-p. J B io l Chem  264  1 8 6 0 -  1869.
Patel, K.V. and Schrey, M.P. (1995) Human breast cancer cells contain a 
phosphoramidon-sensitive metalloproteinase which can process expgenous big endothelin- 
1 to endothelin-1 : a proposed m itogen for human breast fibroblasts. Br J Cancer 7 1 4 4 2  - 
447.
Pajouh, S. M., N agle, R .B ., Breathnach, R., Finch, J.S., Brawer, M. K. and Bow den G. 
T. (1991) Expression o f  metalloproteinase genes in human prostate cancer. J Cancer Res 
Clin Oncol 117 1 4 4 -  150.
Paulsson, M. (1992) Basem ent membrane proteins : structure, assem bly, and cellular 
interactions. Crit R ev B iochem  M olec B iol 27 93 - 127.
212
Pei, D. and W eiss, S. J. (1995) Furin-dependent intracellular activation o f  the human 
stromelysin-3 zym ogen. Nature 375 244  - 247.
Peterson, O. W ., R 0nnov-Jessen, L., Howlett, A . R. and B issell, M. J. (1992) 
Interaction with basement membrane serves to rapidly distinguish growth and 
differentiation pattern o f  normal and malignant human breast epithelial cells. Proc Natl 
Acad Sci U SA  89 9064  - 9068.
Pohl, J., Radler-Pohl, A . and Schirrmacher, V . (1988) A  m odel to account for the 
effects o f oncogenes, TPA, and retinoic acid on the regulation o f  genes involved in
metastasis. Cancer and M etastasis R evs 7 347 - 356.
Polette, M ., Gilbert, N ., Stas, I., Nawrocki, B ., N oel, A ., R em ad e, A ., Stetler- 
Stevenson, W . G ., Birembaut, P. and Foidart, M. (1994) Gelatinase A  expression and 
localization in human breast cancers. An in situ hybridization study and 
immunohistochemical detection using confocal m icroscopy. Virchows Archiv. 424  641 -
645.
Poli, V ., M ancini, F. and Cortese, R. (1990) I1-6DBP, a nuclear protein involved in  
interleukin-6 signal transduction, defines a new  fam ily o f  leucine zipper proteins related to 
C/EBP. Cell 63 6 4 3 - 6 5 3 .
Postel, E.H., Berberich, S.J., Flint, S J . and Ferrone, C.A. (1993) Human c-myc 
transcription factor PuF identified as nm 23-H 2 nucleoside diphosphate kinase, a candidate 
suppressor o f  tumor metastasis. Science 261 478  - 480.
Poulsom , R., Pignatell, M ., Stetler-Stevenson, W .G ., Liotta, L .A ., Wright, P.A .,
Jeffrey, R.E., Longcroft, J.A., Rogers, L  and Stamp, G .W . (1992) Stromal expression  
o f  72 kDa type IV collagenase (M M P-2) and TIM P-2 m R N A s in colorectal neoplasia. 
Am  J Pathol 141 3 8 9 - 3 9 6 .
Pow ell, W .C., K nox, J.D., Navre, M ., Grogan, T.M ., K ittelson, J., Nagle, R.B. and 
Bowden, G.T. (1993) Expression o f  the metalloproteinase matrilysin in D U -145 cells  
increases their invasive potential in severe com bined im m unodeficient mice. Cancer Res 
53 417 - 422.
Pyke, C., Ralfkiaer, E., Huhtala, P., Hurskainen, T., D an0 , K. and Tryggvason, K.
(1992) Localization o f messanger R N A  for M r 72 ,000  and 92 ,000  type IV collagenases in 
human skin cancers by in situ hybridization. Cancer Research 52 1336 - 1341.
Quinones, S., Saus, J., Otani, Y ., Harris, E. Jr. and Kurkinen, M. (1989) Transcriptional 
regulation o f human stromelysin. J B iol Chem 264  8339 - 8344.
Rappolee, D . A ., W ang, A ., Mark, D . andW erb, Z. (1989) N ovel method for studying 
m RNA phenotypes in single or small numbers o f cells. J Cell B iochem  39 1 - 1 1 .
213
Rasko, I. and D ow nes, C. S. (1995) G enes in M edicine. Chapman and Hall, London, pp 
78 - 112.
Real, F. X , Rettig, W. J., Chesa, P. G., M elam ed, M. R., Old, L. J. and M endelsohn, J. 
(1986) Expression o f  epidermal growth factor receptor in human cultured cells  and 
tissues : relationship to cell lineage and stage o f differentiation. Cancer Res 4 6  4 7 2 6  - 
4731.
Ries, C., Kolb, H. and Petrides, P. E. (1994) Regulation o f  92kD  gelatinase release in  
H L-60 leukaemia c e l l s : Tumor necrosis factor-a as an autocrine stimulus for basal- and 
phorbal ester-induced secretion. B lood  83 3638 - 3646.
Rochefort, H., Capony, F. and Garcia, M. (1990) Cathepsin D  : a protease involved  in 
breast cancer metastasis. Cancer M etastasis R ev 9  321 - 331.
Roeder, R. G. (1991) The com plexities o f  eukaryotic transcription initiation : Regulation  
o f preinitiation com plex assem bly. Trends B iochem  Sci 1 6  4 02  - 407.
Rogler, C. E., Yang, D ., R ossetti, L ., D onahoe, J., A lt, E., Chang, C. J., R osenfeld, R., 
N eely, K. and Hintz, R. (1994) Altered body com position and increased frequency o f  
diverse malignancies in insuliin-like growth factor II transgenic m ice. J B iol Chem 269  
13779 - 13784.
Rosanelli, G.P., Steindorfer, P., W im sberger, G .M ., Klim pfinger, M ., Ratscher, M., 
Puerstner, P., Auner, H. and Berhold, A . (1995) M utant p53 expression and D N A  
analysis in human breast ca n cer: comparison with conventional clinico-pathological 
parameters. Anti-Cancer Res 15  581 - 584.
Rosen, P.P., Groshen, S., Saigo, P.E., Kinne, D .W . and H eilm an, S. (1989) A  long­
term follow -up study o f  survival in stage I (TiNoMo) and stage II (T1N 1M0) breast 
carcinomas. J Clin Oncol 7 355 - 366.
Rosenberg, S.A ., M ule, J.J., Speiss, P .J.(1987) R egression o f  established pulmonary 
metastasis and subcutaneous tumor mediated by the system ic administration o f  high dose  
recombinant IL-2 . J Exp M ed
Ross, L. L. and Laurenza, A. (1995) D etection by ELISA o f  laminin released by 
endothelial cells from a collagen coated layer o f  Matrigel. M eths Cell Sci 17  47 -52.
Rothwell, N. V. (1993) Understanding Genetics. A  M olecular Approach. W iley-L iss 
Inc., N ew  York, pp 262 - 270.
Russell, S. J. (1990) Lym phokine gene therapy for cancer. Im m unology Today H  196 
- 199.
214
Saarialho-Kere, U . K., Crouch, E. C and Parks, W . C. (1995) Matrix m etalloproteinase 
matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Derm  
105 1 9 0 -  196.
Sager, R. (1989) Tumor suppressor genes : the puzzle and the promise. Science 246  1406  
- 1412.
Sakyo, K., Ito, A ., O gawa, C. and M ori, Y. (1986) Hormonal control o f  collagenase  
inhibitor production in  rabbit uterine cervical fibroblast-like cells. B iochem  Biophys Acta 
883 517 - 522.
Samples, J. R., Alexander, J. P. and Acott, T. S. (1993) Regulation o f  the levels o f  
human trabecular matrix metalloproteinases and inhibitor by interleukin-1 and 
dexamethasone. Invest Ophthal V is Sci 34 3386  - 3395.
Sanchez-Lopez, R ., Alexander, C. M ., Behrendtsen, O., Breathnach, R. and Werb, Z.
(1993) Role o f  zinc-binding and hem opexin dom ain-encoded sequences in the substrate 
specificity o f  collagenase and stromelysin-2 as revealed by chimeric proteins. J B iol Chem  
268 7238 - 7247.
Sancho-Gamier, H ., Delarue, J.C., M ouriessa, H ., Contesso, G ., M ay Levin, F., 
Gotteland M. and M ay E. (1995) Is the negative prognostic value o f  high oestrogen  
receptor (ER) levels in post-m enopausal breast cancer patients due to a m odified ER gene 
product? Eur J Cancer 31A 1851 - 1855.
Sassone-Corsi, P., Ransone, L. J., Lamph, W . W . and Verma, I. M . (1988) Direct 
interaction between fos and jun nuclear oncoproteins : role o f the ‘leucine zipper’ domain. 
Nature 336 692 - 695.
Sato, H., Takino, T., Okada, Y ., Cao, J., Shinagawa, A ., Yam am oto, E. and Seiki, M.
(1994) A  matrix metalloproteinase expressed on the surface o f  invasive tumour cells. 
Nature 370 61 - 65.
Sato, T., Ito, A . and M ori, Y. (1990) Interleukin-6 enhances the production o f  tissue 
inhibitor o f  metalloproteinases (TIMP) but not that o f  matrix metalloproteinases by human 
fibroblasts. B iochem  Biophys Res Comms 1 7 0  824  - 829.
Scambia, G., Benedetti-Panicini, P., Ferrandino, G., D istefano, M ., Salerno, G., 
Romanini, M .E., Fagotti, A. and M ancuso, S. (1995) Epidermal growth factor, 
oestrogen and progesterone receptor expression in promary ovarian cancer : correlation 
with clinical outcom e and response to chemotherapy. Br J Cancer 7 2  361 - 366.
Schonbom , I., M inguillon C., Lichtenegger, W ., Zschiesche, W. and Spitzer, C. (1995) 
C-erbB-2, EGF Rezeptor, p53 und PC N A . D ie  prognostische Bedeutung neuer Faktoren 
für das Lymphknoten-negative Mamarkarzinom. Geburtshilfe Frauenheilkd 55 566 - 571.
215
Schor, S. L. (1994) Cytokine control o f  cell m otility : modulation and mediation by the 
extracellular matrix. Prog Growth Factor Res 5 223 - 248.
Schultz, D. C., Bazel, S., W right, L. M ., Tucker, S., Lange, M . K, T achovsky, T., 
Longo, S., Niedbala, S. and Alhadeff, J. A . (1994) W estern blotting and enzym atic 
activity analysis o f  cathepsin D  in breast tissue and sera o f  patients with breast cancer and 
benign breast disease and sera o f  patients with breast cancer and benign breast disease and 
o f  normal controls. Cancer Res 54 48 - 54.
Schütte, J., V iallet, J., Nau, M ., Segal, S., Fedorko, J. and M inna, J. (1989) Juti-B 
inhibits and c -fos stimulates the transforming and ira/w-activating activities o f  c-jun. Cell 
59_ 987 - 997.
Sedlacek, H.H. and M öröy , T. (1995) Im mune Reactions. Springer, Berlin, pp 1 - 53.
Seftor, R. E .B ., Seftor, E. A ., Stetler-Stevenson, W . G. and Hendrix, M . J.C. (1993) 
The 72 kDa type IV collagenase is modulated via differential expression o f  Ovß3 and asß i 
integrins during human m elanoma cell invasion. Cancer Res 53 3411 -3 4 1 5 .
Sen, G. C. and L engyel, P. (1992) The interferon system. J B io l Chem 267 5017 - 
5020.
Senior, R.M ., Connolley, N .L., Clery, J.D., W elgus, H.G. and Campbell, E.J. (1989) 
Elastin degradation by human alveolar macrophages : a prominant role o f  
metalloproteinase activity. Am  Rev Respir D is 139 1251 - 1256.
Serve, H., Steinhäuser, G ., Oberberg, D ., F legel, W . A ., Northoff, H. and Berde, W . E. 
(1991) Studies on the in traction between interleukin 6 and human malignant 
nonhaematopoietic cell lines. Cancer Res 51 3 8 6 2 -  3866.
Shapiro, S. D ., Kobayashi, D . K. and L ey, T. J. (1993) C loning and characterization o f a 
unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol 
Chem 268 23824  - 23829.
Shapiro, S. D . (1994) Elastolytic m etalloproteinases produced by human mononuclear 
phagocytes. Am  J Respir Crit Care M ed 150 S 160 - S 164.
Shi, Y. E., Torri, J., Y ieh, L., W ellstein, A ., Lippman, M. E. and D ickson, R. B.
(1993) Identification and characterization o f  a novel matrix-degrading protease from  
hormone dependent human breast cancer cells. Cancer Res 53 1409 - 1415.
Shima, I., Sasaguri, Y ., Kusukawa, J., Nakano, R., Yamana, H ., Fujita, H ., Kakegawa, 
T. and Morimatsu, M. (1993) Production o f  matrix m etalloproteinase 9 (92 kDa  
gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal 
growth factor. Br J Cancer 67 721 - 727.
216
Sires, U .I., Griffin, G .L., Broekelmann, T.J., M echam , R.P., Murphy, G ., Chung, A .E ., 
W ejgus, H.G. and Senior, R.M . (1993) Degradation o f  entactin by matrix 
metalloproteinases, susceptibility to matrilysin and identification o f  cleavage sites. J B iol 
Chem 268 2 0 6 9 - 2 0 7 4 .
Sloane, B. F., Cao, L., Sam eni, M ., Rohzin, J., M oin, K. and Zigler, G. (1993) 
Cathepsin B in tumor progression. Proc A m  A ssoc Cancer Res 34 602  - 603.
Smith, K. A. (1989) Interleukin futures. B io/T echnology 7 661 - 667.
Smith, M. M ., Shi, L. andN avre, M. (1995) Rapid identification o f  highly active and 
selective substrates for stromelysin and matrilysin using bacteriophage peptide display 
libraries. J B iol Chem  270 644 0  - 6449.
Soini, Y ., Hurskainen, T., H oyh tya , M ., Oikarinen, A . and Autio-Harmainen, H. (1994) 
72 kD and 92  kD type IV collagenase, type IV  collagen and laminen m R N A s in  breast 
ca n cer: a study by in situ hybridisation. J H istochem  C ytochem  42  945 - 951.
Soler, D ., N om izu, T., Brown, W .E ., Chen, M ., Y e, Q .Z., Van Wart, H.E. and Auld,
D .S. (1994) Zinc content o f  promatrilysin, matrilysin and the stromelysin catalytic 
domain. B iochem  Biophys Res Com m s 201 9 17  - 923.
Spratt, J.S., Greenberg, R .A . and H euser, L .S. (1986) G eom etry, growth rates and 
duration o f  cancer and carcinoma in situ o f  the breast before detection by screening. 
Cancer Res 46  9 7 0  - 974.
Springman, E .B ., Angleton, E .L., Birkedal-Hansen, H. and Van Wart, H. (1990) 
Multiple m odes o f  activation o f  latent human fibroblast collagenase : evidence for the role 
o f a C ys73 active site-zinc com plex in latency and a ‘cysteine sw itch’ m echanism  for 
activation. Proc Natl Acad Sci U S A  87 17374 - 17378.
Spyratos, F., M audelonde, T., Brouillet, J., Brunet, M , Defrenne, A ., Andrieu, C., 
Hacene, K., D esp laces, A ., R ouesse, J. and Rochefort, H. (1989) Cathepsin D  : an 
independent prognostic factor for m etastasis o f  breast cancer. The Lancet I I 1115 -1 1 1 8 .
Stahl, J. A ., L eone, A ., Rosengard, A. M ., Porter, L., Richter, K. C. and Steeg, P. S. 
(1991) Identification o f  a second human nm23 gene, nm23-H2. Cancer Res 51 4 4 5 -  
449.
Stetler-Stevenson, W .G ., Krutzsch, H .C., W acher, M .P., M argulies, I.M.K. and Liotta, 
L.A. (1989a) The activation o f  type IV collagenase proenzym e : sequence identification o f  
the major conversion product fo llow ing organomercurial activation. J B iol Chem 264  
17374 - 17378.
Stetler-Stevenson, W .G ., Krutzsch, H .A . and Liotta, L .A . (1989b) Tissue inhibitor o f  
metalloproteinase (T IM P -2): a new member o f  the metalloproteinase inhibitor fam ily. J 
Biol Chem 2 M  17374 - 17378.
217
Stetler-Stevenson, W .G ., Bersch, N . and G olde, D .W . (1992) T issue inhibitor o f  
m etalloproteinase-2 (TIM P-2) has erythroid-potentiating activity. FEBS Lett 296 231 -
234.
Stracke, M. L. and Liotta, L. A . (1992) M ulti-step cascade o f  tumor ce ll metastasis. In
Vivo 6  309 - 316.
Stricklin, G. P., Li, L ., Jancic, V ., W enczak, B. A. and Nanney, L. B. (1993) 
Localization o f m R N A s representing collagenase and TIM P in sections o f  healing human 
bum wounds. A m  J Path 143 1 6 5 7 -  1666.
Takeshita, S., K awase, H., Yam aom ot, M , Fujisawa, T, Sekine, I and Y oshioka, S (1994) 
Increased expression o f  human 63-kD  heat shock protein in Kawasaki disease determined 
by quantitative reverse transcription-polymerase chain reaction. Pediatr Res 35 179 - 183.
Takino, T., Sato, H ., Y am am oto, E. and Seiki, M. (1995a) C loning o f  a human gene  
potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane 
domain. Gene 155 293 - 298.
Takino, T., Sato, H., Shinagawa, A . and Seiki, M. (1995b) Identification o f  the second  
membrane-type matrix metalloproteinase (M T-M M P-2) gene from a human placenta 
cD N A  library. J B iol Chem 270  23013  - 23020.
Tamai, K ,  Ishikawa, H., M auviel, A . and Uitto, J. (1995) Interferon-y coordinately 
upregulates matrix m etalloprotease (M M P )-l and M M P-3, but not tissue inhibitor o f  
metalloproteases (TIM P) expression in cultured keratinocytes. J Invest Derm 104 384  - 
390.
Tanaka, K ., Iwam oto, Y ., Ito, Y ., Ishibashi, T., Nakebeppu, Y ., Sekiguchi, M. and 
Sugioka, Y. (1995) C yclic AM P-regulated synthesis o f  the tissue inhibitors o f  
metalloproteinases suppresses the invasive potential o f  the human fibrosarcoma cell line 
H T1080. Cancer R es 55 2927 - 2935.
Tanaka, T., Akira, S., Yoshida, K., U m em oto, M ., Y oneda, Y ., Shirafuji, N.,
Fujiwara, H., Suematsu, S., Yoshida, N. and Kishim oto, T. (1995) Targeted disruption 
o f the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by 
macrophages. C ell 80 353 -3 6 1 .
Tartour, E., Dorval, T., M osseli, V ., D eneux, L., Mathiot, C., Brailly, H ., M ontero, 
F., Joyeux, I., Pouillart, P. and Fridman, W .H. (1994) Serum interleukin-6 and C- 
reactive protein levels correlate with resistance to IL-2 therapy and poor survival in 
m elanoma patients. Br J Cancer 69 911 -9 1 3 .
Teng, Y .T., Sodek, J. and M cCulloch, C.A.G. (1992) G ingival crevicular fluid  
gelatinase and its relationship to peridontal disease in human subjects. J Peridont Res 27 
544 - 552.
218
Thom ssen, C., Schmitt, M ., Goretzk, L., Oppelt, P., Pache, L ., Dettmar, P., Janicke,
F. and Graeff, H. (1995) Prognostic value o f  the cysteine proteases cathepsins B and L in 
human breast cancer. Clin Cancer R es 1 741 - 746.
Thorpe, (1993) Eur J Cancer 29A  971 - 977.
Tijssen, P. (1985) Practice and Theory o f  Immunoassay. In the series Laboratory 
Techniques in Biochem istry and M olecular B iology, Burdon, R.H. and Van Knippenberg, 
P.H. eds. E lsevier, Rotterdam.
Urbanski, S.J., Edwards, D .R ., M aitland, A ., L eco, K.J., W atson, A . and K ossakowska, 
A.E. (1992) Expression o f  m etalloproteinases and their inhibitprs in  primary pulmonary 
carcinomas. Br J Cancer 66  1188 - 1194.
U r ia , J. A ., Ferrando, A. A ., V elasco, G., Freije, J. M .P. and L o p ez -O tin , C. (1994) 
Structure and expression in breast tumours o f  human TIM P-3, a new  member o f  the 
metalloproteinase inhibitor fam ily. Cancer Res 54 2091 - 2094.
Van Roy, F. and Mareel, M. (1992) Tumour invasion : effects o f  ce ll adhesion and 
motility. Trends Cell B iol 2_  163 - 169.
Van Wart, H. E. and Birkedal-Hansen, H. (1990) The cysteine switch : A  principle o f  
regulation o f metalloproteinase activity with potential applicability to the entire matrix 
metalloproteinase fam ily. Proc Natl A cad Sci U SA  87 5578 - 5582.
Van W eem an, B.K. and Schorrs, A .H .W .M . (1971) Immunoassay using antigen enzym e 
conjugate. FEBS Lett 15 232  - 234.
Vartio, T. and Baumann, M. (1989) Human gelatinase/type IV collagenase is a regular 
plasma com ponent. FEBS Lett 155 285  - 289.
V ile, R. G. (1995) Cancer M etastasis : From M echanism s to Therapies. John W iley and 
Sons, Chichester.
Villela, B., Cogan, R .B ., Bartolucci, A A  and Birkedal-Hensen, H. (1987)
Collagenolytic activity in crevicular fluid from patients with chronic adult periodontitis, 
localised juvenile periodonitis and gingivitis and from healthy contol subjects. J Periodont 
Res 22 381 - 389.
Vlodavsky, I., Komer, G., Ishai-M ichaeli, R., Bashkin, P., Bar-Shivat, R. and Fuks, Z. 
(1990) Extracellular matrix-resident growth factors and enzym es : possible involvem ent in  
tumour metastasis and angiogenesis. Cancer and M aetastasis R ev 9  203 - 226.
V ogelstein, B. and Kinzler, K. W. (1993) The multistep nature o f  cancer. Trends Gens_9 
1 3 8 - 141.
219
Von Bredow, D .C ., Cross, A .E ., B ow den, G .T., Howard, E.W . and N agle, R.B. (1996) 
Activation o f  gelatinases by matrilysin in the presence o f  their tissue inhibitors o f  
metalloproteinases (TIMPs). Proc A m  A ssoc Cancer Res 37 91
Wacher, M .P., Krutzch, H .C., Liotta, L .A . and Stetler-Stevenson, W .G. (1990) 
D evelopm ent o f a novel substrate capture im m unoassay for the detection o f  aneutral 
metalloproteinase capable o f  degrading basement membrane (type IV) collagen. J 
Immunol M eths 126 239 - 245.
Walker, R .A ., Dearing, S.J. and Gallacher, B. (1994) Relationship o f  transforming 
growth factor Pi to extracellular matrix and stromal infiltrates in invasive breast 
carcinomas. Br J Cancer 69 1 1 6 0 -  1165.
W allon, U . Margaretha, Shassetz, L. Richard, Cress, Anne E., Bow den, G. Tim  and 
Gemer, Eugene W . (1994) Polyam ine dependent expression o f  the matrix 
metalloproteinase matrilysin in a human colon cancer derived cell line. M olec  
Carcinogenesis 11 138 - 144.
W ang, M ., Steam s, M. and Steam s, M .E. (1994) Identification o f  the receptor for a 
novel Mr 78,000 ‘invasion stimulating factor’ from metastatic human prostatic PC-3 ML  
clones. Cancer R es 54 2492 - 2495.
W aterfield, M .D. (1985) The role o f  growth factors in cancer. In : Introduction to the 
cellular and m olecular biology o f  cancer, eds Franks, L.M. and Teich, N. Oxford Science  
Publications.
W asylyk, B ., W asylk, C., Flores, P ., Beque, A ., LePrince, D . and Stehelin, D . (1990) 
The c-ets protooncogenes encode transcription factors that cooperate with c-F os and c- 
Jun for transcriptional activation. Nature 346  191 - 193.
W eber, B.H., Vogt, G., W olz, W ., Ives, E.J. and Ew ing, C.C. (1994a) Sorsby’s fundus 
dystrophy is genetically linked to chrom osom e 2 2 q l3  qter. Nat G enet 7 158 - 161.
W eber, B .H ., Vogt, G., Pruett, R .C ., Stohr, H. and Felbor, U . (1994b) Mutations in the 
tissue inhibitor o f  metalloproteinases-3 (TIM P-3) in patients with Sorsby’s fundus 
dystrophy. Nat Genet 8 352  - 356.
Weinberg, R.A. (1985) The action o f  oncogenes in the cytoplasm  and nucleus. Science 
230 770  - 776.
W elgus, H.G. (1991) Strom elysin : structure and function. Prog Inflamm Res Therapy 
61 - 67.
W elgus, H.G. and Stricklin, G.P. (1983) Human skin fibroblast inhibitor. J B iol Chem  
258 12259 - 12264.
220
Werb, Z., Tremble, P. M ., Behrendsten, O., Crowley, E. and D am sky, C. H. (1989) 
Signal transduction through the fibronectin receptor induces collagenase and stromelysin  
gene expression. J Cell B io l 109 877 - 889.
W est, W .H., Tauer, K .W ., Yannelli, J.R. (1987) Constant infusion o f  recombinant 
interleukin-2 in adoptive immuntherapy o f  advanced cancer. N  Engl J Med.
W estley, B.R. and M ay, F .E .B . (1995) Insulin-like growth factors : the unrecognised  
oncogenes. Brit J Cancer 72  1065 - 1066.
W ilhelm , S. M ., Collier, I. E., K ., A ., Eisen, A . Z., Marmer, B . L ., Grant, G. A ., Bauer,
E. A. and Goldberg, G. I. (1987) Human skin fibroblast strom elysin : structure, 
glycosylation, substrate specificity, and differential expression in  normal and tumorigenic 
cells. Proc Natl Acad Sei U S A  M  6725 - 6729.
W ilhelm , S.M ., Collier, I.E., Marmer, B .L ., Eisen, A .Z ., Grant, G .A. and Goldberg,
G.I. (1989) SV40-transform ed human lung fibroblasts secrete a 94-kD a type IV  
collagenase which is identical to that secreted by normal human macrophages. J B io l 
Chem 264 1 7 2 1 3 -  17221.
W ilson, C. L., Heppner, K. J., Rudolph, L. A. and Matrisian, L. M . (1995) The matrix 
metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue- 
restricted pattern in the m ouse. M olec B io l C ell 6_ 851 - 869.
W itty, J. P., M cD onnell, S., N ew ell, K., Cannon, P ., Navre, M ., Tressler, R. and 
Matrisian, L. M. (1994) M odulation o f  matrilysin levels in colon carcinoma cell lines 
affects tumorigenicity in vivo. Cancer Res 54 4805  - 4812 .
W laschek, M., H einen, G., P osw ig , A ., Schwarz, A ., Krieg, T., and Seharffater 
Kochanak, K .(1994) U V A -induced autocrine stimulation o f  fibroblast-derived  
collagenase/M M P-1 by interrelated loops o f  interleukin-1 and interleukin-6. Photochem  
Photobiol 59 550  - 556.
W oessner, J. F. Jr (1991) Matrix m etalloproteinases and their inhibitors in connective  
tissue remodelling. FASEB J 5  2145  - 2154.
W olf, C., Chenard, M ., Durand de Grossouvre, P., B ellocq , J., Chambon, P. and 
Basset, P. (1992) Breast cancer associated strom elysin-3 gene is expressed in basal cell 
carcinoma and during cutaneous wound healing. J Invest Dermatol 99 870 - 872.
W olf, C., Rouyer, N ., Lutz, Y., Adida, C., Loriot, M ., B ellocq , J., Chambon, P. and 
Basset, P. (1993) Strom elysin-3 belongs to a subgroup o f  proteinases expressed in breast 
carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad  
Sei U SA  90  1843 - 1847.
221
Yam am oto, H., Itoh, F., H inoda, Y . and Imai, K. (1995) Suppression o f  matrilysin 
inhibits colon cancer cell invasion in vitro. Int J Cancer 6 1 2 1 8  -222.
Yam am oto, H ., Itoh, F., Hinoda, Y ., Senota, A ., Y oshim oto, M ., Nakamura, H ., Imai, 
K. and Yachi, A. (1994) Expression o f  matrilysin m R N A  in colorectal adenomas and its 
induction by truncated fibronectin. B iochem  Biophys Res Com m s 201 657 - 664.
Yam am oto, H ., Itoh, F ., Seota, A ., Adachi, Y ., Y oshim oto, M ., Endoh, T„ Hinoda, 
Y., Yachi, A. and Imai, K. (1995) Expression o f matrix metalloproteinase matrilysin 
(M M P-7) w as induced by activated Ki-ras via AP-1 activation in SW 1417 colon cancer 
cells. J Clin Lab Anal 9 297 - 301.
Yamashita, J-I., O gawa, M ., Ikei, S., Omachi, H., Yamashita, S-I., Saishoji, T., 
Nomura, K. and Sato, H. (1994) Production o f  im m unoreactive polymorphonuclear 
leucocyte elastase in human breast cancer cells : possible role o f  polymorphonuclear 
leucocyte elastase in the progression o f  breast carcinomas. Brit J Cancer 69 7 2  - 76.
Y oshim oto, M ., Itoh, F., Y am am oto, H., Hinoda, Y ., Imai, K. and Yachi, A. (1993) 
Expression o f  M M P-7 (PU M P-1) m R N A  in human colorectal cancers. Int J Cancer 54 
6 1 4 - 6 1 8 .
Yu, M ., Sato, H., Seiki, M. and Thom pson, E. W . (1995) C om plex regulation o f  
membrane type matrix metalloproteinase expression and matrix metalloproteinase-2 
activation by concanavalin A  in M D A -M B -231 human breast cancer cells. Cancer Res 55 
3272 - 3277.
Yuan, Z., Feng, R., Castelhano, A. and Billedeau, R. (1994) Electrospray mass 
spectrometry study o f  metal ions in matrilysin. Ann N Y  Acad Sci 732 489  - 492.
Zeng, Z., Cohen, A. M ., Zhang, Z., Stetler-Stevenson, W. and Guillem , J. G. (1995) 
Elevated tissue inhibitor o f  m etalloproteinase-1 R N A  in colorectal cancer stroma 
correlates with lymph node and distant metastases. Clin Cancer Res 1  899 - 906.
Zeng, Z .S., Hsu, S., Zhang, Z.F., Cohen, A .M ., Enker, W .E ., Turnbull, A .A . and 
Guillem , J.G. (1994) High level o f  N m 23-H l gene expression is associated with local 
colorectal cancer progression not with metastases. Brit J Cancer 70 1025 - 1030.
Zhang, J., Fujimoto, N ., Iwata, K., Sakai, T., Okada, Y. and Hayakawa, T. (1993) A  
one-step sandwich enzym e im m unoassay for human matrix metalloproteinase 1 (interstitial 
collagenase) using m onoclonal antibodies. Clin Chim Acta 219 1 - 1 4 .
Zou, M ., Shi, Y ., Al-Sedairy, S. and Farid, N.R. (1993) H igh levels o f  Nm 23 gene 
expression in advanced stage o f  thyroid carcinomas. Brit J Cancer 68 385 -3 8 8 .
Zucker, S., M oll, U . M ., L ysik, R. M ., D iM assim o, E., Stetler-Stevenson, W . G.,
Liotta, L. A. and Schw edes, J. W . (1990) Extraction o f  type-IV collagenase/gelatinase  
from plasma membranes o f  human cancer cells. Int J Cancer 45 1137 - 1142.
222
Zucker, S., Lysik, R. M., Gurfinkei, M., Zarrabi, M. H., Stetler-Stevenson, W., Liotta, 
L. A., Birkedal-Hansen, H. and Mann, W. (1992) Im m unoassay o f  type IV 
collagenase/gelatinase (M M P-2) in human plasma. J Immun M eths 148 189 - 198.
Zucker, S., Lysik, R. M., Zarrabi, M. H. and M oll, U . (1993) M r 92 ,000  type IV  
collagenase is increased in plasma o f  patients with colon cancer and breast cancer. Cancer 
Res 53 140 - 146.
223
APPENDIX A
PLASMID MAPS
y ' y
pG7PumpEX
The cDNA coding for the human matrilysin protein 
has been inserted between the T7 and SP6 promoters,
The restriction sites used for linearising the plasmid 
are indicated by dashed lines.
pgQMp;
i
pG7PumpXE
The cDNA coding for the human matrilysin protein 
has been inserted between the T7 and SP6 promoters,
The restriction sites used for linearising the plasmid 
are indicated by dashed lines.
i
pCHllO
This plasmid contaiiis a functional Lac Z gene, under the control of an 
SV40 promoter.
Pvu II cleavage sites are indicated by dashed lines.
i
A
m 
p
ic
pFLCAT
The SV40 promoter has been placed after the 
gene encoding the CAT protein so that no transcription 
should occur.
■
?u
?
fp295HPCAT & p933HPCAT
Two different lengths of the human matrilysin promoter 
(295 bp or 933 bp) have been inserted immediately in 
front of the gene encoding the CAT protein.
5
pGL2-MMP
2.7 Kb of the mouse matriiysin promoter has been 
inserted ahead of the luciferase gene.
6
